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Bipolar	   mood	   disorder	   (BD),	   previously	   referred	   to	   as	   folie	   circulaire	   (circular	  
madness),	  is	  a	  major	  psychiatric	  illness	  that	  affects	  2-­‐5%	  of	  the	  worldwide	  population.	  It	  
is	   characterized	   by	   intermittent	   cycles	   of	   severe	   mania	   and	   depression,	   with	   a	   high	  
tendency	  for	  suicide.	  The	  underlying	  causes	  and	  the	  molecular	  basis	  of	  this	  debilitating	  
disease	  are	  not	  known.	  Mood	  stabilizing	  drugs,	   including	   lithium,	  valproate	   (VPA),	  and	  
carbamazepine,	   are	   used	   for	   the	   treatment	   of	   BD.	   However,	   they	   are	   not	   completely	  
effective,	   and	   are	   associated	   with	   serious	   side	   effects,	   including	   teratogenicity	   and	  
hepatotoxicity.	  Furthermore,	  the	  mechanism	  underlying	  the	  therapeutic	  effect	  of	  these	  
three	  structurally	  dissimilar	  drugs	  is	  not	  well-­‐understood.	  Intriguingly,	  all	  three	  of	  them	  
lead	  to	   inositol	  depletion,	  albeit	  by	  different	  mechanisms,	  suggesting	  that	  depletion	  of	  
inositol	  may	  underlie	  the	  therapeutic	  effect	  of	  these	  drugs,	  and	  that	  inositol,	  or	  inositol	  
compounds	  may	  play	  a	  key	  role	  in	  the	  pathophysiology	  of	  BD.	  	  
The	   work	   presented	   in	   this	   thesis	   was	   carried	   out	   to	   elucidate	   cellular	  
consequences	  of	  inositol	  depletion	  mediated	  by	  the	  anticonvulsant	  drug	  VPA.	  This	  study	  
led	  to	   three	  major	   findings.	  First,	   I	   identified	  a	  novel	   regulatory	  mechanism	  of	   inositol	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biosynthesis	   characterized	   by	   phosphorylation	   of	   the	   rate-­‐limiting	   enzyme	   in	   inositol	  
biosynthesis.	   Second,	   I	   demonstrated,	   for	   the	   first	   time,	   that	   the	   highly	   conserved	  
vacuolar	   ATPase	   (V-­‐ATPase)	   is	   a	   target	   of	   VPA.	   Third,	  my	   studies	   indicated	   that	   VPA-­‐
mediated	   inositol	   depletion	   perturbs	   endocytosis	   in	   both	   yeast	   and	  mammalian	   cells.	  
These	  novel	  findings	  suggest	  new	  mechanisms	  that	  may	  underlie	  the	  therapeutic	  action	  
of	   VPA,	   and	   suggest	   novel	   targets	   that	   may	   be	   used	   for	   the	   development	   of	   more	  
effective	  and	  safer	  drugs.	  
	  
A	  brief	  history	  of	  VPA	  
VPA	   is	  a	  simple,	  8-­‐carbon,	  branched	  chain	  carboxylic	  acid	   that	  was	   first	   synthesized	   in	  
1882	  and	  used	  as	   an	  organic	   solvent	   (Burton,	   1882).	   The	  anticonvulsant	  properties	  of	  
VPA	   were	   fortuitously	   discovered	   eighty	   years	   later	   when	   it	   was	   used	   to	   solubilize	  
khellinic	  compounds	  that	  were	  tested	  for	  potential	  anticonvulsant	  properties	  (Meunier	  
et	  al.,	  1963).	  VPA	  was	  first	  used	  for	  the	  treatment	  of	  BD	  in	  1966	  (Lambert	  et	  al.,	  1966).	  
Since	  then,	  it	  has	  become	  a	  widely	  prescribed	  drug	  for	  the	  treatment	  of	  epilepsy	  and	  BD	  
(Bowden	  et	  al.,	  1994;	  Perucca,	  2002),	  and	  more	  recently,	  for	  the	  treatment	  of	  migraine	  
(Calabresi	   et	   al.,	   2007).	   Although	   several	   targets	   of	   VPA	   have	   been	   identified,	   the	  
mechanism	  of	  action	  that	  underlies	  its	  therapeutic	  effect	  is	  not	  known.	  The	  decrease	  in	  
inositol	  caused	  by	  VPA	  has	  many	  implications	  especially	  in	  light	  of	  the	  many	  roles	  played	  
by	  inositol	  and	  inositol	  compounds.	  In	  the	  following	  sections,	  I	  highlight	  the	  significance	  
of	  inositol	  and	  consequences	  of	  its	  depletion.	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Inositol	  is	  an	  essential	  metabolite:	  
Inositol	   is	  a	  six-­‐carbon	  cyclitol	   that	   is	  ubiquitous	   in	  biological	  systems.	   It	   is	  a	  precursor	  
for	   the	   synthesis	   of	   numerous	   biologically	   important	   compounds,	   including	   inositol	  
phosphates	   (IP2-­‐IP9)	   and	   phosphoinositides	   such	   as	   phosphatidylinositol	   (PI)	   and	  
glycosylphosphatidylinositol	   (GPI)	   (Breslow	   and	   Weissman,	   2010;	   Pittet	   and	  
Conzelmann,	  2007).	  The	   inositol	  head	  group	  of	  PI	  can	  be	  reversibly	  phosphorylated	  at	  
positions	  3,	  4,	  and	  5	  to	  yield	  a	  variety	  of	  biologically	  active	  phosphoinositides	  that	  can	  
bind	   and	   recruit	   a	   wide	   range	   of	   proteins	   (Strahl	   and	   Thorner,	   2007).	   At	   least	   four	  
phosphoinositides	   have	   been	   identified	   in	   yeast,	   including	   PI3P,	   PI4P,	   PI3,5P2,	   and	  
PI4,5P2	  (Fig.	  1.1).	  In	  higher	  eukaryotes,	  there	  are	  three	  additional	  phosphoinositides	  that	  
include	   PI5P,	   PI3,4P2	   and	   PI3,4,5P3	   (Strahl	   and	   Thorner,	   2007).	   Inositol-­‐containing	  
compounds	  are	  essential	   for	  various	   structural	  and	   functional	  processes	   important	   for	  
cell	  function	  and	  viability.	  Some	  of	  these	  functions	  include	  membrane	  formation,	  gene	  
regulation,	  signaling,	  regulation	  of	  ion	  channels,	  and	  membrane	  trafficking	  (Di	  Paolo	  et	  
al.,	   2006;	   Falkenburger	   et	   al.,	   2010;	   Michell,	   2013).	   	   Furthermore,	   inositol	   regulates	  
hundreds	   of	   genes,	   including	   those	   involved	   in	   biosynthesis	   of	   inositol	   and	  
phospholipids	  (Greenberg	  and	  Lopes,	  1996;	  Carman	  and	  Henry,	  1999),	  as	  well	  as	  genes	  
involved	   in	   stress	   response	  pathways	   (Jesch	   et	   al.,	   2005).	   In	   the	   yeast	   Saccharomyces	  
cerevisiae,	  inositol	  is	  derived	  from	  three	  sources:	  Import	  from	  the	  extracellular	  medium	  
using	  two	  Na+-­‐driven	  myo-­‐inositol	   transporters	  encoded	  by	   ITR1	  and	   ITR2;	   recycling	  of	  
inositol	  1,3-­‐bisphosphate	  	  (IP2),	  which	  is	  derived	  from	  the	  	  breakdown	  of	  PI4,5P2	  	  into	  	  





FIGURE	  1.1.	   	   	   The	   inositol	   biosynthetic	   pathway.	   Inositol	  biosynthesis	   is	   regulated	  by	  
two	  enzymes,	  myo-­‐inositol-­‐3-­‐phosphate	  synthase	  (MIPS),	  which	  converts	  G-­‐6-­‐P	  to	  I-­‐3-­‐P,	  
and	   inositol	   monophosphatase	   (IMPase),	   which	   dephosphorylates	   I-­‐3-­‐P	   to	   generate	  
myo-­‐inositol.	   Inositol	   is	   incorporated	   into	   phosphatidylinositol	   (PI),	   which	   is	   then	  
phosphorylated	   to	   generate	   four	   types	   of	   phosphoinositides	   in	   yeast	   and	   three	  
additional	   phosphoinositides	   in	   higher	   eukaryotes	   (PI5P,	   PI3,4P2,	   and	   PI3,4,5P3).	   The	  
phosphoinositide	   PI4,5P2	   is	   hydrolyzed	   by	   phospholipase	   C	   (PLC)	   to	   generate	   the	   two	  
signaling	  molecules	  DAG	  and	  IP3.	  IP3	  is	  either	  dephosphoylated	  to	  produce	  IP2	  and	  I-­‐3-­‐P,	  
or	  is	  further	  phosphorylated	  to	  produce	  a	  variety	  of	  inositol	  phosphates.	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diacylglycerol	   (DAG)	   and	   inositol	   1,4,5-­‐trisphosphate	   (IP3);	   and	   de	   novo	   biosynthesis	  
using	  glucose-­‐6-­‐phosphate	   (G-­‐6-­‐P)	  as	  a	   substrate.	  To	  maintain	   the	  homeostasis	  of	   this	  
essential	  metabolite,	  a	  high	  level	  of	  regulation	  is	  required.	  
	  
Regulation	  of	  inositol	  biosynthesis:	  
The	   enzyme	   responsible	   for	   the	   first	   and	   rate-­‐limiting	   step	   in	   inositol	   biosynthesis	   is	  
myo-­‐inositol	   3-­‐phosphate	   synthase	   (MIPS)	   (Fig.	   1.1),	   a	   highly	   conserved	   enzyme	   that	  
was	  isolated	  for	  the	  first	  time	  from	  rat	  testes	  by	  Maeda	  et	  al.	  (1980),	  and	  from	  yeast	  by	  
Donahue	   and	   Henry	   (1981).	   	   MIPS	   catalyzes	   the	   conversion	   of	   G-­‐6-­‐P	   to	   inositol-­‐3-­‐
phosphate	   (I-­‐3-­‐P)	   in	   a	   four-­‐step	   catalytic	   reaction	   using	   NAD+	   as	   a	   cofactor.	  
Subsequently,	   I-­‐3-­‐P	   is	   dephosphorylated	   by	   the	   enzyme	   inositol	   monophosphatase	  
(IMPase)	  to	  generate	  myo-­‐inositol.	  
INO1	   is	   the	   structural	   gene	   that	   encodes	   MIPS.	   It	   was	   identified	   and	  
characterized	  for	  the	  first	  time	  in	  S.	  cerevisiae	  (Donahue	  and	  Henry,	  1981).	  Since	  then,	  
over	  60	  INO1	  genes	  have	  been	  identified	  across	  the	  kingdom	  of	  life,	  including	  bacteria,	  
archaea,	  protozoa,	  fungi,	  plants,	  and	  animals.	  The	   INO1	  gene	  is	  tightly	  regulated	  by	   its	  
product,	   inositol.	   Under	   inositol-­‐limiting	   conditions,	   INO1	   is	   derepressed.	   The	  
transcription	  activators	  Ino2	  and	  Ino4	  form	  a	  dimer	  that	  binds	  to	  the	  inositol-­‐regulated	  
upstream	  activating	   sequence	   (UASINO)	   leading	   to	   the	   transcription	  of	   INO1.	  However,	  
when	   inositol	   is	   available,	   transcription	   of	   INO1	   is	   repressed.	   The	   negative	   regulator	  
Opi1	  translocates	  from	  the	  endoplasmic	  reticulum	  to	  the	  nucleus	  where	  it	  binds	  to	  Ino2,	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preventing	  activation	  by	  the	  Ino2-­‐Ino4	  dimer	  and,	  thus,	  repressing	  transcription	  of	  INO1	  
(Henry	  et	  al.,	  2012;	  White	  et	  al.,	  1991).	  	  
While	   transcriptional	   regulation	   of	   inositol	   biosynthesis	   has	   been	   extensively	  
studied	  and	  well	   characterized	   (Carman	  et	  al.,	  1999;	  Greenberg	  et	  al.,	  1996;	  Nunez	  et	  
al.,	   2006),	   regulation	   of	   inositol	   biosynthesis	   at	   the	   enzymatic	   level	   has	   not	   been	  
addressed.	   The	   studies	   in	   Chapter	   2	   show	   that	   both	   yeast	   and	   human	   MIPS	   are	  
phosphoproteins	   regulated	   by	   phosphorylation	   of	   at	   least	   three	   conserved	   residues.	  
This	  identifies	  phosphorylation	  as	  a	  novel	  regulatory	  mechanism	  of	  inositol	  biosynthesis,	  
suggesting	  that	  inositol	  homeostasis	  must	  be	  tightly	  controlled	  in	  eukaryotic	  cells.	  
Indeed,	  perturbation	  of	  inositol	  levels	  in	  brain	  has	  been	  associated	  with	  a	  variety	  
of	   mental	   and	   mood	   disorders,	   including	   BD	   (Belmaker,	   2004),	   Alzheimer’s	   disease	  
(McLaurin	   et	   al.,	   1998;	   Shimohama	   et	   al.,	   1998),	   and	   manic	   depressive	   psychosis	  
(Nahorski	  et	  al.,	  1991).	  As	  mentioned	  earlier,	  inositol	  depletion	  is	  a	  common	  outcome	  of	  
treatment	  with	  mood-­‐stabilizing	  drugs,	   including	   lithium	  and	  VPA.	  Lithium	   inhibits	   two	  
key	   inositol	   biosynthetic	   enzymes,	   IMPase	   (Fig.	   1.1),	   and	   inositol	   polyphosphate	  
phosphatase	   (IPPase),	   which	   dephosphorylates	   IP3	   and	   IP2	   to	   generate	   I-­‐3-­‐P	   (Hallcher	  
and	  Sherman,	  1980).	  VPA,	  in	  contrast,	  inhibits	  the	  enzyme	  MIPS	  leading	  to	  a	  decrease	  in	  
I-­‐3-­‐P	   and	   myo-­‐inositol	   (Shaltiel	   et	   al.,	   2004;	   Ju	   et	   al.,	   2004).	   The	   inositol	   depletion	  
hypothesis	  proposed	  in	  the	  1980s	  by	  Sir	  Michael	  Berridge	  and	  colleagues	  suggested	  that	  
the	  therapeutic	  effect	  of	  Li	  derives	  from	  inositol	  depletion,	  which	  leads	  to	  attenuation	  of	  
IP3	   -­‐mediated	   signaling	   (Berridge,	   1984;	   Berridge	   et	   al.,	   1989).	   Since	   then,	   numerous	  
studies	  have	  been	  done	  to	  identify	  the	  connection	  between	  decreased	  IP3	  signaling	  and	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the	  anticonvulsant	  and	  antimanic	  effects.	  However,	  it	  has	  not	  been	  possible	  to	  directly	  
correlate	   decreased	   IP3	   signaling	  with	   BD.	   This	   led	  many	   to	   argue	   against	   the	   inositol	  
depletion	  hypothesis.	  	  A	  counter-­‐argument	  is	  that	  Inositol	  depletion	  may	  have	  far	  more	  
consequences	  than	  decreased	  IP3	  signaling.	  In	  the	  following	  sections,	  I	  address	  some	  of	  
these	  possibilities.	  
	  
What	  are	  the	  cellular	  consequences	  of	  inositol	  depletion?	  
The	  significance	  of	  inositol	  for	  cell	  physiology	  is	  dramatically	  exemplified	  by	  the	  inositol-­‐
less	   death	   phenomenon	   first	   observed	   in	   yeast,	   in	  which	   cells	   starved	   for	   inositol	   die	  
rapidly	   within	   a	   few	   hours	   of	   starvation	   (Culbertson	   et	   al.,	   1975).	   Inositol	   depletion	  
elicits	   profound	   changes	   in	   lipid	   metabolism,	   alters	   cell	   signaling,	   and	   activates	  
numerous	  stress	  responses	  (Villa-­‐Garcia	  et	  al.,	  2011;	  Henry	  et	  al.,	  2014).	  
	  
Inositol	  depletion	  alters	  lipid	  metabolism:	  
Wild-­‐type	  yeast	  cells	  grown	  in	  inositol-­‐limiting	  conditions	  exhibit	  a	  4-­‐5	  fold	  decrease	  in	  
PI	   levels	   compared	   to	   cells	   grown	   in	   media	   supplemented	   with	   exogenous	   inositol	  
(Gaspar	  et	  al.,	  2006).	  Subsequently,	  this	  leads	  to	  changes	  in	  levels	  of	  phosphoinositides,	  
sphingolipids,	   and	  GPI	   (Jesch	   et	   al.,	   2010;	   Doering	   and	   Schekman,	   1996).	   	   Changes	   in	  
levels	  of	  ceramide	  have	  also	  been	  observed	  (Villa-­‐Garcia	  et	  al.,	  2011).	  Furthermore,	  an	  
increase	   in	   phosphatidic	   acid	   (PA),	   diacylglycerol	   (DAG),	   triacylglycerol	   (TAG),	   and	  
phosphatidylcholine	  (PC)	  in	  response	  to	  inositol	  depletion	  has	  been	  reported	  (Gaspar	  et	  
al.,	  2006).	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A	  more	  drastic	  effect	  of	  inositol	  depletion	  is	  observed	  in	  ino1Δ	  cells	  upon	  deprivation	  of	  
inositol.	  Starvation	  is	  induced	  in	  ino1Δ	  cells,	  which	  cannot	  make	  inositol,	  by	  preculturing	  
them	  in	   I+	  medium	  and	  then	  transferring	  them	  to	   I-­‐	  medium.	   	  A	  study	  by	  Henry	  et	  al.	  
(1977)	  showed	  that	  by	  the	  5th	  hour	  of	  starvation,	  only	  10%	  of	  cells	  survived.	  The	  rate	  of	  
PI	  synthesis	  dropped	  to	  less	  than	  10%	  within	  the	  first	  2	  hours	  after	  shifting	  the	  cells	  to	  
inositol-­‐free	  medium	  (Becker	  and	  Lester,	  1977).	  The	  decrease	  was	  initiated	  as	  early	  as	  2-­‐
25	  minutes	   following	   removal	  of	   inositol	   (Hanson	  and	   Lester,	   1980).	  A	  decrease	   in	  di-­‐	  
and	   tri-­‐phosphoinositides,	   inositol-­‐containing	   sphingolipids,	   and	   cell	   wall	   glycans	   was	  
also	  observed	  in	  the	  same	  study.	  Thus,	  inositol	  starvation	  clearly	  has	  a	  drastic	  impact	  on	  
cells.	  This	  may	  be	  caused	  by	   increased	  levels	  and	  accumulation	  of	  some	  lipids,	  such	  as	  
PC	   and	   TAG,	   or	   by	   the	   decrease	   in	   inositol	   phospholipids	   such	   as	   PI	   and	   other	  
phosphoinositides,	  which	  are	  indispensable	  mediators	  of	  signaling	  events,	  motility,	  and	  
membrane	  trafficking	  (Michell	  et	  al.,	  2006;	  Sbrissa	  et	  al.,	  2007).	  
The	  significance	  of	  phosphoinositides	  is	  underscored	  by	  the	  variety	  of	  roles	  they	  
play.	  PI4,5P2,	  predominantly	  found	  in	  the	  plasma	  membrane,	  serves	  as	  the	  precursor	  for	  
IP3	  and	  DAG	  and	  is	  involved	  in	  the	  regulation	  of	  actin	  cytoskeleton	  organization,	  and	  in	  
the	  cell	  wall	  integrity	  and	  heat	  shock	  response	  pathways	  (Di	  Paolo	  and	  Di	  Camilli,	  2000;	  
Audhya	  and	  Emr,	  2002;	  Levin,	  2011).	  PI4P,	   found	   in	   the	  Golgi	   complex,	  plays	  a	   role	   in	  
vesicular	   trafficking	   of	   secretory	   proteins	   (Hama	   et	   al.,	   1999;	   D’Angelo	   et	   al.,	   2008).	  	  
PI3P,	   predominantly	   found	   in	   late	   endosomes	   and	   multivesicular	   bodies	   (MVB),	   is	  
involved	  in	  endosomal	  and	  vesicular	  trafficking	  (Herman	  and	  Emr,	  1990;	  Odorizzi	  et	  al.,	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2000).	   PI3,5P2,,	   the	   most	   recently	   identified	   phosphoinositide,	   is	   associated	  
predominantly	  with	   the	  vacuolar	  membrane	   (Yamamoto	  et	  al.,	  1995).	  Despite	   the	   low	  
abundance	   of	   this	   phosphoinositide,	   it	   is	   involved	   in	   numerous	   functions	   in	   the	   cell,	  
including	   control	   of	   endolysosomal	   vesicular	   trafficking,	   control	   of	   ion	   channels	   and	  
pumps	   (Michell,	   2013),	   and	   the	  most	   recently	  discovered	   role	   is	   the	   regulation	  of	   key	  
genes	   involved	   in	   the	   metabolic	   switch	   from	   glycolysis	   to	   gluconeogenesis	   (Han	   and	  
Emr,	  2013).	  	  
The	  phosphoinositides	  PI3,4P2	  	  and	  PI3,4,5P3	  (PIP3),	   	   found	  in	  higher	  eukaryotes,	  	  
activate	   a	   wide	   range	   of	   effector	   proteins	   by	   targeting	   them	   to	   specific	   membrane	  
locations,	  where	  they	  activate	  signal	  transduction	  pathways	  (Dowler	  et	  al.,	  2000;	  Mora	  
et	  al.,	  2004).	  PIP3	  signaling	  plays	  a	  role	  in	  synaptic	  transmission	  (Xu	  et	  al.,	  2007),	  axonal	  
guidance	  (Chadborn	  et	  al.,	  2006),	  and	  synaptogenesis	  (Martin-­‐Pena	  et	  al.,	  2006).	  Thus,	  
the	   wide	   range	   of	   roles	   played	   by	   phosphoinositides	   suggests	   that	   inositol	   depletion	  
may	   have	   far	   reaching	   consequences.	   For	   example,	   decreased	   PIP3	   production	   in	  
response	   to	   Li	   and	  VPA	  causes	  an	   increase	   in	   the	   size	  and	   spread	  of	  neuronal	   growth	  
cones	   needed	   for	   the	   formation	   of	   synaptic	   trees	   (Williams	   et	   al.,	   2002).	   Reduced	  
phosphoinositide	  synthesis	  in	  response	  to	  VPA	  is	  suggested	  to	  have	  a	  therapeutic	  role	  in	  
treatment	  of	  epilepsy	  (Chang	  et	  al.,	  2011).	  This	   is	  consistent	  with	  the	  observation	  that	  
phosphoinositide	   production	   is	   increased	   during	   seizures	   (Van	   Rooijen	   et	   al.,	   1986;	  
Backman	  et	  al.,	  2001).	  
	  
	  
	  	  	  	  
	  
10	  
Inositol	  depletion	  alters	  signaling:	  
Inositol	   is	   essential	   for	   the	   production	   of	   several	   signaling	   molecules,	   including	   PIP3,	  
PI4,5P2,	  IP3,	  and	  DAG	  (King	  et	  al.,	  2009;	  Strahl	  and	  Thorner,	  2007).	  In	  response	  to	  stimuli,	  
phospholipase	  C	  (PLC)	  hydrolyzes	  PI4,5P2	  to	  generate	  IP3	  and	  DAG,	  which	  are	  important	  
for	  neuronal	  activity.	  Binding	  of	  IP3	  to	  its	  receptors	  triggers	  the	  release	  of	  Ca+2	  from	  the	  
ER	  (or	  from	  the	  vacuole	  in	  yeast)	  (Mikoshiba	  et	  al.,	  1993).	  DAG	  activates	  PKC	  and,	  along	  
with	  Ca+2,	  plays	  a	  role	  in	  regulating	  vesicle	  fusion	  and	  recycling	  (De	  Camilli	  et	  al.,	  1996).	  
Both	   VPA	   and	   Li	   lower	   the	   cellular	   concentration	   of	   IP3	   leading	   to	   attenuation	   of	   IP3	  
signaling	   (King	   et	   al.,	   2009).	   Tokuoka	   et	   al.	   (2008)	   showed	   that	   levels	   of	   IP3	   and	  DAG	  
were	   decreased	   in	   VPA-­‐treated	   Caenorhabditis	   elegans,	   and	   that	   three	   activities	  
regulated	   by	   IP3	   and	   DAG	   were	   inhibited	   in	   response	   to	   VPA	   treatment,	   including	  
ovulation,	  defecation,	  and	  acetylcholine	  release.	  	  
Phosphorylation	   of	   IP3	   generates	   a	   variety	   of	   inositol	   polyphosphates	   (IPs),	  
including	   IP4,	   IP5,	   IP6,	   or	   inositol	   pyrophosphates	   IP7	   and	   IP8.	   IPs	   are	   involved	   in	  
regulation	  of	  gene	  expression	  at	  the	  level	  of	  transcription,	  chromatin	  remodeling,	  mRNA	  
editing	  and	  mRNA	  export	  from	  the	  nucleus	  (Alcazar-­‐Roman	  and	  Wente,	  2008).	  IP4	  	  and	  
IP5	  	  increase	  expression	  of	   INO1	   by	  activating	   the	  SWI/SNF	   complex,	  while	   IP6	   reduces	  
expression	  of	   INO1	  by	   inhibiting	  nucleosome	  mobilization	   (Rando	  et	  al.,	  2003;	  Shen	  et	  
al.,	  2003;	  Steger	  et	  al.,	  2003;	  Ye	  et	  al.,	  2013).	  Inositol	  pyrophosphates	  are	  distinguished	  
by	   their	   high	   energy	   bonds.	   In	   addition,	   they	   are	   able	   to	   directly	   phosphorylate	  
prephosphorylated	  proteins	   in	   an	  ATP-­‐independent	  manner	   (Burton	  et	   al.,	   2009).	   It	   is	  
very	  likely	  that	  a	  reduction	  in	  IP3	  levels	  caused	  by	  VPA	  would	  alter	  levels	  of	  other	  inositol	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phosphates	  derived	  from	  IP3.	  Thus	  a	  wide	  range	  of	  cellular	  processes	  may	  be	  affected	  by	  
VPA	  treatment.	  
	  
Inositol	  depletion	  activates	  stress	  response	  pathways:	  
Inositol	  limitation	  is	  a	  stress-­‐inducing	  growth	  condition.	  The	  unfolded	  protein	  response	  
(UPR)	   pathway	   is	   a	   highly	   conserved	   ER-­‐associated	   stress	   response	   pathway	   that	  
functions	  to	  protect	  cells	  from	  the	  deleterious	  accumulation	  of	  misfolded	  proteins	  (Cox	  
and	   Walter,	   1996;	   Cox	   et	   al.,	   1997).	   Jesch	   et	   al.	   (2006)	   showed	   that	   cells	   grown	   in	  
inositol-­‐limiting	   conditions	   induced	   the	  UPR	   pathway.	   However,	   unfolded	   proteins	   do	  
not	  build	  up	   in	   the	  ER	  of	   inositol-­‐starved	  cells	   (Jesch	  et	  al.,	  2006).	  This	   suggested	   that	  
inositol	  starvation	  may	  trigger	  stress	  by	  causing	  ER-­‐membrane	  lipid	  aberrations	  that,	  in	  
turn,	   induce	   the	   UPR	   (Henry	   et	   al.,	   2014).	   An	   alternative	   possibility	   whereby	   inositol	  
depletion	   may	   induce	   ER	   stress	   is	   through	   secretory	   stress	   caused	   by	   defective	  
membrane	   trafficking	   (Chang	   et	   al.,	   2002).	   Several	   lines	   of	   evidence	   support	   the	  
involvement	   of	   UPR	   dysfunction	   in	   the	   pathophysiology	   of	   BD.	   Hayashi	   et	   al.	   (2009)	  
showed	  that	  the	  ER-­‐stress	  response	  is	  impaired	  in	  lymphoblastoid	  cell	  lines	  derived	  from	  
BD	  patients.	  The	  study	  by	  Konradi	  et	  al.	  (2004)	  indicated	  that	  expression	  of	  genes	  coding	  
for	   proteins	   of	   the	   ubiquitin-­‐proteasome	   system	   is	   greatly	   decreased	   in	   the	  
hippocampus	  of	  BD	  patients.	  One	  interpretation	  of	  these	  findings	  is	  that	  the	  therapeutic	  
benefits	  of	  inositol	  depletion	  induced	  by	  anti-­‐bipolar	  drugs	  may	  derive	  from	  induction	  of	  
the	  UPR	  and/or	  proteasome	  degradation.	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Another	   stress	   response	   induced	   by	   inositol	   starvation	   is	   the	   highly	   conserved	  
protein	   kinase	  C-­‐MAP	   kinase	   cell	  wall	   integrity	   (PKC-­‐CWI)	   pathway.	   Inositol	   starvation	  
activates	   this	   pathway	   in	   actively	   dividing	   cells,	   leading	   to	   upregulation	   of	   genes	  
involved	   in	  cell	  wall	  biogenesis	   (Nunez	  et	  al.,	  2008).	  The	  PKC-­‐CWI	  pathway	   is	  essential	  
for	   maintaining	   lipid	   homeostasis,	   especially	   when	   cell	   are	   grown	   in	   the	   absence	   of	  
inositol,	   a	   condition	   that	   leads	   to	   accumulation	   of	   PC,	   TAG,	   and	   DAG	   (Gaspar	   et	   al.,	  
2006).	  Mutants	   defective	   in	   the	   PKC-­‐CWI	   pathway	   show	  much	   higher	   levels	   of	   these	  
phospholipids,	  suggesting	  that	  activation	  of	  this	  pathway	  is	  essential	  for	  protecting	  the	  
cell	  against	  damaging	  effects	  that	  may	  be	  caused	  by	  inositol	  depletion.	  
	  
Inositol	  depletion	  and	  mitochondrial	  dysfunction	  
Mitochondrial	  dysfunction	  has	  been	  implicated	  in	  BD	  based	  on	  the	  findings	  of	  impaired	  
oxidative	  phosphorylation,	  decreased	   intracellular	  pH,	  and	   increased	   level	  of	   lactate	   in	  
the	  brains	  of	  BD	  patients	  (Stork	  and	  Renshaw,	  2005;	  Hamakawa	  et	  al.,	  2004;	  Kato	  and	  
Kato,	   2000;	   Regenold	   et	   al.,	   2009).	   Neural	   mitochondria	   play	   an	   important	   role	   in	  
apoptosis	  and	   in	  the	  regulation	  of	   intracellular	  calcium,	  which	   is	  ultimately	  needed	  for	  
the	  release	  of	  neurotransmitters.	  Further	  evidence	  for	  mitochondrial	  dysfunction	  in	  BD	  
comes	   from	   gene	   array	   analysis	   of	   expression	   of	   12,558	   nuclear	   genes	   in	   the	  
hippocampus	  of	  healthy	   individuals,	  patients	  with	  BD,	  and	  patients	  with	  schizophrenia	  
(Konardi	  et	  al.,	  2004).	  This	  study	  identified	  43	  genes	  that	  exhibited	  decreased	  expression	  
in	   BD	   but	   not	   in	   schizophrenia	   or	   healthy	   controls.	   Of	   these,	   18	   genes	   coded	   for	  
mitochondrial	   proteins.	   Stork	   and	   Renshaw	   (2005)	   suggested	   that	   impaired	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phospholipid	   metabolism	   in	   BD,	   as	   perceived	   by	   alteration	   in	   levels	   of	   choline,	  myo-­‐
inositol,	   inositol	  monophosphates,	  and	  phosphomonoesters	  (PMEs),	   is	  the	  direct	  result	  
of	  energy	  shortages	  caused	  by	  mitochondrial	  dysfunction	  (Stork	  and	  Renshaw,	  2005).	  A	  
study	  carried	  out	  by	  Ju	  and	  Greenberg	  (2004)	  indicated	  that	  inositol	  depletion	  in	  yeast	  
caused	   by	   VPA	   led	   to	   an	   increase	   in	   the	   level	   of	   the	   mitochondrial	   phospholipid,	  
cardiolipin.	  It	  is	  tempting	  to	  speculate	  that	  the	  therapeutic	  role	  of	  VPA	  may	  derive	  from	  
improved	  mitochondrial	  function	  as	  a	  result	  of	  increased	  cardiolipin	  levels.	  	  
	  
VPA	  causes	  inositol	  depletion:	  
The	   first	   demonstration	   that	  VPA	   causes	   inositol	   depletion	  was	   shown	  using	   rat	   brain	  
(O’Donnell	  et	  al.	  2000).	  	  A	  subsequent	  study	  showed	  that	  VPA	  causes	  a	  20%	  reduction	  of	  
inositol	  in	  mouse	  frontal	  cortex	  where	  the	  decrease	  was	  due	  to	  inhibition	  of	  the	  inositol-­‐
synthesizing	  enzyme,	  MIPS	  (Shaltiel	  et	  al.,	  2004).	  Decreased	  inositol	  and	  MIPS	  activity	  in	  
response	   to	  VPA-­‐treatment	  was	  also	  observed	   in	   the	  yeast	  S.	   cerevisiae	   (Vaden	  et	  al.,	  
2001;	   Ju	  et	   al.,	   2004).	   In	   vitro	   studies	   showed	   that	  VPA	  does	  not	  affect	  MIPS	  directly,	  
suggesting	  that	  other	  factors	  or	  regulators	  are	  involved	  in	  the	  inhibition	  (Ju	  et	  al.,	  2004).	  	  
In	   Chapter	   2,	   I	   show	   that	   VPA	   inhibits	   MIPS	   by	   increasing	   its	   phosphorylation.	   The	  
implications	   of	   decreased	   inositol	   biosynthesis	   in	   response	   to	   VPA	   treatment	   are	   far	  
reaching	  because	  of	  the	  numerous	  roles	  played	  by	  inositol-­‐containing	  compounds.	  It	   is	  
likely	  that	  more	  than	  one	  mechanism	  pertaining	  to	  inositol	  depletion	  may	  contribute	  to	  
the	  therapeutic	  efficacy	  of	  this	  drug	  in	  the	  treatment	  of	  BD.	   	   In	  Chapter	  3,	   I	  show	  that	  
VPA	  perturbs	  the	  V-­‐ATPase	  and	  alters	  the	  dynamics	  of	  PI3,5P2,	  and	  in	  Chapter	  4	  I	  show	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that	   VPA	   perturbs	   endocytic	   trafficking.	   This	   suggests	   that	   the	   effect	   of	   VPA	  may	   be	  
multi-­‐faceted,	  taking	  into	  consideration	  that	  factors	  other	  than	  inositol	  may	  contribute	  
to	  the	  effects	  caused	  by	  VPA.	  	  
	  
VPA	  potentiates	  an	  inhibitory	  GABA-­‐dependent	  response:	  
	  Several	   studies	   have	   shown	   that	   VPA	   dampens	   neuronal	   excitability	   by	   potentiating	  
GABA-­‐mediated	   postsynaptic	   inhibition	   (Loscher,	   1999),	   an	   effect	   that	   could	  mitigate	  
the	  manic	   episodes.	   However,	   it	   is	   not	   clear	   how	   this	   effect	   is	   achieved.	  While	   some	  
studies	  show	  that	  VPA	  increases	  the	  levels	  of	  the	  inhibitory	  neurotransmitter	  (Czapinski	  
et	  al.,	  2005;	  Loscher	  and	  Schmidt,	  1980;	  Patsalos	  et	  al.,	  1981),	  other	  studies	  show	  that	  
VPA	   elicits	   its	   effect	   by	   modulating	   the	   response	   of	   the	   postsynaptic	   neurons	  
(Cunningham	  et	   al.	   2003).	   VPA	  has	   also	   been	   shown	   to	  modulate	   gene	   expression	   by	  
inhibiting	   histone	   deacetylases	   (HDACs)	   (Phiel	   et	   al.,	   2001)	   and	   by	   activating	   AP-­‐1	  
transcription	   factors	   (Chen	   et	   al.,	   1999).	   HDAC-­‐mediated	   regulation	   of	   the	   GABA	  
synthetic	  enzyme,	  glutamate	  decarboxylase,	  has	  been	  associated	  with	  the	  antiepileptic	  
effect	  of	  VPA	  (Nalivaeva	  et	  al.,	  2009).	  	  
	  
VPA	  inhibits	  glycogen	  synthase	  kinase	  (GSK3)	  
	  VPA	  has	  been	   implicated	   in	   the	   inhibition	  of	  GSK3,	  a	  ubiquitous	  kinase	   that	   regulates	  
many	   processes	   and	   is	   involved	   in	   signaling,	   cell	   cycle	   progression,	   and	   cell	   survival	  
(Grimes	   et	   al.,	   2001).	   Inhibition	   of	   GSK3-­‐ß	   has	   been	   shown	   to	   protect	   neurons	   from	  
programmed	   cell	   death	   (Hetman	   et	   al.,	   2000).	   This	   is	   consistent	   with	   the	   observed	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neuroprotective	  effects	  of	  VPA.	  Furthermore,	  VPA	  was	  shown	  to	  protect	  cells	   from	  ER	  
stress	  by	  inhibiting	  GSK3-­‐ß	  (Kim	  et	  al.,	  2005).	  The	  reports	  regarding	  the	  effect	  of	  VPA	  on	  
GSK3	   are	   controversial.	   Several	   studies	   have	   shown	   that	   VPA	   directly	   inhibits	   GSK3-­‐ß	  
(Chen	  et	  al.,	  1999;	  De	  Sarno	  et	  al.,	  2002;	  Grimes	  et	  al.,	  2001;	  Kim	  et	  al.,	  2005).	  	  Others	  
report	  no	  inhibition	  of	  GSK3-­‐ß	  by	  VPA	  (Phiel	  et	  al.,	  2001).	  The	  studies	  in	  Chapter	  3	  show	  
that	   one	   of	   the	   three	   phosphosites	   identified	   in	   MIPS,	   S296,	   is	   in	   a	   potential	   GSK3	  
recognition	   sequence.	  Mutating	   this	   residue	   caused	   a	   decrease	   in	   the	   activity	   of	   the	  
enzyme.	   Furthermore,	   dephosphorylation	   of	   a	   mutated	   MIPS,	   with	   an	   intact	   S296,	  
caused	  a	  decrease	   in	  activity,	   suggesting	   that	   this	   residue	   is	  part	  of	  an	  activation	   site,	  
and	  that	  GSK3	  may	  be	  the	  activator.	  If	  VPA	  indeed	  inhibits	  GSK3,	  this	  could	  explain	  the	  
decrease	  in	  MIPS	  activity	  observed	  in	  cells	  that	  are	  treated	  with	  VPA.	  
	  
VPA	  inhibits	  protein	  kinase	  C	  (PKC):	  
VPA	  induces	  alterations	  in	  PKC	  activity	  (Manji	  et	  al.,	  2001).	  In	  S.	  cerevisiae,	  there	  is	  only	  
one	  PKC	  (Pkc1),	  while	  in	  humans,	  there	  are	  15	  different	  PKC	  isozymes	  comprising	  three	  
groups	  based	  on	  their	   requirement	   for	  activation	  by	  DAG	  and	  Ca+2	  (Mellor	  and	  Parker,	  
1998).	   PKCs	   are	   serine/threonine	   protein	   kinases	   that	   phosphorylate	   a	   variety	   of	  
proteins,	   including	   neurotransmitter	   receptors,	   transcriptional	   factors,	   signaling	  
molecules,	  and	  cytoskeletal	  proteins.	  In	  rat	  C6	  glioma	  cells,	  chronic	  exposure	  to	  VPA	  was	  
found	   to	   decrease	   PKC	   activity	   in	   membrane	   and	   cytosolic	   fractions,	   specifically	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inhibiting	   the	   isozymes	   PKC-­‐α	   and	   PKC-­‐ε	   (Chen	   et	   al.,	   1994),	   suggesting	   that	   this	  
inhibition	  may	  play	  a	  role	  in	  the	  antimanic	  effects	  of	  VPA.	  	  
Interestingly,	   PKC-­‐ε	   regulates	   GABAA	   receptor	   trafficking	   (Chou	   et	   al.,	   2010).	  
Phosphorylation	  of	  the	  receptors	  by	  PKC	   is	  a	  prerequisite	  for	  successful	   internalization	  
and	   trafficking	   of	   those	   receptors	   (Brandon	   et	   al.,	   2000).	   Furthermore,	   gephyrin,	   a	  
synaptogenic	  molecule	   that	   regulates	  GABAergic	   synaptic	   plasticity,	   is	   phosphorylated	  
by	  GSK3-­‐β	  (Tyagarajan	  et	  al.,	  2010).	  Phosphorylation	  of	  dynamin	  by	  GSK3-­‐β	   is	  required	  
for	   activity-­‐dependent	   bulk	   endocytosis	   of	   synaptic	   vesicles	   (Clayton	   et	   al.,	   2010).	  
Delayed	  trafficking	  of	  GABAA	  receptors	  may	  be	  an	  outcome	  of	  the	  effect	  of	  VPA	  on	  PKC	  
and	   GSK3.	   In	   Chapter	   4,	   I	   propose	   a	   new	   mechanism	   whereby	   VPA	   may	   elicit	   its	  
GABAergic	   inhibitory	  effect.	  My	  finding	  that	  VPA	  slows	  the	  endocytic	  process	  suggests	  
that	  VPA	  may	  be	  responsible	  for	  decreasing	  the	  internalization	  of	  the	  GABAA	  receptors,	  
prolonging	  their	  exposure	  to	  the	  inhibitory	  effect	  of	  GABA.	  	  
	  
VPA	  inhibits	  histone	  deacetylases	  (HDACs):	  
VPA	   is	   a	   histone	   deacetylase	   (HDAC)	   inhibitor	   that	   causes	   hyperacetylation	   of	   genes	  
(Phiel	  et	  al.,	  2001;	  Yildirim	  et	  al.,	  2003).	  Histone	  acetylation	   is	  an	   important	  regulatory	  
mechanism	  that	  controls	  about	  2%	  of	  transcribed	  genes,	  many	  of	  which	  regulate	  the	  cell	  
cycle	  and	  cellular	  differentiation	  (Van	  Lint	  et	  al.,	  1996).	  The	  finding	  that	  VPA	  is	  an	  HDAC	  
inhibitor	  prompted	  many	  to	  attribute	  the	  therapeutic	  effects	  of	  VPA	  to	  changes	  in	  gene	  
expression.	   For	   example,	   Akt	   activation	   by	   VPA	   has	   been	   associated	   with	   HDAC	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inhibition	   (De	   Sarno	   et	   al.,	   2002).	  Many	   of	   the	   side	   effects	   caused	   by	   VPA,	   including	  
teratogenicity	  and	  hepatotoxicity,	  have	  been	  linked	  to	  HDAC	  inhibition	  as	  well	  (Gurvich	  
et	  al.,	  2004).	  
In	   studies	   to	   identify	   the	  molecular	  mechanism	   that	   underlies	   the	   therapeutic	  
efficacy	   of	   VPA,	   many	   molecular	   targets	   and	   pathways	   affected	   by	   VPA	   have	   been	  
identified.	  This	  prompted	  use	  of	  this	  drug	  for	  the	  treatment	  of	  other	  diseases.	  The	  anti-­‐
proliferative	  effects	  of	  VPA	  and	  its	  ability	  to	  inhibit	  angiogenesis	  (Michaelis	  et	  al.,	  2004)	  
have	  led	  to	  its	  use	  as	  a	  chemotherapeutic	  agent	  in	  cancer	  treatment	  (Blaheta	  and	  Cinatl,	  
2002;	   Blaheta	   et	   al.,	   2005;	   Kuendgen	   and	   Gattermann,	   2007).	   The	   neuroprotective	  
effect	  of	  VPA	  suggests	  that	  it	  may	  be	  useful	  in	  treatment	  of	  Alzheimer’s	  disease	  (Tariot	  
et	  al.,	  2002),	  while	   its	  HDAC	   inhibitory	  effect	  prompted	  trials	   for	  HIV	  elimination	   from	  
resting	  CD4+	  T-­‐cells	  (Lehrman	  et	  al.,	  2005).	  	  
Currently,	   VPA	   is	   one	   of	   the	  most	   commonly	   used	   drugs	   for	   the	   treatment	   of	  
epilepsy,	  BD,	  and	  migraine	  (Calabresi	  et	  al.,	  2007;	  Macritchie	  et	  al.,	  2003),	  however,	  less	  
than	  50%	  of	  patients	  respond	  effectively	  to	  this	  drug.	  Furthermore,	  VPA	  causes	  severe	  
side	   effects,	   including	   hepatotoxicity	   (Powell-­‐Jackson	   et	   al.,	   1984)	   and	   teratogenicity	  
(Brown	   et	   al.,	   1985).	   It	   also	   induces	  weight	   gain	   and	   alopecia	   (Terbach	   and	  Williams,	  
2009).	   For	   treatment	   to	   be	   effective,	   intake	   cannot	   be	   interrupted.	   Elucidating	   the	  
therapeutic	  mechanism	  of	  action	  of	  VPA	  will	  not	  only	  enable	  the	  development	  of	  better	  
drugs	  with	  fewer	  side	  effects	  and	  increased	  effectiveness,	  but	  will	  also	  shed	  light	  on	  the	  
pathophysiology	  of	  BD.	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Yeast	  as	  a	  model	  system:	  	  
The	  yeast	  Saccharomyces	  cerevisiae	  offers	  many	  advantages	  as	  a	  model	  to	  elucidate	  the	  
mechanism	  of	  action	  of	  VPA.	  The	  relevance	  of	  the	  yeast	  model	  to	  neurological	  human	  
disorders	   is	   underscored	   by	   the	   fact	   that	   at	   least	   60%	   of	   yeast	   genes	   have	   human	  
homologs,	   and	  more	   than	   25%	   of	   cloned	   human	   disease	   genes	   have	   yeast	   homologs	  
(Khurana	   and	   Lindquist,	   2010).	   In	   addition,	   several	   cell	   biological	   processes,	   including	  
membrane	   trafficking,	   cell	   signaling,	   and	   inositol	   and	   lipid	   metabolism,	   are	   highly	  
conserved	  between	  yeast	  and	  mammalian	  cells.	   	  A	  great	  advantage	  to	  this	  study	  is	  the	  
availability	   of	   viable	   yeast	   deletion	   mutants,	   especially	   for	   the	   inositol	   biosynthetic	  
pathway.	   The	   ino1Δ	   mutant,	   for	   example,	   has	   been	   instrumental	   in	   elucidating	   the	  
cellular	   consequences	   of	   inositol	   depletion	   and,	   furthermore,	   in	   determining	   the	  
functional	  relevance	  of	  the	  phosphosite	  mutations	  for	  the	  activity	  of	  MIPS	  from	  yeast	  as	  
well	  as	  human	  cells.	  Another	  advantage	  offered	  by	  yeast	   is	  the	  availability	  of	  viable	  V-­‐
ATPase	  deletion	  mutants	   (vma	  mutants),	  as	   inactivation	  of	   the	  ubiquitous	  V-­‐ATPase	   is	  
lethal	  in	  all	  organisms	  except	  fungi	  (Li	  and	  Kane,	  2009).	  This	  makes	  yeast	  an	  invaluable	  
model	  for	  the	  study	  of	  drugs	  or	  mechanisms	  that	  perturb	  the	  activity	  of	  the	  V-­‐ATPase.	  	  
	   Although	  the	  use	  of	  yeast	  provides	  many	  advantages,	  including	  ease	  of	  handling,	  
short	  generation	  time,	  and	  genetic	  tractability,	  there	  are	  some	  limitations	  to	  its	  use.	  	  For	  
example,	  because	  of	  the	  unicellular	  nature	  of	  yeast,	  VPA-­‐treatment	  effects	  that	  rely	  on	  
multicellularity	   and	   cell-­‐cell	   interactions	   may	   be	   obscured	   and	   may	   go	   undetected.	  
Furthermore,	   the	   drug	   may	   perturb	   a	   cellular	   specialization	   in	   mammalian	   cells	   for	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which	  there	  is	  no	  homology	  in	  yeast.	  Therefore,	  a	  complementary	  approach	  using	  more	  
than	  one	  model	  system	  provides	  an	  ideal	  option	  for	  studies	  to	  elucidate	  the	  mechanism	  
whereby	  VPA	  elicits	  its	  effect.	  
	  
Project	  outline:	  
The	  two	  main	  objectives	  of	   the	  studies	  described	   in	   this	   thesis	  were	   to	  1)	   identify	   the	  
mechanism	  whereby	   VPA	   causes	   inositol	   depletion,	   and	   2)	   identify	  molecular	   targets	  
and	  cellular	  consequences	  of	  inositol	  depletion	  that	  arise	  from	  VPA-­‐treatment.	  
The	  studies	  described	   in	  Chapter	  2	   identify	  phosphorylation	  of	  the	  rate-­‐limiting	  
enzyme	  of	  de	  novo	  inositol	  synthesis,	  MIPS,	  as	  a	  novel	  regulatory	  mechanism	  of	  inositol	  
biosynthesis.	   This	   is	   the	   first	   demonstration	   that	   both	   yeast	   and	   human	   MIPS	   are	  
regulated	  at	  the	  post-­‐translational	  level.	  	  The	  finding	  that	  MIPS	  is	  a	  phosphoprotein	  was	  
based	  on	  the	  observation	  that	  MIPS	  purified	  from	  VPA-­‐treated	  cells	  shows	  a	  higher	  level	  
of	   phosphorylation	   compared	   to	  MIPS	   purified	   from	  untreated	   cells.	   Three	   conserved	  
phosphosites	  were	  identified,	  including	  two	  in	  the	  NAD+	  binding	  domain	  and	  one	  in	  the	  
catalytic	   domain.	   Of	   the	   three	   phosphosites	   identified,	   two	   are	   inhibitory	   when	  
phosphorylated,	  and	  one	  is	  a	  potential	  activation	  site.	  The	  finding	  that	  the	  elimination	  of	  
the	   two	   inhibitory	   residues	   confers	   resistance	   to	   VPA	   suggests	   that	   VPA-­‐mediated	  
inositol	  depletion	  may	  result	  from	  phosphorylation	  of	  MIPS.	  
The	  studies	   in	  Chapter	  3	  show	  that	  VPA	  treatment	  and	  inositol	  depletion	  cause	  
perturbation	   of	   the	   vacuolar	   ATPase.	   Both	   proton	   pumping	   carried	   out	   by	   the	  
membrane	  embedded	  V0	  sector	  and	  ATP	  hydrolysis	  carried	  out	  by	  the	  cytosolic	  V1	  sector	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are	   decreased.	   Inositol	   supplementation	   rescues	   the	   pumping	   defect	   of	   the	   V-­‐ATPase	  
but	  not	  the	  activity.	  Furthermore,	  VPA	  perturbs	  the	  synthesis	  of	  PI3,5P2,	   the	  signature	  
phosphoinositide	   of	   the	   vacuole,	   inhibits	   vacuole	   fission,	   and	   leads	   to	   vacuolar	  
enlargement.	  These	  findings	  suggest	  that	   inositol	  depletion	  caused	  by	  VPA	  results	   in	  a	  
decrease	  in	  PI3,5P2,	  destabilizing	  the	  membrane	  embedded	  V0	  sector	  of	  the	  	  V-­‐ATPase.	  	  
Chapter	   4	   describes	   a	   cDNA	   library	   screen	   to	   identify	   novel	   pathways	   and	  
processes	  affected	  by	  VPA.	  The	   studies	   show	   that	  VPA	  decreases	  endocytosis	   in	  yeast	  
and	  human	  cells,	  most	   likely	  due	   to	  perturbation	  of	  PI4,5P2	   in	   the	  plasma	  membrane.	  
VPA	  also	  inhibits	  the	  PKC-­‐CWI	  pathway,	  suggesting	  that	  the	  drug	  may	  inhibit	  the	  kinase	  
PKC	  in	  yeast.	  This	  possibility	  is	  exciting	  because	  VPA	  has	  been	  shown	  to	  inhibit	  PKCα	  and	  
ε	   in	   mammalian	   cells,	   in	   which	   PKC	   is	   required	   for	   the	   internalization	   of	   the	   GABA	  
receptors.	  
Included	  in	  Chapter	  5	  are	  some	  questions	  that	  have	  emerged	  from	  this	  work	  and	  



















PHOSPHORYLATION	  OF	  MYO-­‐INOSITOL	  PHOSPHATE	  3-­‐SYNTHASE:	  A	  NOVEL	  
REGULATORY	  MECHANISM	  OF	  INOSITOL	  BIOSYNTHESIS	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Myo-­‐inositol-­‐3-­‐phosphate	  synthase	  (MIPS)	  is	  the	  enzyme	  responsible	  for	  the	  first	  
and	   rate-­‐limiting	   step	   of	   de	   novo	   synthesis	   of	   inositol.	   It	   catalyzes	   the	   conversion	   of	  
glucose-­‐6-­‐phosphate	  (G-­‐6-­‐P)	  to	  inositol	  3-­‐phosphate	  (I-­‐3-­‐P)	  in	  the	  cytosol	  in	  a	  four-­‐step	  
catalytic	   reaction	   using	   NAD+	   as	   a	   cofactor	   (Fig.	   2.1A).	   MIPS	   has	   been	   isolated	   from	  
bacteria	  (Bachhawat	  and	  Mande,	  1999),	  archaea	  (Chen	  et	  al.,	  2000),	  protozoa	  	  (Lohia	  et	  
al.,	   1999),	   plants	   (Loewus	   and	   Loewus,	   1971),	   and	   animals	   (Adhikari	   and	   Majumder,	  
1988;	  Maeda	  and	  Eisenberg,	  1980).	  In	  yeast,	  MIPS	  is	  encoded	  by	  the	  well	  characterized	  
INO1	  gene	  (Dean-­‐Johnson	  and	  Henry,	  1989);	   in	  mammals,	   it	   is	  encoded	  by	   ISYNA1	  and	  
exists	  as	  multiple	  isoforms	  (Guan	  et	  al.,	  2003;	  Seelan	  et	  al.,	  2009;	  Neelon	  et	  al.,	  2011).	  	  	  






FIGURE	   2.1.	   	   MIPS	   catalyzes	   the	   rate	   limiting	   step	   in	   inositol	   biosynthesis.	  A,	  MIPS,	  
encoded	   by	   INO1,	   catalyzes	   the	   first	   and	   limiting	   step	   in	   the	  de	   novo	   biosynthesis	   of	  
inositol.	  B,	  the	  three-­‐dimensional	  structure	  of	  yeast	  MIPS	  (Protein	  Data	  Bank	  code	  1P.1I)	  
(Jin	  and	  Geiger,	  2003).	  G-­‐6-­‐P,	  glucose	  6-­‐phosphate;	  I-­‐3-­‐P,	  inositol	  3-­‐phosphate.	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The	  crystal	  structure	  of	  yeast	  MIPS	  shows	  that	   it	   is	  a	  homotetramer	  (Fig.	  2.1B)	  (Geiger	  
and	  Jin,	  2006;	  Jin	  and	  Geoger,	  2003)	  while	  mammalian	  MIPS	  exists	  as	  a	  trimer	  (Maeda	  
and	  Eisenberg,	  1980).	  Each	  monomer	  has	  three	  major	  domains:	  a	  catalytic	  domain	  that	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
binds	  	  the	  substrate	  G-­‐6-­‐P,	  an	  NAD+	  binding	  domain,	  and	  a	  central	  domain,	  consisting	  of	  
the	  N-­‐	  and	  C-­‐termini,	  which	  stabilizes	  the	  two	  other	  domains	  (Stein	  and	  Geiger,	  2002).	  
Sequence	   analysis	   showed	   that	   the	   enzyme	   is	   highly	   conserved,	   with	   remarkable	  
conservation	   of	   the	   amino	   acid	   residues	   that	   are	   important	   for	   catalytic	   activity	  
(Majumder	  et	  al.,	  2003).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Maintaining	  inositol	  homeostasis	  is	  essential	  for	  cell	  physiology	  and	  viability.	  This	  
is	   clearly	  demonstrated	  by	   the	   inositol-­‐less	  death	  phenomenon,	   in	  which	  cells	   starved	  
for	  inositol	  die	  within	  a	  few	  hours	  of	  starvation	  (Culbertson	  and	  Henry,	  1975;	  Henry	  et	  
al.,	   1977;	   Becker	   and	   Lester,	   1977).	   Inositol	   depletion	   leads	   to	   various	   consequences	  
(Deranieh	   and	   Greenberg,	   2009).	   Growth	   in	   the	   absence	   of	   inositol	   elicits	   profound	  
changes	  in	  lipid	  metabolism,	  and	  activates	  numerous	  stress	  responses	  including	  the	  cell	  
wall	   integrity	  (CWI),	  and	  unfolded	  protein	  response	  (UPR)	  pathways	  (Villa-­‐Garcia	  et	  al.,	  
2011;	  Henry	  et	  al.,	  2014).	  	  
Although	  the	  regulation	  of	  inositol	  biosynthesis	  at	  the	  level	  of	  INO1	  transcription	  
has	   been	   extensively	   characterized	   (Greenberg	   and	   Lopes,	   1996;	   Carman	   and	   Henry,	  
1999;	   Nunez	   et	   al.,	   2006),	   the	   regulation	   of	  MIPS	   activity	   has	   not	   been	   studied.	   The	  
anticonvulsant	  drug	   valproate	   (VPA)	   induces	  depletion	  of	   inositol,	   and	  MIPS	  has	  been	  
suggested	  as	  a	  possible	  target	  of	  the	  drug	  (Ju	  et	  al.,	  2004;	  Shaltiel	  et	  al.,	  2004;	  Vaden	  et	  
al.,	   2001).	   The	   initial	   finding	   that	   VPA	   leads	   to	   a	   decrease	   in	   inositol-­‐3-­‐phosphate	   in	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yeast	   (Vaden	   et	   al.,	   2001)	   suggested	   that	   VPA	   inhibits	  MIPS	   activity.	   The	   subsequent	  
observation	   that	  VPA-­‐mediated	   inhibition	  was	   indirect	   (Ju	  et	  al.,	   2004)	   suggested	   that	  
MIPS	   is	   regulated	   post-­‐translationally.	   	   Phosphorylation	   controls	   the	   regulation	   and	  
localization	   of	   numerous	   enzymes,	   many	   of	   which,	   like	   MIPS,	   are	   transcriptionally	  
regulated	  by	  UASINO	  elements	  (Chang	  et	  al.,	  2007;	  Choi	  et	  al.,	  2010;	  Choi	  et	  al.,	  2011).	  	  
In	   this	  Chapter,	   I	   show	   that	  MIPS,	   from	  yeast	  and	  human	  cells,	   is	   regulated	  by	  
phosphorylation	  of	  at	   least	   three	  residues,	  one	   in	  the	  catalytic	  domain	  and	  two	   in	  the	  
NAD+	   binding	   domain,	   thus	   identifying	   a	   novel	   mechanism	   of	   regulation	   of	   inositol	  
biosynthesis.	   These	   sites	   are	   conserved	   in	   yeast	   and	   human	   MIPS,	   suggesting	   that	  
regulation	   by	   phosphorylation	   is	   a	   conserved	   regulatory	   mechanism	   of	   inositol	  
biosynthesis.	   I	   also	   show	   that	  mutation	   of	   the	   two	   inhibitory	   phosphosites,	   S184	   and	  
S374,	   leads	   to	   decreased	   sensitivity	   to	   VPA,	   suggesting	   that	   VPA	   may	   inhibit	   MIPS	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MATERIALS	  AND	  METHODS	  
	  
Strains,	  media,	  and	  growth	  conditions:	  
The	  Escherichia	  coli	  and	  Saccharomyces	  cerevisiae	  strains	  used	  in	  this	  work	  are	  listed	  in	  
Table	  2.1.	  Yeast	  cells	  were	  grown	  in	  synthetic	  minimal	  media	  containing	  2%	  glucose	  and	  
lacking	   inositol	   unless	   otherwise	   stated.	   Media	   were	   supplemented	   with	   the	   amino	  
acids	  histidine,	   leucine,	  methionine,	  and	   lysine,	  and	  the	  nucleobase	  uracil	  using	  Difco®	  
standard	   concentrations.	   For	   selection	   of	   cells	   carrying	   specific	   plasmids,	   appropriate	  
amino	   acids	   were	   omitted	   from	   the	   media.	   For	   overexpression	   purposes,	   induction	  
media	   contained	   2%	   galactose	   and	   1%	   raffinose	   with	   no	   glucose	   added.	   Where	  
indicated,	   VPA	   was	   used	   at	   a	   concentration	   of	   1	   mM,	   and	   inositol	   at	   75	  µM.	   	   Yeast	  
strains	  were	  grown	  at	  30°C.	  	  E.	  coli	  strain	  DH5α	  was	  used	  for	  plasmid	  maintenance	  and	  
amplifications.	   	   Bacteria	   were	   grown	   at	   37°C	   in	   LB	   medium	   (0.5%	   yeast	   extract,	   1%	  
tryptone,	   1%	  NaCl),	   supplemented	  with	   ampicillin	   (100	  µg/ml)	   for	   selection	  purposes.	  
For	  growth	  on	  plates,	  media	  were	  supplemented	  with	  1.5%	  and	  2%	  agar	  for	  E.	  coli	  and	  
yeast,	  respectively.	  Growth	  in	  liquid	  cultures	  was	  monitored	  spectrophotometrically	  by	  
measuring	  absorbance	  at	  550	  nm.	  
	  
DNA	  manipulations,	  PCR,	  and	  DNA	  sequencing:	  
Standard	  methods	   were	   followed	   for	   isolation	   of	   genomic	   DNA,	   plasmid	   purification,	  
digestion	  with	   restriction	  endonucleases,	  and	   ligation.	  Transformation	  of	  bacterial	  and	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yeast	  cells	  was	  carried	  out	  using	  electroporation	  (2.4	  V	  for	  bacteria,	  and	  1.4	  V	  for	  yeast).	  
All	   PCR	   reactions	   were	   optimized.	   DNA	   sequencing	   was	   carried	   out	   using	   ACGT	   Inc.	  
sequencing	  facility	  (Illinois).	  	  
	  
Construction	  of	  plasmids	  and	  expression	  of	  yeast	  and	  human	  MIPS	  in	  S.	  cerevisiae:	  	  
All	  plasmids	  and	  primers	  used	  in	  this	  work	  are	  listed	  in	  Tables	  2.2	  and	  2.3,	  respectively.	  
The	  INO1	  gene	  was	  amplified	  from	  S.	  cerevisiae	  genomic	  DNA	  using	  the	  primer	  pair	  5’-­‐
GTTGTCGGGTTCCTAATGTT-­‐3’	   and	   5’-­‐CAACAATCTCTCTTCGAATCT-­‐3’,	   and	   tagged	  with	   a	  
6xHis	  and	  an	  Xpress	  epitope	  on	  the	  N-­‐terminus	  using	  pRSETA	  as	  the	  source	  of	  the	  tag.	  
The	   tagged	   INO1	   was	   then	   subcloned	   into	   pYES6	   containing	   the	   blasticidin	   marker.	  	  
HindIII	   and	   Xho1	   were	   used	   to	   transfer	   the	   tagged	   INO1	   into	   pRD015	   to	   make	   the	  
pRDINO1	   construct,	   a	   high	   copy	   GAL1-­‐driven	   plasmid	   containing	   a	  URA3	   marker.	   All	  
subsequent	   manipulations	   and	   mutagenesis	   experiments	   utilizing	   yeast	   MIPS	   were	  
carried	  out	  using	  the	  pRDINO1	  vector.	  All	  mutations	  were	  confirmed	  by	  sequencing.	  The	  
low	   copy	   set	   of	   all	   mutants	   was	   prepared	   by	   transferring	   the	   mutated	   genes	   to	   the	  
centromeric	   low	   copy	   vector	   p415-­‐ADH	   purchased	   from	   ATCC.	   For	   human	  MIPS,	   the	  
human	   INO1	   gene	   (hINO1)	   was	   transferred	   from	   pRSETA-­‐hINO1	   (Ju	   et	   al.,	   2004)	   and	  
cloned	   into	   pRD015.	   All	   subsequent	   experiments	   for	   the	   human	   MIPS,	   including	  








Site	   mutations	   were	   constructed	   using	   a	   two-­‐step	   PCR	   protocol	   developed	   for	   this	  
study.	  For	  each	  mutation,	  two	  overlapping,	  non-­‐phosphorylated	  primers	  were	  designed.	  
Two	   PCR	   reactions	   were	   run	   simultaneously,	   using	   one	   primer	   in	   each	   reaction.	  
pRDINO1	   and	   pRDhINO1	   were	   used	   as	   templates	   for	   yeast	   MIPS	   and	   human	   MIPS,	  
respectively.	  The	  first	  PCR	  reaction	  was	  run	  for	  10	  cycles.	  The	  two	  samples	  from	  the	  first	  
PCR	  reaction	  were	  then	  pooled	  together,	  and	  the	  PCR	  reaction	  was	  resumed	  for	  another	  
20	  cycles.	  After	  cooling,	   ligase	  was	  added	  to	  the	  reaction	  mix	  and	  incubated	  for	  1	  h	  at	  
room	   temperature.	   Gel	   analysis	   was	   used	   to	   detect	   the	   presence	   of	   the	   amplified	  
plasmid.	   The	   parent	   strands	   were	   digested	   using	   Dpn1	   treatment	   for	   2	   h	   at	   37°C.	  
Transformation	   of	   competent	   E.	   coli	   cells	   was	   carried	   out	   using	   electroporation.	  
Selection	   was	   carried	   out	   on	   LB	   plates	   supplemented	   with	   ampicillin.	   Plasmids	   were	  
purified	  and	  all	  mutations	  were	  verified	  by	  sequencing	  using	  the	  ACGT	  Inc.	  sequencing	  
services.	   	   The	   constructs	   harboring	   the	  mutations	  were	   then	   used	   to	   transform	   yeast	  
ino1Δ	  cells.	  	  
	  
Purification	  of	  recombinant	  MIPS:	  
S.	  cerevisiae	  BY4741	  ino1∆	  mutant	  bearing	  the	  pRDINO1	  construct	  was	  used	  to	  express	  
the	   recombinant	   6xHis-­‐tagged	   MIPS.	   Cells	   were	   grown	   at	   30°C	   in	   synthetic	   minimal	  
medium	   lacking	   uracil.	   Galactose	   (2%)	   was	   used	   to	   induce	   overexpression	   of	   the	  
recombinant	   protein.	   Cell	   extracts	  were	   prepared	   by	   disrupting	   cells	  with	   glass	   beads	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(0.5	   mm	   diameter),	   vortexing	   for	   30	   min	   intermittently,	   keeping	   cells	   on	   ice.	   The	  
disruption	   buffer	   contained	   50	   mM	   Tris-­‐Cl	   (pH	   7.4)	   and	   300	   mM	   NaCl.	   A	   cocktail	   of	  
protease	  and	  phosphatase	  inhibitors	  was	  added	  to	  the	  disruption	  buffer	  before	  breaking	  
the	   cells.	  MIPS	  was	   purified	   using	   ProBond	   nickel-­‐chelating	   resin	   to	   bind	   the	   protein,	  
gently	  mixing	  at	  4°C	  for	  1	  h.	  The	  resin	  was	  washed	  twice	  with	  cold	  20	  mM	  then	  60	  mM	  
imidazole	   in	   Tris	   buffer	   (50	  mM	   Tris-­‐Cl	   (pH	   7.4)	   and	   300	  mM	  NaCl).	   The	   protein	  was	  
eluted	  with	  300	  mM	  imidazole	  in	  Tris	  buffer,	  dialyzed,	  concentrated,	  and	  resuspended	  in	  
(50	  mM	  Tris-­‐Cl,	  50	  mM	  NaCl,	  10	  mM	  DTT).	   	  Protein	  concentration	  was	  determined	  by	  
the	  Bradford	  method	  using	  bovine	  serum	  albumin	  as	  the	  standard.	  
	  
MIPS	  activity	  assay:	  
Purified	   MIPS	   enzyme	   activity	   was	   determined	   by	   the	   rapid	   colorimetric	   method	   of	  
Barnett	  et	  al.,	   (1970)	  with	  minor	  modifications.	  Purified	  protein	  was	  suspended	   in	   the	  
reaction	  buffer	  containing	  100	  mM	  Tris	  acetate	  (pH	  8.0),	  0.8	  mM	  NAD,	  2	  mM	  DTT,	  and	  
14	  mM	  NH4Cl.	  After	  addition	  of	  5	  mM	  G-­‐6-­‐P	   to	  a	   final	   volume	  of	  150	  µl,	   the	   reaction	  
mixture	  was	  incubated	  for	  1	  h	  at	  37°C.	  The	  reaction	  was	  terminated	  by	  the	  addition	  of	  
50	  µl	   of	   20%	   (w/v)	   trichloroacetic	   acid	   and	   kept	   on	   ice	   for	   10	  min.	   The	   precipitated	  
protein	  was	   removed	  by	   centrifugation.	   The	   supernatant	   (200	  µl)	  was	   incubated	  with	  
200	  µl	  of	  0.2	  M	  NaIO4	  for	  1	  h	  at	  37°C.	  This	  was	  followed	  by	  the	  addition	  of	  200	  µl	  of	  1	  M	  
Na2SO3	  to	  remove	  excess	  NaIO4.	  For	  the	  measurement	  of	  phosphate,	  a	  600	  µl	   reagent	  
mixture	   consisting	  of	   240	  µl	   of	  H2O,	   120	  µl	   of	   2.5%	  ammonium	  molybdate,	   120	  µl	   of	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10%	  ascorbic	   acid,	   and	  120	  µl	  of	  6	  N	   sulfuric	   acid	  was	  added	   to	   the	   reaction	  mix	  and	  
incubated	   for	   1	   h	   at	   37°C.	   Absorbance	   was	   measured	   at	   820	   nm,	   and	   activity	   was	  
determined	  by	  the	  amount	  of	   inorganic	  phosphate	   liberated.	  A	  unit	  of	  MIPS	  activity	   is	  
defined	   as	   the	   amount	   of	   enzyme	   that	   catalyzes	   the	   formation	   of	   1	   nmol	   of	  
phosphate/min.	  Specific	  activity	  is	  defined	  as	  units	  per	  mg	  of	  protein.	  	  
	  
Dephosphorylation	  of	  MIPS:	  
Dephosphorylation	  reactions	  were	  performed	  at	  37°C	  in	  a	  total	  volume	  of	  50	  µl	  for	  1	  h.	  
Ten	  µg	  of	  purified	  MIPS	  was	  gently	  mixed	  with	  Ni-­‐coated	  magnetic	  beads	  for	  1	  h	  at	  4°C.	  
The	   supernatant	   was	   aspirated,	   and	   the	   beads	   were	   resuspended	   in	   alkaline	  
phosphatase	  buffer	  consisting	  of	  50	  mM	  Tris-­‐HCl	  (pH	  8.0),	  100	  mM	  NaCl,	  10	  mM	  MgCl2,	  
and	   1	   mM	   dithiothreitol	   (DTT).	   Alkaline	   phosphatase	   (10	   units)	   was	   added	   and	   the	  
mixture	  was	  incubated	  at	  37°C	  for	  45	  min,	  after	  which	  orthovanadate	  was	  added	  to	  the	  
reaction	  mix	   to	   a	   final	   concentration	  of	   10	  mM	   to	   inactivate	   the	  AP.	   The	  beads	  were	  
then	  collected	  and	  washed	  3	   times	  with	  Tris	  purification	  buffer	   in	  preparation	   for	   the	  
MIPS	  assay.	  	  
	  
In	  vivo	  phosphorylation	  of	  MIPS:	  
Cells	  with	  recombinant	  MIPS	  were	  precultured	  in	  synthetic	  minimal	  medium,	  inoculated	  
to	  A550	  0.03	  in	  20	  ml	  phosphate-­‐free	  medium	  to	  which	  2	  mCi	  32Pi	  was	  added,	  and	  grown	  
to	   the	   early	   stationary	   phase	   with	   or	   without	   VPA.	   Cells	   were	   harvested	   by	  
	  	  	  	  
	  
30	  
centrifugation,	   washed	   with	   water,	   and	   disrupted	   with	   glass	   beads	   in	   100	   µl	   buffer	  
containing	   150	   mM	   NaCl,	   50	   mM	   Tris-­‐Cl	   (pH	   7.5),	   0.5%	   deoxycholate,	   0.1%	   SDS,	   1%	  
NP40,	   10	  mM	  NaF,	   5	  mM	  β-­‐glycerophosphate,	   1	  mM	  sodium	  vanadate,	   and	  protease	  
inhibitor	  cocktail.	  The	  cell	  extracts	  were	  precleaned	  with	  10	  µl	  protein	  G	  plus	  protein	  A	  
agarose	  for	  1	  h	  at	  4°C	  and	  incubated	  with	  2	  µg	  anti-­‐Xpress	  antibody,	  50	  µl	  protein	  G	  plus	  
protein	  A	  agarose	  overnight	  at	  4°C.	  After	  washing	  with	  the	  same	  buffer,	  the	  MIPS-­‐Anti-­‐
Xpress	  antibody	  complex	  was	  dissociated	  by	  boiling	  for	  5	  min	  in	  protein	  sample	  buffer	  
containing	   2%	   	   SDS,	   10%	   glycerol,	   100	  mM	  DTT,	   60	  mM	   Tris-­‐Cl	   (pH	   6.8),	   and	   0.001%	  
bromophenol	   blue.	   After	   a	   brief	   low	   speed	   centrifugation,	   proteins	  were	   analyzed	   by	  
SDS-­‐PAGE.	  Bands	  were	  visualized	  by	  Coomassie	  Blue	  staining,	  and	  32Pi	  -­‐labeled	  proteins	  
were	  identified	  by	  autoradiography.	  	  
	  
Phosphoaminoacid	  analysis:	  	  
MIPS	   labeled	  with	   32Pi	   	  was	   digested	  with	   6N	  HCl	   .	   The	   acid	  was	   evaporated	   and	   the	  
sample	   was	   dissolved	   in	   10	   μl	   TLE	   buffer	   (pH	   1.9)	   and	   mixed	   with	   1	   μg	   cold	  
phosphoserine,	  phosphothreonine,	  and	  phosphotyrosine	  standards.	  The	  phosphoamino	  
acids	   were	   separated	   in	   two	   dimensions,	   by	   electrophoresis	   followed	   by	   thin	   layer	  
chromatography	   (TLC).	   Standard	   phosphoamino	   acids	   were	   visualized	   by	   Ninhydrin	  
staining	   of	   the	   TLC	   plate.	   Labeled	   phosphoamino	   acids	   were	   visualized	   by	  
autoradiography.	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Mass	  spectrometry	  analysis	  of	  MIPS	  phosphorylation	  sites:	  	  
Purified	   protein	   samples	   were	   reduced	   with	   dithiothreitol,	   alkylated	   with	  
iodoacetamide,	   and	   digested	   overnight	   with	   sequencing	   grade	   trypsin	   (Promega)	   or	  
chymotrypsin	  (Roche)	  at	  37⁰C.	  	  Peptides	  were	  desalted	  and	  separated	  by	  reverse	  phase	  
chromatography	  before	   introduction	   into	  a	   linear	   ion	  trap	  mass	  spectrometer	  (LTQ-­‐XL,	  
Thermo	  Scientific).	  The	  top	  5	  peaks	   in	  the	  MS1	  scan	  (400-­‐1700	  m/z)	  were	  sequentially	  
selected	  for	  fragmentation	  by	  collision-­‐induced	  dissociation	  (NCE=30,	  activation	  Q=0.25,	  
activation	  time=30	  ms).	  Dynamic	  exclusion	  was	  turned	  on	  (if	  2	  hits	  in	  5	  s	  then	  excluded	  
for	  20	  s,	  list	  size=200).	  MS2	  spectra	  were	  scored	  against	  a	  yeast	  FASTA	  protein	  database	  
(NCBI,	  6298	  entries)	  using	   the	  SEQUEST	  algorithm	  (ver	  27,	   rev	  13).	  Search	  parameters	  
included	  1.6	  Da/1.0	  Da	  parent/fragment	   ion	  tolerances;	  +57	  on	  Cys	  fixed	  modification;	  
+16	   on	   Met	   and	   +80	   on	   Ser/Thr/Tyr	   variable	   modifications;	   and	   up	   to	   2	   missed	  
cleavages.	  Results	  were	  imported	  into	  Scaffold	  	  (Proteome	  Software,	  ver	  3.5)	  	  and	  MS2	  
spectra	  were	  reanalyzed	  against	  a	  subset	  database	  using	  X!Tandem	  (ver	  2007.01.01.1).	  
Peptide	   probabilities	   were	   scored	   using	   the	   Peptide	   Prophet	   algorithm	   and	   a	   	   ≥90%	  
threshold	   was	   utilized.	   	   Localization	   probabilities	   of	   post-­‐translational	   modifications	  











TABLE 2.1.  Strains used this study: 
	  




E. coli:  
  DH5α 
	  
	  










MATa his3Δ1, leu2Δ0, met15Δ0, ura3Δ0  
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Source / Ref. 
 
    pRSET A 
    pYES6-CT 
    pYES2-CT 
    P415-ADH  
    pYES6-INO1 
    pRD015 
    pRDINO1 
    pRD-T48V 
    pRD-S177A 
    pRD-S184A 
    pRD-S296A 
    pRD-S374A 
    pRD-S177D 
    pRD-S184D 
    pRD-S296D 
    pRD-S374D 
    pRD-S184A/S374A 
    pADH-INO1 
    pADH-T48V 
    pADH-S177A 
    pADH-S184A 
    pADH-S296A 
    pADH-S374A 
    pADH-S177D 
    pADH-S184D 
    pADH-S296D 
    pADH-S374D  
    pADH-S184A/S374A 
    pRSETA/hINO1 
    pRD-hINO1 
    pADH-hINO1 
    pRD –hS177A 
    pRD –hS177D  
    pRD –hS279A 
    pRD –hS279D 
    pRD –hS357A  
    pRD –hS357D 
 
E.coli expression vector 
Multi-copy  shuttle vector with blasticidin marker 
Multi-copy  shuttle vector with URA3 marker 
Low copy shuttle vector containing LEU2 marker 
Plasmid containing yeast INO1 
Dual tag shuttle vector constructed using pYES2-CT  
INO1gene from pYES6-INO1 ligated into Hindlll/Xho1  
INO1 T48V derivative of pRDINO1 
INO1 S177A derivative of pRDINO1  
INO1 S184A derivative of pRDINO1 
INO1 S296A derivative of pRDINO1 
INO1 S374A derivative of pRDINO1 
INO1 S177D derivative of pRDINO1  
INO1 S184Dderivative of pRDINO1 
INO1 S296Dderivative of pRDINO1 
INO1 S374Dderivative of pRDINO1 
INO1 S184A/S374Aderivative of pRDINO1 
INO1 gene from pRDINO1 
INO1 T48V derivative of pADH-INO1 
INO1 S177A derivative of pADH-INO1  
INO1 S184A derivative of pADH-INO1 
INO1 S296A derivative of pADH-INO1 
INO1 S374A derivative of pADH-INO1 
INO1 S177D derivative of pADH-INO1  
INO1 S184Dderivative of pADH-INO1 
INO1 S296Dderivative of pADH-INO1 
INO1 S374Dderivative of pADH-INO1 
INO1 S184A/S374Aderivative of pADH-INO1 
Plasmid containing Human MIP Synthase cDNA 
Human INO1(ISYNA1)from pRSETA/hINO1 
Human INO1(ISYNA1)from pRD-hINO1 
hINO1 S177A derivative of pRD-hINO1 
hINO1 S177D derivative of pRD-hINO1  
hINO1 S279A derivative of pRD-hINO1 
hINO1 S279D derivative of pRD-hINO1 
hINO1 S357A derivative of pRD-hINO1 












































	  	  	  	  
	  
34	  









S184A   F 
S184A   R 
 
S184D   F 
S184D   R 
 
S296A   F 
S296A   R 
 
S296D   F 
S296D   R 
 
S374A   F 
S374A   R 
 
S374D   F 


























hS177A   F 
hS177A   R 
 
hS177D   F 
hS177D   R 
 
hS279A   F 
hS279A   R 
 
hS279D   F 
hS279D   R 
 
hS357A   F 
hS357A   R 
 
hS357D   F 














































VPA	  causes	  a	  decrease	  in	  MIPS	  activity:	  	  
The	   INO1	   coding	   sequence	   (1578	   bp),	   tagged	  with	   6xHis	   and	   an	   Xpress	   epitope,	   was	  
cloned	   under	   the	  GAL1	   promoter	   in	   the	   expression	   vector	   pRD015	  with	  URA3	   as	   the	  
selection	  marker,	  herein,	  the	  construct	  pRDINO1	  (Fig.	  2.2A).	  To	  determine	  if	  the	  tagged	  
MIPS	   is	   functional,	   pRDINO1	   was	   transformed	   into	   ino1Δ	   cells	   that	   lack	   endogenous	  
MIPS	   and	   therefore	   cannot	   grow	   independently	   in	   the	   absence	   of	   inositol.	  
Transformants	  (ino1Δ-­‐INO1)	  were	  selected	  on	  Ura-­‐	  plates	  and	  then	  tested	  for	  growth	  in	  
the	   absence	   of	   inositol	   (I-­‐)	   in	   comparison	   with	   cells	   carrying	   the	   empty	   vector.	   	   The	  
tagged	  MIPS	  rescued	  growth	  on	  I-­‐	  media	  (Fig.	  2.2B).	  It	  has	  previously	  been	  shown	  that	  
cells	  grown	  in	  the	  presence	  of	  VPA	  exhibit	  a	  decrease	  in	  levels	  of	  inositol	  and	  inositol-­‐3-­‐
phosphate	   (Vaden	  et	   al.,	   2001)	   and	   that	  VPA	  does	  not	   directly	   inhibit	  MIPS	   (Ju	   et	   al.,	  
2004).	  To	  test	  the	  possibility	  that	  VPA	  indirectly	  inhibits	  MIPS	  activity	  by	  bringing	  about	  
a	  post-­‐translational	  change	  in	  the	  enzyme,	  MIPS	  was	  expressed	  and	  purified	  from	  ino1Δ-­‐
INO1	  cells	  grown	  to	  the	  mid-­‐logarithmic	  phase	  and	  treated	  with	  1	  mM	  VPA	  for	  3	  hours.	  	  	  
MIPS	   purified	   from	   the	  VPA-­‐treated	   cells	   showed	   a	   decrease	   in	   activity	   of	   about	   40%	  
compared	   to	   enzyme	   purified	   from	   untreated	   cells	   suggesting	   that	  MIPS	   is	   regulated	  
post-­‐translationally	  (Fig.	  2.3A).	  	  	  
	  
	  






FIGURE	  2.2.	   	   	  The	  tagged	  MIPS	   is	   functional	  and	  rescues	  growth	  of	   ino1Δ 	   in	   inositol-­‐
deficient	  media.	   	  A,	  Map	  of	  the	  INO1	  construct	  used	  for	  expression	  and	  purification	  of	  
MIPS.	   	  B,	   ino1Δ	   cells	   transformed	  with	   the	  empty	   vector	   (pRD015)	  or	  with	   the	   vector	  
carrying	  the	  tagged	  INO1	  (pRDINO1)	  were	  precultured	  to	  the	  mid	  logarithmic	  phase	  	  in	  
synthetic	  medium	   (SM)	   supplemented	  with	   75	   uM	   inositol	   .	   Cells	  were	  washed	   twice	  
with	   dH2O	   to	   remove	   residual	   inositol,	   diluted,	   and	   plated	   on	   selective	   SM	   with	   or	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MIPS	  	  	  is	  a	  phosphoprotein:	  	  	  
To	   determine	   if	  MIPS	   is	   post-­‐translationally	   modified	   by	   phosphorylation,	   ino1Δ	   cells	  
harboring	  the	  tagged	  INO1	  were	  grown	  in	  the	  presence	  of	  32Pi	  	  	  with	  or	  without	  VPA,	  and	  
MIPS	   was	   precipitated	   with	   anti-­‐Xpress	   antibody	   using	   protein	   A	   plus	   protein	   G	  
conjugated	  sepharose.	  The	  32P-­‐	  labeled	  MIPS	  protein	  was	  resolved	  using	  SDS-­‐PAGE	  and	  
visualized	  with	  Coomassie	  Blue	  and	  autoradiography.	   	  MIPS	  purified	   from	  VPA-­‐treated	  
cells	   showed	   a	   higher	   degree	   of	   phosphorylation	   compared	   to	   MIPS	   purified	   from	  
untreated	   cells	   (Fig.	   2.3B).	   	   Phosphoamino	   acid	   analysis	   of	   the	   32P-­‐labeled	   protein	  
indicated	  that	  MIPS	  was	  phosphorylated	  mostly	  at	  serine	  residues,	  although	  faint	  label	  
of	  threonine	  residues	  was	  also	  detected	  (Fig.	  2.3C).	  
To	   identify	   the	  putative	  phosphorylated	  residues,	  MIPS	  was	  overexpressed	  and	  
purified	  from	   ino1Δ-­‐INO1	  cells	  grown	  to	  the	  mid-­‐logarithmic	  phase.	  Duplicate	  samples	  
of	  control	  (no	  treatment)	  and	  VPA	  (1mM)	  -­‐	  treated	  cells	  were	  utilized.	  The	  protein	  was	  
purified	  using	  ProBond	  resin,	  dialyzed,	  concentrated,	  and	  digested	  with	  either	  trypsin	  or	  
chymotrypsin.	  The	  resulting	  peptides	  were	  separated	  by	  reverse	  phase	  chromatography	  
and	   analyzed	   by	   tandem	   electrospray	   mass	   spectrometry.	   MIPS	   peptides	   and	  
phosphopeptides	   were	   identified	   using	   an	   algorithm	   that	   compares	   MS/MS	   spectra	  
against	   database	   sequences.	   A	   total	   sequence	   coverage	   of	   88.4%	   was	   obtained	   with	  
both	  enzymes	  (Fig.	  2.4A).	  
Five	   phosphosites	   were	   identified	   in	   4	   independent	   samples:	   pT-­‐48	   in	   the	   N-­‐
terminal	  domain,	  pS-­‐177,	  pS-­‐184,	  and	  pS-­‐296	  in	  the	  NAD+	  binding	  domain,	  and	  pS-­‐374	  in	  	  







FIGURE	  2.3.	   	  MIPS	   is	  a	  phosphoprotein.	  A,	  MIPS	  purified	  from	  VPA-­‐treated	   ino1Δ	  cells	  
harboring	   the	  pRDINO1	   vector	   showed	  decreased	  activity.	  B,	  MIPS	  purified	   from	  VPA-­‐
treated	  cells	  shows	  an	   increased	   level	  of	  phosphorylation	   in	  comparison	  to	  MIPS	  from	  
untreated	   cells.	   C,	   Phosphoamino	   acid	   analysis	   of	   MIPS	   protein	   using	   32Pi	   labeling	  
showed	  that	  phosphorylation	   is	  mostly	  at	  serine	  residues.	  The	  data	  are	  representative	  
of	  2	  independent	  experiments.	  Parts	  B	  and	  C	  were	  carried	  out	  by	  Quan	  He	  (Deranieh	  et	  
al.,	  2013).	  
	  






FIGURE	  2.4.	   	   Domains	   and	   phosphosites	   of	  MIPS.	  A,	   Protein	   sequence	  of	   yeast	  MIPS	  	  
(NCBI	   accession	  NP_012382.2).	   Sequenced	   residues	   are	   highlighted	   (471/533	   =	   88.4%	  
sequence	   coverage).	   Phosphosites	   sequenced	   in	   at	   least	   2	   of	   4	   samples	   analyzed	   are	  
marked	  with	  an	  asterisk	  (*).	  B,	  A	  schematic	  diagram	  illustrating	  the	  domain	  structure	  of	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the	   catalytic	   domain	   (Fig.	   2.4B).	   For	   pS-­‐48,	   pS-­‐177,	   pS-­‐184	   and	   pS-­‐296,	   unambiguous	  
localization	   of	   the	   phosphosites	  was	  made	   on	   the	   basis	   of	   the	   corresponding	  MS/MS	  
spectra.	   A	   representative	   fragmentation	   spectrum	   for	   the	   identification	   of	   pS-­‐296	   is	  
shown	  in	  Fig.	  2.5A.	  	  
The	   termini	   of	   peptides	   do	   not	   yield	   fragmentation	   information	   as	   robustly	   as	  
the	   central	   region;	   therefore,	   phosphosite	   determination	   for	   the	  
374SSVIDDIIASNDILYNDK392	   phosphopeptide	   was	   not	   as	   direct.	   The	   b4-­‐b9	   ion	   series	  
indicated	  that	  the	  phosphosite	  was	  either	  at	  S-­‐374	  or	  S-­‐375	  and	  not	  S-­‐383	  or	  Y-­‐388	  (Fig.	  
2.5B).	  A	  doubly	  charged	  y17	   ion	  was	  consistently	  seen	   in	  MS/MS	  spectra	  that	  matched	  
this	   phosphopeptide.	   Although	   it	   has	   relatively	   low	   abundance,	   this	   fragment	   ion	  
indicated	   that	   S-­‐375	  was	   not	   phosphorylated	   (Fig.	   2.5B).	   Finally,	   the	   serine	   residue	   at	  
position	   374	   of	   yeast	   MIPS	   is	   conserved	   across	   disparate	   species	   (Fig.	   2.5C).	   This	  
correlative	  evidence	  suggests	  that	  S-­‐374	  has	  a	  critical	  role	  for	  protein	  function.	  
	  
Three	  phosphosites	  modulate	  activity	  of	  yeast	  MIPS:	  	  
To	   determine	   which	   of	   the	   identified	   phosphorylation	   residues	   are	   functionally	  
important	   for	   the	  activity	  of	  MIPS,	   two	  site	  mutants	  were	  constructed	   for	  each	  of	   the	  
residues:	   a	   phosphorylation-­‐deficient	   mutant	   in	   which	   serine	   (S)	   was	   changed	   to	   the	  
unphosphorylatable	   alanine	   (A),	   or	   threonine	   (T)	   to	   valine	   (V);	   and	  a	  phosphomimetic	  
mutant,	  in	  which	  serine	  (S)	  was	  changed	  to	  the	  phosphorylation-­‐mimicking	  aspartate	  (D)	  
(Fig.	   2.6A).	   	   All	   the	   mutations	   were	   confirmed	   by	   sequencing.	   Each	   mutation	   was	  





FIGURE	   2.5.	   	   MIPS	   is	   phosphorylated	   at	   5	   serine	   and	   threonine	   residues.	   A,	  
Representative	   MS/MS	   spectrum	   of	   the	   doubly-­‐charged	   MIPS	   phosphopeptide	  
293INGpSPQNTFVPGLVQLAEHEGTF315.	   	   The	   phosphorylation	   site	   was	   unambiguously	  
assigned	  to	  pS-­‐296	  based	  on	  the	  mass	  assignment	  of	  b4.	  Not	  all	  peaks	  are	  annotated.	  B,	  
the	  b4	  fragment	  ion	  within	  the	  MS/MS	  spectrum	  of	  374SSVIDDIIASNDILYNDK391	  indicates	  
that	   one	   of	   the	   N-­‐terminal	   serine	   residues	   is	   phosphorylated.	   Two	   lines	   of	   evidence	  
suggest	  that	  the	  phosphorylated	  residue	  is	  pS-­‐374:	  the	  y172+	  fragment	  ion	  indicates	  that	  
S-­‐375	   is	   not	   phosphorylated;	   and	   the	   S-­‐374	   residue	   within	   yeast	   MIPS	   is	   highly	  
conserved	  across	  several	  species	  (shown	  in	  C).	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constructed	  in	  two	  vectors:	   	  a	  centromeric	   low	  expression	  vector,	  p415-­‐ADH	  driven	  by	  
the	  ADH	  promoter,	  used	  for	  growth	  experiments;	  and	  a	  high	  expression	  vector,	  pRD015	  
driven	  by	  the	  GAL1	  promoter,	  used	  for	  overexpression	  and	  purification	  of	  the	  enzyme.	  
All	   constructs	  were	   transformed	   into	   ino1Δ	   cells.	   To	   assess	   the	  physiological	   effect	   of	  
the	   mutations	   on	   growth,	   cells	   transformed	   with	   the	   empty	   vector,	   wild-­‐type	   INO1	  
gene,	  or	  mutated	  genes	  were	  grown	  on	  synthetic	  media	  with	  or	  without	  inositol.	  When	  
MIPS	  was	  expressed	  from	  the	  high	  copy	  vector,	  all	  the	  site-­‐mutants	  supported	  growth	  of	  
ino1Δ	   cells	   (data	   not	   shown).	   However,	   clear	   differences	   in	   growth	  were	   observed	   in	  
ino1Δ	  cells	  transformed	  with	  the	  MIPS	  mutants	  on	  the	  low	  copy	  vector	  	  (Fig.	  2.6B).	  Cells	  
carrying	   the	  plasmid	  with	  wild-­‐type	   INO1	   grew	  normally	  on	   inositol-­‐deficient	  medium.	  
Mutations	  in	  residues	  in	  the	  NAD-­‐binding	  domain,	  S184	  and	  S296,	  affected	  growth.	  Cells	  
carrying	   S184A	   grew	   well,	   but	   S184D	   did	   not	   support	   growth,	   suggesting	   that	  
phosphorylation	  of	  this	  residue	  inhibits	  the	  activity	  of	  MIPS,	  and	  hence,	  the	  synthesis	  of	  
inositol.	   Both	  mutants	   S296A	   and	   S296D	   did	   not	   support	   growth	   on	   inositol	   deficient	  
medium,	   suggesting	   that	   a	   serine	   residue	   is	   essential	   at	   that	   position.	   Mutants	   of	  
residue	  S374	  in	  the	  catalytic	  domain	  were	  also	  assessed.	  Cells	  carrying	  S374A	  grew	  well,	  
but	   S374D	   did	   not	   support	   growth,	   suggesting	   that	   phosphorylation	   of	   this	   residue	  
inhibits	  MIPS	  activity.	  Cells	  carrying	  mutations	  of	  T48	  and	  S177	  showed	  the	  same	  growth	  
pattern	   as	   that	   of	  WT	   (data	   not	   shown),	   indicating	   that	   these	   sites	   are	   not	   critical	   or	  
regulated	  by	  phosphorylation.	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To	   determine	   if	   the	   altered	   growth	   patterns	   seen	   in	   the	  mutants	   was	   due	   to	  
altered	  MIPS	  activity,	  wild-­‐type	  and	  mutant	  MIPS	  were	  overexpressed	  and	  purified	  from	  
ino1Δ	  cells	  grown	  to	  the	  late	  log	  phase	  in	  selective	  medium	  supplemented	  with	  inositol.	  	  
Using	   equivalent	   amounts	   of	   purified	   protein	   from	   all	   mutants,	   MIPS	   activity	   was	  
assayed	   using	   the	   method	   of	   Barnett	   et	   al.,	   (1970).	   The	   activity	   of	   MIPS	   from	  
phosphorylation	  deficient	  mutants	   S184A	  and	   S374A	  was	   similar	   to	  or	   slightly	   greater	  
than	  that	  of	  the	  wild	  type	  MIPS	  (Fig.	  2.6C).	  In	  contrast,	  MIPS	  from	  the	  phosphomimetic	  
mutants	  S184D	  and	  S374D	  showed	  a	  decrease	  in	  activity	  to	  about	  30%	  and	  60%	  of	  wild-­‐
type	  levels,	  respectively.	  This	  suggests	  that	  phosphorylation	  of	  residues	  S184	  and	  S374	  
has	  an	  inhibitory	  effect	  on	  the	  activity	  of	  MIPS.	  	  	  
	   In	   contrast	   to	   S184	   and	   S374,	   both	   mutations	   of	   residue	   S296	   (S296A	   and	  
S296D),	  led	  to	  a	  decrease	  in	  MIPS	  activity	  (Fig.	  2.6C),	  suggesting	  that	  a	  serine	  residue	  at	  
this	  site	  is	  important	  for	  maintaining	  catalytic	  activity.	  	  
The	   effect	   of	   phosphorylation	   on	   MIPS	   activity	   was	   also	   addressed	   by	  
dephosphorylating	   the	   protein	   using	   alkaline	   phosphatase	   (AP).	   Dephosphorylation	  
increased	  the	  activity	  of	  wild	  type	  MIPS	  by	  about	  130%	  (Fig.	  2.7).	  	  Dephosphorylation	  of	  
the	  S184A	  and	  S374A	  mutants	  showed	  a	  smaller	   increase	   in	  activity	  (50%	  and	  83%	  for	  
S184A	  and	  S374A,	  respectively),	  suggesting	  that	  each	  of	   these	  putative	   inhibitory	  sites	  
partially	  contributes	  to	  the	  overall	  inhibitory	  effect.	  Dephosphorylation	  of	  S296A	  caused	  
more	   of	   an	   increase	   in	   activity	   than	   either	   S184A	   or	   S374A,	   suggesting	   that	   the	   two	  
phosphosites	  S184	  and	  S374	  have	  a	  greater	  inhibitory	  effect	  than	  either	  site	  alone.	  	  






FIGURE	  2.6.	  	  	  Effect	  of	  site	  mutations	  of	  yeast	  MIPS	  on	  growth	  and	  enzyme	  activity.	  A,	  
Schematic	   representation	   of	   the	   mutated	   phosphorylation	   sites	   in	   the	   yeast	   MIPS	  
protein.	   (*)	  Phospho-­‐deficient	  mutation,	   (D)	  phosphomimetic	  mutation.	   	  B,	   ino1Δ	  cells	  
transformed	   with	   the	   empty	   vector	   pADH,	   vector	   carrying	   wild-­‐type	   yeast	   INO1	   or	  
vector	   carrying	   the	   indicated	   mutated	   INO1	   gene	   were	   spotted	   in	   a	   10-­‐fold	   dilution	  
series	  on	  Leu-­‐	  medium	  in	  the	  presence	  or	  absence	  of	  75	  µM	  inositol	  (I).	  C,	  Effect	  of	  site	  
mutations	   on	   activity	   of	   yeast	   MIPS.	   The	   results	   are	   representative	   of	   three	  
experiments.	  Values	  are	  mean	  ±	  S.E.	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To	  examine	  the	  effect	  of	  a	  phosphorylated	  S296,	  a	  double	  mutant	  S184A/S374A	  
was	   constructed.	   Dephosphorylation	   of	   the	   double	   mutant	   did	   not	   significantly	   alter	  
MIPS	  activity	  (Fig.	  2.7),	  suggesting	  that	  under	  the	  physiological	  conditions	  in	  which	  the	  
protein	  was	  purified,	  phosphorylation	  of	  S296	  was	  not	  significant.	  Taken	  together,	  these	  
results	   indicate	   that	   yeast	   MIPS	   is	   regulated	   by	   phosphorylation	   of	   at	   least	   three	  
residues,	  two	  of	  which	  are	   inhibitory	  when	  phosphorylated	  (S184	  and	  S374).	  The	  third	  
residue,	  S296,	  is	  strictly	  dependent	  on	  the	  presence	  of	  a	  serine	  at	  that	  position.	  	  
	  
The	  phosphorylation	  sites	  are	  conserved	  in	  human	  MIPS	  :	  
Ju	  et	  al.	  (2004)	  have	  previously	  cloned	  and	  expressed	  a	  human	  cDNA	  encoding	  MIPS	  and	  
showed	   that	  human	  MIPS	   (hMIPS)	   is	   functional	   in	   yeast	   (Ju	   et	   al.,	   2004).	   	   Amino	  acid	  
sequence	  alignment	  of	  yeast	  and	  hMIPS	  showed	  that	  the	  three	  residues	  I	  have	  found	  to	  
modulate	   yeast	  MIPS	   are	   conserved	   in	   the	   human	   enzyme	   (Fig.	   2.4B).	   	   These	   hMIPS	  
residues	  are	  S177	  and	  S279,	  both	  of	  which	  are	  in	  the	  NAD+-­‐binding	  domain,	  and	  S357,	  
which	   lies	   in	   the	   catalytic	   domain	   (Fig.	   2.4B).	   To	   determine	   if	   hMIPS	   is	   regulated	   by	  
phosphorylation,	  the	  hINO1	  gene	  was	  transferred	  from	  pRSETA-­‐hINO1	   (Ju	  et	  al.,	  2004)	  
and	  cloned	   into	   the	  overexpression	  vector	  pRD015.	  Two	   independent	  mutations	  were	  
created	  for	  each	  residue:	  a	  phosphodeficient	  S	  to	  A,	  and	  a	  phosphomimetic	  S	  to	  D	  (Fig.	  
2.8A).	  All	  the	  mutations	  were	  confirmed	  by	  sequencing.	  	  
To	   determine	   if	   any	   of	   the	   three	   conserved	   residues	   are	   important	   for	   the	  
function	  of	  hMIPS,	  all	  constructs	  along	  with	  the	  controls	  were	  transformed	   into	   ino1Δ	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cells.	   	   Transformants	  were	   grown	   on	   selective	  medium	  with	   or	  without	   inositol.	   	   The	  
wild	   type	  hINO1	   gene	   rescued	  growth	  on	   I-­‐	  medium,	   indicating	   that	  hMIPS	  expressed	  
from	  the	  pRD015	  vector	   is	   functional	   in	  yeast	   (Fig.	  2.8B).	  Mutations	  S177A	  and	  S177D	  
did	   not	   support	   growth	   in	   the	   absence	   of	   inositol	   (Fig.	   2.8B).	   Consistent	   with	   this	  
observation,	  hMIPS	  purified	  from	  these	  mutants	  showed	  decreased	  activity	  (Fig.	  2.8C),	  
suggesting	   that	  a	   serine	   residue	   is	   required	  at	   this	   site	   for	   the	  activity	  of	   the	  enzyme.	  	  
For	  residue	  S279,	  the	  S279A	  mutation	  supported	  growth	  on	  I-­‐	  media	  although	  enzyme	  
activity	  was	   lower	   than	  wild	   type.	   The	   S279D	  mutation	   did	   not	   support	   growth	   on	   I-­‐	  
media,	   and	   caused	   a	   big	   decrease	   in	   activity,	   suggesting	   that	   phosphorylation	   of	   this	  
residue	  inhibits	  hMIPS	  activity,	  and	  hence,	  the	  synthesis	  of	  inositol.	  The	  S357A	  mutation	  
of	   the	   catalytic	   domain	   supported	   growth,	   but	   S357D	   did	   not.	   Consistent	   with	   this,	  
S357A	   caused	   a	   slight	   increase	   in	   activity	   while	   S357D	   caused	   a	   decrease	   in	   activity,	  
suggesting	  that	  phosphorylation	  of	  S357	  inhibits	  hMIPS	  activity.	  	  
Similar	   to	   the	   yeast	   enzyme,	   dephosphorylation	   of	   hMIPS	   led	   to	   increased	  
activity	   (data	   not	   shown).	   Taken	   together,	   hMIPS,	   similar	   to	   its	   yeast	   counterpart	   is	  










FIGURE	  2.7.	  	  Effect	  of	  dephosphorylation	  on	  MIPS	  activity.	  ino1Δ	  cells	  expressing	  wild-­‐
type	  (WT)	  or	  mutated	  yeast	  MIPS	  were	  grown	  to	  the	  exponential	  phase	  in	  SM	  I+.	  MIPS	  
was	  purified	  	  and	  mixed	  with	  Ni-­‐coated	  magnetic	  beads	  and	  gently	  mixed	  for	  about	  one	  
h	  at	  4°C.	   	   The	  beads	  were	  collected,	   rinsed,	  and	   resuspended	   in	  alkaline	  phosphatase	  
(AP)	  buffer	  with	  or	  without	  AP,	  and	   incubated	  at	  37°C	  for	  1	  hr.	   	  The	  beads	  were	  then	  
washed	  thrice	  with	  buffer	  to	  get	  remove	  AP	  and	  free	  phosphate.	  Activity	  of	  the	  bound	  
MIPS	   was	   assayed	   as	   described	   under	   “Materials	   and	   Methods.”	   The	   %	   change	   in	  
activity	   after	   dephosphorylation	   is	   indicated.	   Values	   are	   mean	   of	   at	   least	   two	  
experiments	  ±	  S.E.	  





FIGURE	  2.8.	  	  	  Effect	  of	  site	  mutations	  of	  human	  MIPS	  on	  growth	  and	  enzyme	  activity.	  
A,	   Schematic	   representation	  of	   the	  mutated	  phosphorylation	  sites	   in	   the	  human	  MIPS	  
protein.	   (*)	  Phospho-­‐deficient	  mutation,	   (D)	  phosphomimetic	  mutation.	  B,	   ino1Δ	   	  cells	  
transformed	  with	   the	  empty	  vector	  pRD015,	  vector	  carrying	  wild-­‐type	  human	   INO1	  or	  
vector	  carrying	  the	  indicated	  site	  mutations	  were	  spotted	  in	  a	  10-­‐fold	  dilution	  series	  on	  
Ura-­‐	  medium	   in	   the	   presence	   or	   absence	   of	   75	  µM	   inositol,	   and	   grown	   for	   3	   days	   at	  
30°C.	  C,	  Effect	  of	  site	  mutations	  on	  the	  activity	  of	  human	  MIPS.	  Values	  are	  mean	  of	  at	  
least	  two	  experiments	  ±	  S.E.	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The	   S184A/S374A	   double	   mutation	   in	   yeast	   MIPS	   confers	   growth	   advantage	   and	  
resistance	  to	  VPA:	  
To	  determine	  the	  effect	  of	   loss	  of	  both	  S184	  and	  S374	  phosphosites,	   ino1Δ	   cells	  were	  
transformed	  with	  a	  vector	  containing	  the	  yeast	  INO1	  gene	  with	  both	  S184A	  and	  S374A	  
mutations.	  As	   shown	   in	   Fig.	   2.9A,	   cells	   carrying	   the	  S184A/S374A	  mutated	   INO1	   (DM)	  
exhibited	   a	   greatly	   increased	   growth	   rate	   and	   reduced	   lag	   phase	   compared	   to	   cells	  
carrying	   the	   wild-­‐type	   INO1	   gene	   (WT).	   Importantly,	   the	   double	   mutant	   exhibited	  
significantly	  better	  growth	  in	  the	  presence	  of	  VPA	  (Fig.	  2.9A,B).	  	  
Consistent	  with	  increased	  growth	  conferred	  by	  the	  double	  mutation,	  the	  activity	  
of	   the	   double	   mutant	   MIPS	   was	   almost	   twice	   that	   of	   wild-­‐type	   MIPS	   (Fig.	   2.9C).	  
Importantly,	  the	  decrease	  in	  activity	  in	  response	  to	  VPA	  was	  twice	  as	  much	  in	  wild-­‐type	  
MIPS	  (50%)	  as	  in	  the	  double	  mutated	  MIPS	  (25%).	  Together,	  the	  data	  show	  that	  loss	  of	  
the	   two	   phosphosites	   S184	   and	   S374	   leads	   to	   increased	  MIPS	   activity	   and	   decreased	  













FIGURE	   2.9.	   	   The	   double	  mutation	   S184A/S374A	   (DM)	   confers	   a	   growth	   advantage,	  
increases	  MIPS	  activity,	  and	  partially	  rescues	  sensitivity	  to	  VPA.	  A,	  ino1Δ	  cells	  carrying	  
the	  double	  mutation	  S184A/S374A	  (DM)	  grow	  better	  than	  cells	  carrying	   	  the	  wild	  type	  
INO1	   (WT).	   B,	   The	   double	   mutant	   grows	   better	   than	   WT	   on	   plates.	   C,	   The	   double	  
mutation	   causes	   an	   increase	   in	  MIPS	   activity,	   and	   partially	   rescues	   sensitivity	   to	   VPA.	  
Values	  are	  mean	  of	  at	  least	  two	  experiments	  ±	  S.E.	  
	  
	  





The	   current	   study	   shows	   for	   the	   first	   time	   that	  MIPS	   is	   regulated	   at	   the	   post-­‐
translational	   level	   by	   phosphorylation.	   The	   findings	   are:	   (1)	   Yeast	   MIPS	   activity	   is	  
regulated	   by	   phosphorylation	   of	   at	   least	   three	   residues.	   (2)	   Phosphorylation	   of	   the	  
corresponding	  residues	  affects	  activity	  of	  human	  MIPS.	  (3)	  Eliminating	  the	  two	  inhibitory	  
phosphosites	   confers	   resistance	   to	   VPA.	   	   These	   findings	   identify	   phosphorylation	   as	   a	  
novel	   mechanism	   of	   regulation	   of	   inositol	   synthesis,	   and	   suggest	   that	   VPA-­‐mediated	  
inositol	  depletion	  may	  result	  from	  phosphorylation	  of	  MIPS.	  	  	  
MIPS	  was	  identified	  as	  a	  phosphoprotein	  by	  phospholabeling	  and	  phosphoamino	  
acid	   analysis	   (Fig.	   2.3).	   Consistent	  with	   this	   finding,	  mass	   spectrometry	   identified	   five	  
phosphosites	  in	  MIPS	  isolated	  from	  VPA-­‐treated	  cells,	  (T48,	  S177,	  S184,	  S296,	  and	  S374).	  
Mutation	  of	   three	  of	   the	   five	  sites	  modulated	  MIPS	  activity,	   including	  S184,	  S296,	  and	  
S374.	   Phosphomimetic	   mutations	   of	   these	   three	   sites	   decreased	   enzymatic	   activity.	  
Among	   the	   three	   residues,	   only	   one	   phosphorylation-­‐deficient	   mutation,	   S296A,	  
decreased	  the	  activity	  of	  MIPS,	  indicating	  that	  this	  site	  is	  crucial	  for	  function.	  
The	   decreased	   activity	   of	   MIPS	   carrying	   either	   the	   S184D	   or	   S374D	   mutation	  
suggests	  that	  phosphorylation	  of	  these	  two	  residues	  promotes	  conformational	  changes	  
that	   alter	   the	   activity	   of	   the	   enzyme,	   or	   block	   access	   of	   the	   substrate	   to	   its	   catalytic	  
domain.	  These	   residues	   lie	   in	   two	   functionally	   critical	  domains.	  Residue	  S184	   is	   in	   the	  
middle	  of	  the	  NAD+-­‐binding	  domain,	  which	  encompasses	  residues	  66-­‐326,	  and	  is	  one	  of	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fourteen	  residues	  that	  directly	  interact	  with	  NAD+	  (Stein	  and	  Geiger,	  2002).	  The	  adenine	  
portion	  of	  NAD+	  specifically	  forms	  tight	  hydrogen	  bonds	  between	  N1	  and	  S184	  (Jin	  and	  
Geiger,	  2003).	  Structural	  studies	  suggest	  that	  the	  binding	  of	  NAD+	  to	  the	  apo-­‐enzyme	  is	  
a	  prerequisite	  for	  the	  orderly	  binding	  of	  the	  substrate	  G-­‐6-­‐P	  to	  the	  active	  site	  (Jin	  et	  al.,	  
2004	  ;Jin	  and	  Geiger,	  2003).	  	  Therefore,	  it	  is	  likely	  that	  NAD+	  binding	  is	  disrupted	  when	  
S184	  is	  phosphorylated,	  resulting	  in	  decreased	  activity	  of	  MIPS,	  which	  is	  dependent	  on	  
NAD+	  as	  a	  cofactor.	  	  
Residue	  S374	  lies	  within	  the	  catalytic	  domain	  of	  MIPS.	  	  For	  MIPS	  to	  complete	  its	  
catalytic	   cycle,	   the	   active	   site	   folds	   and	   completely	   encapsulates	   the	   substrate	   in	   an	  
extreme	  example	  of	  induced	  fit	  	  (Jin	  et	  al.,	  2004;	  Jin	  and	  Geiger,	  2003;	  Stein	  and	  Geiger,	  
2002).	  We	  have	  previously	  shown	  that	  multi-­‐substrate	  adducts	  that	  carry	  a	  phosphate	  
group	  attached	  at	  the	  C6	  position	  of	  the	  2-­‐deoxyglucitol	  end	  are	  more	  potent	  inhibitors	  
of	  MIPS,	   suggesting	   that	   the	   presence	   of	   a	   phosphate	   group	   in	   the	   catalytic	   domain	  
inhibits	  activity	  (Deranieh	  et	  al.,	  2012).	  Phosphorylation	  of	  S374	  may	  perturb	  access	  of	  
the	   substrate	   to	   the	   catalytic	   domain,	   or	   may	   destabilize	   the	   induced	   fit	   by	   creating	  
steric	  hindrance,	  thus	  decreasing	  catalytic	  activity.	  	  Additionally,	  the	  catalytic	  domain	  is	  
populated	  with	  hydrophobic	  residues	  (Geiger	  and	  Jin,	  2006;	  Stein	  and	  Geiger,	  2002).	  The	  
negative	   charge	   of	   the	   phosphate	   group	  may	   alter	   the	   electrostatic	   balance	   of	   these	  
residues	  and	  thus	  cause	  further	  perturbation	  of	  enzyme	  activity.	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While	  the	  S184A	  and	  S374A	  mutations	  did	  not	  significantly	  affect	  activity,	  both	  
S296A	   and	   S296D	   mutations	   decreased	   activity	   of	   the	   enzyme,	   suggesting	   that	   the	  
presence	  of	  a	  serine	  residue	  at	  this	  location	  is	  critical.	  	  This	  residue	  is	  also	  in	  the	  NAD+-­‐	  
binding	  domain.	  Interestingly,	  S296	  is	  within	  a	  stretch	  of	  seven	  residues,	  all	  of	  which	  are	  
completely	   conserved.	   It	   is	   possible	   that	   any	   distortion	   in	   this	   region	   destabilizes	   the	  
protein	  structure,	  or	  disrupts	  the	  interaction	  between	  monomers	  that	  is	  needed	  to	  form	  
the	  tetrameric	  structure	  of	  the	  enzyme,	  leading	  to	  loss	  of	  activity.	  	  
Alignment	   of	   the	   amino	   acid	   sequences	   of	   hMIPS	   and	   yeast	   MIPS	   revealed	   a	  
consensus	  of	  49.3%.	  Of	  the	  533	  amino	  acids	  of	  yeast	  MIPS,	  263	  residues	  are	  conserved.	  	  
The	  highest	  level	  of	  conservation	  is	  in	  the	  catalytic	  domain	  (68%).	  The	  observation	  that	  
the	  three	  regulatory	  sites	  identified	  in	  yeast	  MIPS	  are	  conserved	  in	  the	  human	  homolog	  
was	   intriguing.	   The	   inability	   of	   hMIPS	   carrying	   the	   S357D	  mutation	   to	   rescue	   inositol	  
auxotrophy	   of	   yeast	   ino1Δ	   cells	   (Fig.	   2.8B),	   and	   the	   decreased	   activity	   of	   the	   enzyme	  
(Fig.	  2.8C),	  suggest	  that	  phosphorylation	  perturbs	  the	  active	  site,	  or	  obstructs	  binding	  of	  
the	  substrate.	  Similarly,	  phosphorylation	  of	  the	  human	  S279	  may	  perturb	  the	  activity	  of	  
the	   enzyme	   as	   a	   consequence	   of	   altering	   its	   structure,	   or	   obstructing	   the	   binding	   of	  
NAD+.	  The	  decreased	  activity	  of	  both	  S177A	  and	  S177D	  of	  hMIPS	  suggest	  that	  a	  serine	  
residue	   is	  critical	  at	   that	  position.	  The	  crystal	  structure	  of	  MIPS	  has	  been	  solved	  for	  S.	  
cerevisiae	   (Kniewel	   et	   al.,	   2002;	   Stein	   and	   Geiger,	   2002),	  Mycobacterium	   tuberculosis	  
(Norman	   et	   al.,	   2002),	   and	   Archaeoglobus	   fulgidus	   (Neelon	   et	   al.,	   2011).	   	   To	   our	  
knowledge,	   the	   crystal	   structure	   of	   hMIPS	   has	   not	   been	   reported.	   The	   structural	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knowledge	   pertaining	   to	   the	   catalytic	   mechanism	   of	   MIPS	   is	   based	   largely	   on	   the	   S.	  
cerevisiae	   and	   A.	   fulgidus	   models	   (Neelon	   et	   al.,	   2011;	   Stein	   and	   Geiger,	   2002).	   The	  
catalytic	   and	   NAD+	   -­‐binding	   domains	   of	   hMIPS	   are	   recognized	   based	   on	   sequence	  
similarity	   with	   the	   yeast	   homolog.	   The	   current	   study	   is	   the	   first	   to	   shed	   light	   on	   the	  
mechanism	  of	  regulation	  of	  hMIPS	  by	  characterizing	  the	  human	  protein.	  	  
Based	   on	   the	   prediction	   of	   NetPhos	   Yeast,	   the	   three	   identified	   residues	   S184,	  
S296,	  and	  S374	  are	  potential	  phosphorylation	  sites	  for	  PKA,	  GSK3,	  and	  PKC,	  respectively.	  
With	   regard	   to	   the	   human	  MIPS,	   hS177	   is	   predicted	   to	   be	   a	   PKA	   recognition	   site.	   In	  
preliminary	   experiments,	   MIPS	   activity	   decreased	   when	   treated	   with	   PKC,	   suggesting	  
that	  PKC	  may	  be	  one	  of	  the	  regulators	  of	  MIPS	  activity.	  GSK3	  treatment	  increased	  MIPS	  
activity.	   This	   is	   consistent	   with	   the	   slight	   decrease	   in	   activity	   I	   observed	   in	   the	  
dephosphorylated	  double-­‐mutant,	  in	  which,	  out	  of	  the	  three	  phosphosites,	  only	  S296	  is	  
available	   for	  phosphorylation.	   It	   also	   supports	   the	  earlier	   finding	  of	  Azab	  et	   al.	   (2007)	  
that	  the	  GSK-­‐3	  mutant	  shows	  decreased	  MIPS	  activity	  and	  increased	  sensitivity	  to	  VPA.	  	  
A	  previous	  study	  has	  shown	  that	  VPA	  causes	  a	  decrease	  in	  I-­‐3-­‐P	  and	  myo-­‐inositol	  
(Vaden	  et	  al.,	  2001),	  suggesting	  that	  VPA	  inhibits	  MIPS.	  	  Inhibition	  of	  MIPS	  by	  VPA	  was	  
not	   observed	   in	   vitro	   (Ju	   et	   al.,	   2004),	   suggesting	   that	   VPA	   inhibition	   is	   indirect.	   The	  
current	   findings	   suggest	   that	   at	   least	   one	   mechanism	   whereby	   VPA	   causes	   inositol	  
depletion	  may	  involve	  the	  phosphorylation	  of	  S184	  and	  S374.	  First,	  phosphorylation	  of	  
yeast	  MIPS	   is	   increased	   in	  cells	  grown	  in	  VPA	  (Fig.	  2.3B).	  Second,	  the	  double	  mutation	  
S184A/S374A	   partially	   rescues	   sensitivity	   of	   yeast	   cells	   to	   VPA	   (Fig.	   2.9A,B),	   and	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increases	  activity	  of	  the	  enzyme	  (Fig.	  2.9C).	  I	  speculate	  that	  VPA	  triggers	  a	  signal(s)	  that	  
culminates	  in	  the	  phosphorylation	  of	  MIPS.	  	  
It	  is	  possible	  that	  MIPS	  is	  regulated	  by	  phosphorylation	  of	  additional	  sites,	  which	  
may	  not	  have	  been	  detected	   in	   the	   current	   study.	   The	  use	  of	   the	  GAL1-­‐driven	   vector	  
was	   essential	   for	   obtaining	   sufficient	   amounts	   of	   the	   enzyme	   for	   characterizing	  MIPS	  
activity	   and	   for	   the	   MS	   analysis.	   However,	   overexpression	   may	   have	   perturbed	   the	  
stoichiometric	   balance	   of	   phosphorylation,	   thus	   underestimating	   the	   importance	   of	  
phosphorylation	   of	   some	   residues.	   It	   is	   also	   possible	   that	   overexpression	   may	   have	  
mistargeted	   the	   protein	   and	   exposed	   it	   to	   non-­‐physiological	   phosphorylation.	  
Phosphorylation	   of	   some	   amino	   acids	   may	   be	   transient	   (rapidly	   reversible).	   It	   is	   also	  
possible	  that	  phosphorylation	  may	  occur	  in	  a	  sequential	  manner,	  in	  which	  a	  phosphate	  
at	   one	   residue	   may	   be	   required	   to	   activate	   a	   kinase	   that	   phosphorylates	   another	  
residue(s).	  For	  example,	  phosphorylation	  of	  S374	  may	  facilitate	  the	  phosphorylation	  of	  
S184	  because	  the	  increase	  in	  activity	  following	  dephosphorylation	  of	  a	  single	  mutant	  is	  
almost	   half	   of	   that	   observed	   for	   the	  WT.	   Alternatively,	   phosphorylation	  may	   occur	   at	  
different	  growth	  stages	  in	  response	  to	  different	  cues	  or	  signals.	  	  	  
While	   the	   replacement	   of	   serine	   with	   alanine	   or	   aspartate	   creates	  
phosphodeficient	  or	  phosphomimetic	  mutations,	  respectively,	  these	  mutations	  may	  not	  
recapitulate	   the	   phosphorylated	   residues’	   functions.	   The	   mutations	   may	   alter	   the	  
structural	   conformation	   of	   the	   enzyme,	   triggering	   changes	   in	   activity	   that	   are	   not	  
necessarily	  reflective	  of	  a	  phosphosite.	  However,	  my	  findings	  are	  strongly	  supported	  by	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MS	   data,	   which	   unambiguously	   show	   that	   the	   residues	   identified	   in	   MIPS	   are	  
phosphosites.	   The	   correlation	   between	   the	   growth	   experiments	   and	   enzyme	   activity	  
demonstrates	  that	  MIPS	  activity	  is	  regulated	  by	  phosphorylation.	  
The	   work	   reported	   here	   identifies	   for	   the	   first	   time	   a	   novel	   mechanism	   of	  
regulation	   of	   inositol	   biosynthesis.	   	   The	   knowledge	   that	   MIPS	   is	   regulated	   by	  
phosphorylation	  will	  facilitate	  studies	  to	  identify	  signals	  that	  play	  a	  role	  in	  regulating	  this	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INTRODUCTION	  
	  
The	   “inositol	   depletion	   hypothesis”	   proposed	   by	   Sir	   Michael	   Berridge	   in	   the	  
1980s	   suggested	   that	   inositol	   depletion	   caused	   by	   lithium	   leads	   to	   a	   decrease	   in	   IP3-­‐
mediated	   signaling	   (Berridge,	   1988).	   However,	   the	   mechanism	   underlying	   the	  
therapeutic	   effect	   of	   decreased	   signaling	   is	   not	   obvious,	   suggesting	   that	   alternate	  
consequences	  of	  inositol	  depletion	  may	  underlie	  the	  therapeutic	  mechanism.	  Valproate	  
(VPA),	   an	   anticonvulsant	   drug	   that	   for	   decades	   has	   been	   used	   successfully	   for	   the	  
treatment	  of	  epilepsy	  and	  bipolar	  disorder,	  also	  causes	  inositol	  depletion	  (Vaden	  et	  al.,	  
2001).	  The	  mechanism	  that	  underlies	   its	  therapeutic	  efficacy	   is	  not	  known.	  In	  humans,	  
perturbation	   of	   inositol	   and	   phosphoinositide	   metabolism	   is	   associated	   with	   several	  
disorders,	  including	  bipolar	  disorder	  (Belmaker,	  2004),	  Alzheimer’s	  disease	  (McLaurin	  et	  
al.,	  1998;	  Shimohama	  et	  al.,	  1998),	  Lowe’s	  syndrome	  (Lowe,	  2005),	  X-­‐linked	  myotubular	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myopathy	  (Laporte	  et	  al.,	  1996;	  Taylor	  et	  al.,	  2000),	  and	  Type	  2	  diabetes	  (Clement	  et	  al.,	  
2001;	  Marion	  et	  al.,	  2002).	  The	  genetic	  disorders	  Charcot-­‐Marie-­‐Tooth	  disease	  (Chow	  et	  
al.,	  2009),	  and	  fleck	  corneal	  dystrophy	  (Kotoulas	  et	  al.,	  2011)	  are	  specifically	  associated	  
with	  dysfunction	  of	  the	  phosphoinositide	  PI3,5P2.	  	  
PI3,5P2	   is	   	   the	   signature	   phosphoinositide	   of	   the	   vacuole	   (the	   yeast	   lysosome)	  
(Strahl	   and	   Thorner,	   2007)	   .	   It	   is	   generated	   from	   PI3P	   by	   the	   sole	   conserved	   kinase	  
Fab1p	   (the	   homolog	   of	   PIKfyve)	   (Cooke	   et	   al.,	   1998;	   Gary	   et	   al.,	   2002;	   Sbrissa	   et	   al.,	  
1999),	   which	   is	   positively	   regulated	   by	   Vac7p	   and	   Vac14p.	   	   Together,	   Fab1p	   and	   its	  
regulators	   form	   part	   of	   a	   protein	   complex	   that	   localizes	   to	   the	   vacuolar	   membrane	  
during	  PI3,5P2	  synthesis	  (Duex	  et	  al,	  2006;	  Botelho	  et	  al.,	  2008).	  The	  regulated	  synthesis	  
and	   turnover	   of	   PI3,5P2	   is	   proposed	   to	   underlie	   many	   aspects	   of	   vacuole	   function	  
(Weisman,	   2003),	   including	   regulation	   of	   vacuolar	   ion	   transport,	   membrane	   efflux,	  
membrane	  turnover,	  and	  signaling	  (Baars	  et	  al.,	  2007;	  Weisman,	  2003;	  Efe	  et	  al.,	  2005;	  
Odorizzi	  et	  al.,	  2000).	  Although	  PI3,5P2	  makes	  up	  less	  than	  0.1%	  of	  all	  phosphoinositides	  
(Michell	  et	  al.,	  2006),	  its	  absence	  from	  the	  cell	  has	  a	  profound	  effect.	  The	  fab1∆	  mutant	  
(which	   cannot	   synthesize	   PI3,5P2)	   exhibits	   enlarged	   vacuoles,	   reduced	   vacuolar	  
acidification,	  and	  perturbed	  trafficking.	  The	  mechanism	  that	  leads	  to	  these	  phenotypes	  
is	   not	   known.	   It	   was	   suggested	   that	   PI3,5P2	   may	   modulate	   V-­‐ATPase	   activity,	   thus	  
explaining	   the	  decreased	  acidification	   (Weisman,	  2003).	   In	   the	   same	  context,	  Baars	  et	  
al.,	   (2007)	   showed	   that	   acidification	   of	   the	   vacuole	   is	   crucial	   for	   vacuolar	   fission,	  
suggesting	  that	  PI3,5P2	  supports	  vacuolar	  fission	  by	  regulating	  V-­‐ATPase	  activity.	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The	  V-­‐ATPase	  is	  an	  ATP-­‐driven	  proton	  pump	  (Fig.	  3.1).	  It	  plays	  a	  significant	  role	  in	  
maintaining	   the	   pH	   homeostasis	   necessary	   not	   only	   for	   the	   function	   of	   vacuoles,	   but	  
also	  for	  other	  organelles	  (Kane,	  2006).	  It	  mediates	  ATP-­‐driven	  proton	  transport	  across	  	  
membranes	  to	  acidify	  intracellular	  organelles	  and	  regulate	  the	  ionic	  balance	  within	  cells	  
(Kane,	  2007).	  Present	  in	  plasma	  membranes	  of	  specialized	  cells,	  the	  V-­‐ATPase	  regulates	  
extracellular	  pH	  (Breton	  and	  Brown,	  2007).	  In	  osteoclasts,	  the	  V-­‐ATPase	  facilitates	  bone	  
resorption	   (Blair	  et	  al.,	  1989;	  Kartner	  et	  al.,	  2010).	   In	  kidney	  cells,	   it	   is	   involved	   in	   the	  
regulation	  of	  systemic	  acid-­‐base	  balance	  (Brown	  et	  al.,	  2009).	  	  Neuronal	  cells	  require	  the	  
V-­‐ATPase	   for	   uptake	   and	   storage	  of	   neurotransmitters	   in	   synaptic	   vesicles	   (El	   Far	   and	  
Seagar,	  2011;	  El	  Far	  and	  Seagar,	  2011),	  and	  recent	  evidence	  indicates	  that	  the	  V-­‐ATPase	  
is	   required	   for	   endocytosis	   (Zhang	   et	   al.,	   2010)	   as	   well	   as	   for	   exocytosis	   and	  
neurotransmitter	  release	  (Di	  Giovanni	  et	  al.,	  2010;	  Poea-­‐Guyon	  et	  al.,	  2013).	  	  
The	   mechanism	   that	   links	   PI3,5P2	   to	   V-­‐ATPase	   was	   not	   well	   understood	   until	  
recently,	  when	  a	  report	  by	  Li	  et	  al.	  (2014)	  showed	  that	  PI3,5P2	  stabilizes	  the	  V1-­‐V0	  sector	  
interactions	   and	   activates	   the	   V-­‐ATPase.	   In	   this	   study,	   I	   examined	   the	   cellular	  
consequences	   of	   inositol	   depletion	   caused	   by	   VPA.	   As	   mentioned	   previously,	   the	  
therapeutic	  mechanism	  of	   this	  drug	   is	  not	  understood.	   	   I	   show	  that	   inositol	  depletion,	  
induced	   genetically	   (by	   starving	   inositol	   auxotrophs)	   and	   by	   VPA	   treatment,	   causes	   a	  
decrease	  in	  V-­‐ATPase	  activity	  and	  a	  disruption	  in	  PI3,5P2	  synthesis.	  This	  is	  the	  first	  report	  
to	  demonstrate	  a	  role	  of	  inositol	  in	  the	  activity	  of	  the	  V-­‐ATPase,	  and	  suggests	  a	  possible	  
new	  therapeutic	  mechanism	  of	  VPA.	  






FIGURE	   3.1.	   The	   vacuolar	   ATPase.	   The	   vacuolar	   ATPase	   (V-­‐ATPase)	   is	   an	   ATP-­‐driven	  
proton	  pump	  consisting	  of	  a	  membrane-­‐embedded	  V0	  domain	   (subunits	  a,	   c,	   c’,	   c”,	  d,	  
and	   e),	   and	   a	   peripheral	   V1	   domain	   (subunits	   A-­‐H).	   The	   energy	   generated	   from	   ATP	  
hydrolysis	  by	  the	  V1	  domain	  is	  coupled	  to	  the	  transport	  of	  protons	  across	  the	  V0	  domain	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MATERIALS	  AND	  METHODS	  
	  
Strains,	  media	  and	  growth	  conditions:	  
The	  Saccharomyces	  cerevisiae	  strains	  used	  in	  this	  work	  are	  listed	  in	  Table	  3.1.	  	  Cells	  were	  
maintained	  on	  YPD	  medium	  (2%	  bactopeptone,	  1%	  yeast	  extract,	  and	  2%	  glucose).	  For	  
growth	  of	  the	  deletion	  mutants,	  the	  medium	  was	  supplemented	  with	  G418	  (200	  µg/ml).	  
Synthetic	  minimal	  medium	  (SM)	  contained	  all	  the	  essential	  components	  of	  Difco®	  yeast	  
nitrogen	  base	  (minus	   inositol),	  2%	  glucose,	  0.2%	  ammonium	  sulfate,	  vitamins,	  and	  the	  
four	   amino	   acids	   histidine	   (20	   mg/L),	   leucine	   (60	   mg/L),	   methionine	   (20	   mg/L),	   and	  
lysine	   (20	  mg/L),	   and	   the	   nucleobase	   uracil	   (40	  mg/L).	  Where	   indicated,	   inositol	   was	  
used	   at	   a	   concentration	   of	   75	   µM	   (I+).	   For	   selection	   of	   cells	   carrying	   plasmids,	  
appropriate	  amino	  acids	  were	  omitted.	  For	  solid	  media,	  2%	  agar	  was	  added.	  To	  starve	  
cells	   for	   inositol,	   ino1Δ	   cells	  were	  grown	  overnight	   in	   SM	  supplemented	  with	   inositol,	  
harvested,	   washed	   twice	   in	   dH2O,	   and	   resuspended	   in	   inositol-­‐free	   medium	   (I-­‐).	   For	  
osmotic	   stress	   experiments,	   media	   were	   supplemented	   with	   0.9	   M	   NaCl.	   Growth	   in	  
liquid	  cultures	  was	  monitored	  spectrophotometrically	  by	  measuring	  absorbance	  at	  550	  
nm.	  All	  incubations	  were	  at	  30°C	  unless	  otherwise	  stated.	  
	  
Cytosolic	  pH	  measurement	  :	  
Cytosolic	  pH	  was	  measured	  using	  the	  yeast	  pHluorin,	  a	  pH-­‐sensitive,	  ratiometric	  green	  
fluorescent	   protein	   (Orij	   et	   al.,	   2009).	   Wild-­‐type	   cells	   were	   transformed	   with	   the	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construct	  pPGK-­‐pHluorin,	  a	  generous	  gift	  from	  Dr.	  Rajini	  Rao	  (Johns	  Hopkins	  University),	  
in	  which	   the	   yeast	   pHluorin	   is	   under	   control	   of	   a	   phosphoglycerate	   kinase	   promoter.	  
Transformants	  were	  selected	  on	  SM	  lacking	  uracil,	  and	  checked	  for	  fluorescence	  before	  
every	   experiment.	   Cells	   were	   grown	   to	   the	   mid-­‐log	   phase	   in	   selective	   SM	   with	   or	  
without	  75	  µM	  inositol,	   in	  the	  presence	  of	  different	  concentrations	  of	  VPA.	  Cells	  were	  
harvested	  by	   centrifugation,	  washed,	  and	   resuspended	   in	  50	  mM	  MES	  buffer	   (50	  mM	  
MES,	  50	  mM	  HEPES,	  50	  mM	  KCl,	  50	  mM	  NaCl,	  0.2	  M	  NH4	  acetate,	  10	  mM	  NaN3,	  10	  mM	  
2-­‐deoxyglucose).	   Fluorescence	   intensity	   was	  measured	   at	   excitation	   wavelengths	   405	  
and	   485	   nm,	   and	   emission	   wavelength	   508	   nm.	   A	   calibration	   curve	   was	   constructed	  
using	  buffers	  titrated	  to	  pH	  4,	  5,	  6,	  7,	  and	  8.	  Cells	  were	  incubated	  for	  one	  hour	  at	  30°C	  in	  
the	   presence	   of	   75	   µM	   monensin	   and	   10	   µM	   nigericin.	   	   	   A	   standard	   curve	   of	  




To	  visualize	  vacuolar	  membranes	  in	  vivo,	  cells	  were	  stained	  with	  the	  lipophilic	  dye	  FM4-­‐
64	  (Molecular	  Probes)	  as	  described	  (Vida	  and	  Emr,	  1995)	  with	  slight	  modifications.	  Cells	  
were	  grown	  overnight	  at	  30°C	  with	  constant	  shaking.	  One	  ml	  culture	  was	  pelleted	  and	  
resuspended	   in	   fresh	  medium	   containing	   10	  µM	  FM4-­‐64.	   Cells	  were	   incubated	   for	   30	  
min,	   harvested,	   washed	   twice	   and	   chased	   in	   fresh	   medium	   for	   about	   2	   h.	   For	  
microscopy,	   cells	  were	   pelleted	   and	   resuspended	   in	   a	   small	   volume	   of	   fresh	  medium	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with	  50	  mM	  PIPES.	  To	   immobilize	  cells,	  coverslips	  were	  coated	  with	  a	  thin	   layer	  of	  1%	  
agarose	  dissolved	  in	  SM.	  Cells	  were	  examined	  using	  a	  fluorescence	  microscope.	  	  
	  
Vacuole	  isolation,	  V-­‐ATPase	  activity	  and	  coupling	  assays:	  
For	   isolation	   of	   vacuoles	   from	   VPA-­‐treated	   wild-­‐type	   cells,	   the	   cells	   were	   grown	  
overnight	   in	   I-­‐	  medium	   to	   the	  mid-­‐log	   phase.	   	   The	   cells	  were	   diluted	   two-­‐fold	   in	   the	  
same	  medium,	   then	  divided	   into	   three	   separate	   samples:	   	   control	   (no	  additions),	  VPA	  
(0.6	   mM	   VPA	   added),	   and	   VPA	   +	   inositol	   (0.6	   mM	   VPA	   +	   100	   µM	   inositol).	   	   The	  
incubation	  was	   continued	   for	   3.5	   hours	   at	   30°C	  with	   shaking.	   	   	   For	   experiments	  with	  
ino1∆,	   cells	   were	   grown	   overnight	   in	   I+	   medium	   to	   the	   mid-­‐log	   phase,	   washed,	   and	  
resuspended	   in	   I-­‐	   medium	   buffered	   to	   pH	   5	   with	   50	   mM	   2-­‐(N-­‐
morpholino)ethanesulfonic	   acid.	   	   For	   the	   I+	   samples,	   cells	   were	   resuspended	   to	   a	  
density	  of	  0.3	  OD600/ml	  (to	  allow	  for	  growth	  during	  the	  incubation)	  and	  75	  µM	  inositol	  
was	  added.	  	  The	  I-­‐	  samples	  were	  resuspended	  to	  1.0	  OD600/ml	  and	  showed	  little	  growth	  
during	  the	  incubation.	  	  Both	  samples	  were	  incubated	  for	  4	  hours	  at	  30°C	  with	  shaking.	  	  
After	  incubation,	  cells	  from	  both	  types	  of	  experiments	  were	  converted	  to	  spheroplasts	  
and	   washed	   and	   vacuolar	   vesicles	   were	   isolated	   through	   two	   Ficoll	   density	   gradient	  
centrifugation	  steps	  as	  described	  (Roberts	  et	  al.,	  1991).	  
ATPase	  activity	  was	  assessed	  by	  a	  coupled	  enzyme	  assay	  (Lotscher	  et	  al.,	  1984)	  
and	  V-­‐ATPase	  activity	  was	  determined	  by	  measuring	  ATPase	  activity	  in	  the	  presence	  and	  
absence	   of	   the	   V-­‐ATPase	   specific	   inhibitor	   concanamycin	   A	   (VWR).	   	   Total	   vacuolar	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protein	   was	   measured	   by	   Lowry	   assay	   (Lowry	   et	   al.,	   1951).	   	   Proton	   pumping	   was	  
measured	  by	   the	  9-­‐amino-­‐6-­‐chloro-­‐2-­‐methoxyacridine	   (ACMA)	   fluorescence	  quenching	  
assay	   (Liu	   et	   al.,	   2005).	   	   Pumping	   was	   initiated	   by	   addition	   of	   ATP	   and	  Mg2+	   to	   final	  
concentrations	   of	   0.5	   mM	   and	   1	   mM,	   and	   was	   inhibited	   by	   the	   addition	   of	   100	   nM	  
concanamycin	   A.	   Coupling	   ratios	   were	   calculated	   by	   determining	   the	   rate	   of	  
fluorescence	  quenching	  per	  mg	  of	  vacuolar	  protein	  during	  the	  first	  10	  sec	  after	  MgATP	  
addition	  and	  dividing	  that	  rate	  by	  the	  rate	  of	  concanamycin-­‐sensitive	  ATP	  hydrolysis	  per	  
mg	  protein.	  	  
	  
Fluorescence	  microscopy:	  	  
Imaging	   of	   yeast	   cells	   was	   performed	   using	   an	   Olympus	   BX41	   epifluorescence	  
microscope.	  Images	  were	  acquired	  using	  an	  Olympus	  Q-­‐Color3,	  a	  digital	  charge-­‐coupled	  
device	  (CCD)	  camera	  operated	  by	  QCapture2	  software.	  The	  plasmids	  pRS415-­‐FYVE-­‐GFP	  
used	   to	   localize	   PI3P,	   and	  pRS416-­‐Atg18-­‐GFP	  used	   to	   localize	   PI3,5P2	  were	   a	   kind	   gift	  
from	  Dr.	  Scott	  Emr	  (Cornell	  University).	  
	  
Electron	  microscopy	  :	  
Cells	   were	   grown	   in	   synthetic	   minimal	   medium	   to	   the	   mid-­‐log	   phase.	   	   Cells	   were	  
harvested,	  and	  fixed	  in	  3%	  glutaraldehyde,	  0.1	  M	  Na-­‐Cacodylate	  pH	  7.4,	  5	  mM	  CaCl2,	  5	  
mM	  MgCl2,	   2.5%	   sucrose,	   stained	  with	   osmium-­‐thiocarbohydrazide,	   and	   subjected	   to	  
EM	  analysis	  at	  the	  Integrated	  Imaging	  Center	  at	  Johns	  Hopkins	  University.	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MATa,	   his	   3Δ1,	   	   leu	   2Δ0,	   met	   15Δ0,	   ura	  
3Δ0	  
	  Invitrogen	  
ino1Δ 	   MATa,	   his	   3Δ1,	   leu	   2Δ0,	   met	   15Δ0,	   ura	  
3Δ0,	  ino1Δ::KanMX4	   Invitrogen	  
vma3Δ 	   MATa,	   his	   3Δ1,	   leu	   2Δ0,	   met	   15Δ0,	   ura	  
3Δ0,	  vma3Δ::KanMX4	   Invitrogen	  
vma9Δ 	   MATa,	   his	   3Δ1,	   leu	   2Δ0,	   met	   15Δ0,	   ura	  
3Δ0,	  vma9Δ::KanMX4	   Invitrogen	  
vma11Δ 	   MATa,	   his	   3Δ1,	   leu	   2Δ0,	   met	   15Δ0,	   ura	  
3Δ0,	  vma11Δ::KanMX4	   Invitrogen	  
vma16Δ 	   MATa,	   his	   3Δ1,	   leu	   2Δ0,	   met	   15Δ0,	   ura	  
3Δ0,	  vma16Δ::KanMX4	   Invitrogen	  
vph1Δ 	   MATa,	   his	   3Δ1,	   leu	   2Δ0,	   met	   15Δ0,	   ura	  
3Δ0,	  vph1Δ::KanMX4	   Invitrogen	  
stv1Δ 	   MATa,	   his	   3Δ1,	   leu	   2Δ0,	   met	   15Δ0,	   ura	  
3Δ0,	  stv1Δ::KanMX4	  
Invitrogen	  

















VPA	   perturbs	   the	   vacuolar	   structure	   in	   a	  manner	   similar	   to	   that	   caused	   by	   inositol	  
starvation:	  	  
The	   vacuolar	   structure	   is	   dependent	   on	   the	   delicate	   balance	   of	   solutes	   between	   the	  
vacuolar	  and	  cytosolic	  compartments.	  This	  balance	  is	  largely	  determined	  by	  the	  vacuolar	  
membrane,	  which	  has	  a	  distinctive	  lipid	  composition	  (Li	  and	  Kane,	  2009)	  and	  a	  variety	  of	  
protein	   pumps	   that	   transport	   ions	   and	   protons	   across	   the	  membrane	   (Cagnac	   et	   al.,	  
2010).	  The	  proton	  gradient	  is	  maintained	  by	  the	  V-­‐ATPase,	  which	  acidifies	  the	  vacuole.	  
In	   yeast,	   loss	   of	   function	   of	   the	   V-­‐ATPase	   results	   in	   a	   vma-­‐	   phenotype,	   partly	  
characterized	  by	  poorly	   acidified	   vacuoles,	   and	   sensitivity	   to	   elevated	  extracellular	   pH	  
and	  high	  concentrations	  of	  calcium	  (Kane,	  2006).	  	  
A	  screen	  of	  the	  yeast	  deletion	  collection	  was	  previously	  carried	  out	  by	  Yihui	  Shi	  
(Ph.D.	  Dissertation,	  2005).	  Several	  vma	  mutants	  were	  found	  to	  be	  sensitive	  to	  VPA.	  This	  
suggested	  that	  VPA	  may	  perturb	  the	  vacuolar	  structure.	  To	  test	  this	  possibility,	  WT	  cells	  
were	   grown	   overnight	   in	   synthetic	  medium	   in	   the	   presence	   or	   absence	   of	   VPA.	   VPA-­‐
treated	   cells	   exhibited	  decreased	   incorporation	  of	   FM4-­‐64	   (Fig.	   3.2),	  which	  enters	   the	  
cells	  by	  endocytosis	  and	   labels	  the	  vacuolar	  membrane.	   In	  contrast,	  cells	  grown	  in	  the	  
absence	  of	  VPA	  exhibited	  clear,	  well-­‐defined	  vacuoles.	  Inositol	  supplementation	  rescued	  
the	   vacuolar	   defect	   of	   VPA-­‐treated	   cells,	   suggesting	   that	   inositol	   depletion	   caused	   by	  
VPA	  is	  responsible	  for	  perturbing	  the	  vacuolar	  membrane.	  To	  determine	  if	  vacuolar	  	  







FIGURE	   3.2.	   	   Vacuolar	   defects	   in	   VPA-­‐treated	   cells	   are	   rescued	   by	   supplementation	  
with	   inositol.	  To	  determine	   the	  effects	  of	  VPA	  on	  wild-­‐type	  cells,	   cells	  were	  grown	  to	  
the	  mid-­‐log	  phase	  in	  SM	  with	  or	  without	  1	  mM	  VPA	  and	  75	  µM	  inositol.	  The	  effects	  of	  
inositol	   starvation	  were	  determined	   in	   ino1Δ	   cells	  precultured	   in	  SM	   I+,	  washed	  2x	   to	  
remove	   inositol,	   and	   resuspended	   in	   SM	   I-­‐	   .	   To	   visualize	   vacuoles,	   cells	   were	   stained	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perturbation	   is	   inositol	  dependent,	   ino1Δ	  cells,	  which	  cannot	  synthesize	   inositol,	  were	  
grown	   overnight	   in	   the	   presence	   of	   inositol	   (I+)	   and	   then	   switched	   to	   I-­‐	   medium	   to	  
induce	   inositol	   starvation.	   FM4-­‐64	   staining	   showed	  a	  pattern	  of	   vacuolar	  perturbation	  
similar	   to	   that	   observed	   in	   the	   VPA-­‐treated	   cells	   (Fig.	   3.2).	   Taken	   together,	   these	  
findings	   suggest	   that	   VPA	   perturbs	   vacuolar	   structure	   as	   a	   consequence	   of	   inositol	  
depletion.	  	  
	  
VPA	  decreases	  V-­‐ATPase	  proton-­‐pumping:	  	  
V-­‐ATPases	   catalyze	  ATP-­‐driven	   proton	   transport.	   	   To	   determine	   if	   perturbation	   of	   the	  
vacuole	   is	   a	   consequence	   of	   altered	   V-­‐ATPase	   function,	   the	   activity	   of	   ATPase	   and	  
proton	   pumping	   was	   measured	   in	   vacuolar	   vesicles	   isolated	   from	   wild-­‐type	   cells	  
deprived	   of	   inositol	   and	   treated	   with	   0.6	   mM	   VPA,	   in	   the	   presence	   and	   absence	   of	  
inositol	   (100	   mM).	   	   As	   shown	   in	   Fig.	   3.3A,	   VPA	   reduced	   ATPase	   activity,	   and	   this	  
reduction	  was	  not	  rescued	  by	  the	  presence	  of	  inositol.	  	  VPA	  had	  an	  even	  more	  striking	  
effect	   on	   proton	   pumping,	   as	   shown	   in	   Fig.	   3.3B.	   	   Addition	   of	   MgATP	   to	   untreated	  
vacuolar	  vesicles	   results	   in	   rapid	  quenching	  of	  ACMA	   fluorescence,	  which	   is	   reversible	  
upon	   addition	   of	   the	   V-­‐ATPase	   inhibitor	   concanamycin	   A.	   In	   contrast,	   VPA-­‐treated	  
vacuoles	  exhibited	  no	  MgATP-­‐driven	  proton	  pumping.	   	  (In	  some	  preparations,	  reduced	  
levels	  of	  proton	  pumping	  were	  observed.)	  	  In	  vacuolar	  vesicles	  treated	  with	  inositol	  and	  
VPA,	  a	  small	  amount	  of	  proton	  pumping	  was	  observed.	  	  
	  





FIGURE	  3.3.	  	  VPA	  inhibits	  V-­‐ATPase	  activity	  and	  reduces	  coupling	  in	  WT	  cells.	  A,	  Mean	  
concanamycin	   A-­‐sensitive	   ATPase	   activity	   (mmol	   ATP	   hydrolyzed/min/mg	   protein)	   for	  
two	  independent	  vacuolar	  preparations	  is	  shown;	  error	  bars	  represent	  the	  range	  of	  the	  
two	  measurements.	  	  B,	  Proton	  pumping	  assay	  for	  one	  of	  the	  two	  vacuole	  preparations	  is	  
shown.	   At	   the	   indicated	   times,	   MgATP	   was	   added	   to	   initiate	   proton	   pumping,	   and	  
concanamycin	  A	  was	  added	  to	   inhibit	  the	  V-­‐ATPase.	  C,	  Coupling	  ratios	  were	  calculated	  
for	  each	  sample	  as	  described	  under	  “Materials	  and	  Methods.”	  	  The	  average	  ratio	  of	  two	  
independent	  measurements	  is	  shown,	  with	  error	  bars	  corresponding	  to	  the	  range.	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   The	  coupling	  ratio	  represents	  a	  ratio	  of	  the	   initial	  rates	  of	  proton	  pumping	  and	  
ATP	   hydrolysis;	   if	   ATPase	   activity	   and	   proton	   pumping	   are	   compromised	   to	   the	   same	  
degree	   by	   valproate	   treatment,	   the	   coupling	   ratio	  will	   be	   the	   same	   as	   in	   the	   control.	  	  
The	  average	   coupling	   ratio	   for	   the	   two	   independent	   vacuole	  preparations	   is	   shown	   in	  
Fig.	  3.3C.	  	  VPA	  treatment	  reduced	  the	  coupling	  ratio,	  consistent	  with	  a	  greater	  inhibition	  
of	   proton	  pumping	   than	  ATPase	   activity,	   but	   the	   vesicles	   from	   inositol	   and	   valproate-­‐
treated	   cells	   had	   a	   wild-­‐type	   coupling	   ratio.	   	   These	   results	   suggest	   that	   valproate	  
partially	   uncouples	   ATP	   hydrolysis	   from	   proton	   pumping,	   but	   loss	   of	   coupling	   can	   be	  
prevented	   by	   the	   presence	   of	   inositol.	   Although	   the	   inositol	   dependence	   of	   the	   VPA	  
effect	   on	   coupling	   was	   striking,	   inositol	   did	   not	   rescue	   the	   reduced	   activity	   of	   the	  
enzyme	  in	  the	  presence	  of	  valproate	  (Fig.	  3.3A).	  	  	  
In	  order	  to	  further	  explore	  the	  possibility	  that	  inositol	  deprivation	  could	  account	  
for	   uncoupling	   of	   the	   V-­‐ATPase	   by	   VPA,	   vacuolar	   vesicles	   were	   isolated	   from	   ino1∆	  
mutants	  incubated	  in	  the	  presence	  or	  absence	  of	  added	  inositol.	  	  As	  shown	  in	  Fig.	  3.4A,	  
inositol	   deprivation	   reduced	   ATP	   hydrolysis	   by	   an	   average	   of	   59%,	   but	   had	   a	   much	  
greater	  effect	  on	  proton	  pumping	  and	  coupling	   ratio	   (Figure	  3.4B	   and	  C).	   	   Figure	  3.4B	  
shows	  a	  complete	  loss	  of	  proton	  pumping;	  some	  preps	  showed	  a	  low	  level	  of	  pumping	  
after	  inositol	  deprivation,	  but	  in	  all	  cases,	  the	  coupling	  ratio	  was	  reduced.	  	  These	  results	  
are	  similar	  to	  those	  observed	  for	  vesicles	  from	  VPA-­‐treated	  cells,	  and	  indicate	  that	  VPA	  
may	  uncouple	  the	  V-­‐ATPase	  by	  inositol	  depletion,	  even	  though	  inositol	  supplementation	  
does	  not	  fully	  reverse	  the	  effects	  of	  VPA.	  	  	  





FIGURE	  3.4.	  	  Inositol	  depletion	  inhibits	  V-­‐ATPase	  activity	  and	  reduces	  coupling.	  	  ino1∆	  
cells	  were	  grown	  in	  SM	  I+	  	  overnight,	  then	  washed	  twice	  and	  resuspended	  in	  either	  SM	  
I+	  	  or	  SM	  I-­‐	  	  and	  incubated	  for	  4	  hrs	  at	  30°C.	  	  Vacuolar	  vesicles	  were	  isolated	  as	  
described	  under	  “Materials	  and	  Methods.”	  A,	  Mean	  concanamycin	  A-­‐sensitive	  ATPase	  
activity	  (in	  mmol	  ATP	  hydrolyzed/min/mg	  protein)	  is	  shown	  for	  three	  independent	  
vacuole	  preparations.	  	  Error	  bars	  represent	  S.E.	  	  B,	  Proton	  pumping	  assay	  for	  one	  of	  the	  
three	  preparations	  is	  shown.	  C,	  The	  coupling	  ratio	  was	  calculated	  for	  each	  sample	  as	  
described	  under	  “Materials	  and	  Methods”.	  The	  mean	  is	  shown,	  with	  error	  bars	  
corresponding	  to	  S.E.	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To	   determine	   if	   VPA	   causes	   growth	   defects	   associated	   with	   loss	   of	   V-­‐ATPase	  
function,	  I	  examined	  wild-­‐type	  (WT)	  cells	  for	  their	  ability	  to	  grow	  at	  pH	  7.5	  and	  100	  mM	  
CaCl2	  	  in	  the	  presence	  or	  absence	  of	  VPA	  (Fig.	  3.5).	  The	  vma3Δ	  cells	  (used	  as	  a	  control)	  
showed	  a	  clear	  vma-­‐	  phenotype,	   including	   inability	  to	  grow	  at	  elevated	  pH	  and	  in	  high	  
calcium.	  In	  contrast,	  WT	  cells	  grown	  in	  the	  presence	  of	  VPA	  were	  able	  to	  grow	  in	  these	  
conditions.	  Thus,	  although	  VPA	  causes	  a	  decrease	  in	  V-­‐ATPase	  activity,	  the	  effect	  is	  not	  
sufficient	  to	  cause	  a	  vma-­‐	  phenotype.	  	  	  
Because	  only	  a	  subset	  of	  the	  vma	  mutants	  were	  identified	  in	  the	  screen	  for	  VPA	  
sensitivity,	  I	  further	  explored	  the	  sensitivity	  of	  the	  vma	  	  mutants,	  and	  particularly	  those	  
disrupting	  subunits	  of	  the	  membrane	  bound	  V0	  sector,	  to	  VPA.	  All	  of	  the	  vmaΔ	  mutants	  
tested	  showed	  sensitivity	  to	  VPA,	  and	  this	  sensitivity	  was	  rescued	  by	  inositol	  (Fig.	  3.6).	  
Vph1	  and	  Stv1	  encode	  two	  isoforms	  of	  the	  largest	  membrane	  subunit	  of	  the	  V-­‐ATPase.	  
Single	  deletion	  mutants	  of	  these	  subunits	  exhibit	  modest	  VPA	  sensitivity	  that	  is	  rescued	  
by	   inositol.	  These	  findings	  suggest	   that	  VPA	  triggers	  an	   inositol-­‐dependent	  mechanism	  
that	  exacerbates	  the	  vma-­‐	  phenotype.	  At	  least	  three	  possible	  mechanisms	  may	  explain	  
this	  outcome:	  
First,	   VPA	   may	   alter	   cytosolic	   pH,	   which	   could	   be	   detrimental	   to	   the	   vma-­‐	  
mutants	   already	   defective	   in	   cellular	   pH	   homeostasis.	   To	   test	   this,	   I	   used	   a	   pHluorin-­‐
based	  assay	  (Orij	  et	  al.,	  2009)	  to	  measure	  the	  effect	  of	  different	  VPA	  concentrations	  on	  	  
cytosolic	  pH.	  Within	   the	   range	  of	  concentrations	  of	  VPA	  used	   therapeutically,	  VPA	  did	  
not	  alter	  the	  cytosolic	  pH	  (Fig.	  3.7).	  A	  second	  possibility	  is	  that	  VPA	  triggers	  a	  mechanism	  






FIGURE	   3.5.	   	   VPA	   does	   not	   cause	   a	   vma-­‐	   phenotype.	   Wild-­‐type	   (WT)	   BY4741	   and	  
isogenic	   vma3Δ	   mutant	   cells	   were	   precultured	   in	   SM	   I+,	   washed	   twice	   to	   remove	  
inositol,	  and	  spotted	  in	  a	  10-­‐fold	  dilution	  series	  on	  SM	  in	  the	  presence	  or	  absence	  of	  75	  
µM	  inositol	  and	  2	  mM	  VPA.	  Media	  were	  buffered	  to	  either	  pH	  5.5	  or	  7.5,	  or	  unbuffered	  


















FIGURE	  3.6.	  	  Inositol	  rescues	  sensitivity	  of	  V-­‐ATPase	  V0	  deletion	  mutants	  to	  VPA.	  Wild-­‐
type	  (WT)	  BY4741	  and	   isogenic	  vmaΔ	  mutant	  cells	  were	  precultured	   in	  SM	  I+,	  washed	  
twice	  to	  remove	  inositol,	  and	  spotted	  in	  a	  10-­‐fold	  dilution	  series	  on	  SM	  in	  the	  presence	  












FIGURE	  3.7.	  	  Cytosolic	  pH	  is	  not	  altered	  by	  VPA	  treatment.	  	  Cytosolic	  pH	  was	  measured	  
in	  wild-­‐type	  cells	   containing	   the	  construct	  pPGK	  pHluorin	  harboring	   	  a	  yeast	  pHluorin.	  
Cells	  were	  grown	  to	  the	  mid	  log	  phase	  in	  SM	  (Ura-­‐)	  with	  or	  without	  75	  µM	  inositol	  and	  
the	  indicated	  concentrations	  of	  VPA.	  Cells	  were	  harvested,	  washed,	  and	  resuspended	  in	  
neutral	  buffer.	  Fluorescence	  intensity	  was	  measured	  at	  excitation	  wavelengths	  405	  and	  
485	   nm,	   and	   emission	   wavelength	   of	   508	   nm.	   A	   calibration	   curve	   constructed	   using	  
buffers	  titrated	  to	  pH	  4,	  5,	  6,	  7,	  and	  8,	  was	  used	  to	  convert	  the	  fluorescence	  values	  to	  
cytosolic	  pH.	  Values	  represent	  the	  mean	  of	  three	  independent	  experiments	  ±	  S.E.	  (error	  
bars).




that	  increases	  intracellular	  calcium	  levels,	  which	  inhibit	  growth	  of	  vma-­‐	  mutants.	  This	  is	  
not	  likely	  as	  VPA	  does	  not	  appear	  to	  inhibit	  growth	  of	  wild-­‐type	  cells	  in	  the	  presence	  of	  
high	   Ca+2	   	   (Fig.	   3.5).	   A	   third	   possibility	   is	   that	   VPA	   disrupts	   the	   synthesis	   of	  
phosphoinositides,	  and	  that	  this	  deleteriously	  affects	  the	  V-­‐ATPase.	  This	  possibility	  was	  
investigated	  further.	  	  
	  
VPA	  alters	  the	  dynamics	  of	  vacuolar	  PI3,5P2	  :	  
I	  addressed	  the	  possibility	   that	  VPA-­‐induced	   inositol	  depletion	  affects	  PI3,5P2	  ,	   the	  key	  
phosphoinositide	  of	  the	  vacuolar	  membrane.	   It	  was	  previously	  shown	  that	  VPA	  causes	  
inositol	   depletion	   within	   the	   first	   few	   hours	   after	   addition	   to	   growing	   cells	   (Ju	   and	  
Greenberg	   (2003);	  Vaden	  et	  al.,	  2001).	  To	  monitor	   the	  effect	  of	  VPA	  treatment	  on	  the	  
dynamics	  of	  PI3,5P2,	  I	  visualized	  this	  phosphoinositide	  in	  the	  vacuolar	  membrane	  over	  a	  
period	  of	  four	  hours	  using	  a	  GFP-­‐tagged	  FLARE	  containing	  an	  atg18	  domain	  (Efe	  et	  al.,	  
2007)	   that	   specifically	   recognizes	  PI3,5P2	   (Fig.	  3.8).	  Within	   the	   first	   two	  hours,	   striking	  
differences	   were	   observed	   between	   the	   treated	   and	   untreated	   cells	   (Fig.	   3.8).	   VPA-­‐
treated	   cells	   showed	   punctate	   fluorescent	   structures	   on	   the	   vacuolar	   membrane,	  
indicative	   of	   localized	   accumulation	   of	   PI3,5P2	   in	   those	   structures.	   These	   punctae	  
persisted	   for	   a	   short	   time	   (less	   than	   an	   hour)	   and	   then	   gradually	   diminished	   as	   the	  
vacuole	   grew	   in	   size.	   In	   the	   untreated	   cells,	   smaller	   punctae	   formed.	   Interestingly,	  
however,	   these	   punctae	   rapidly	   developed	   into	   fluorescent,	  membranous,	   bubble-­‐like	  
structures	   (arrows	   in	   Fig.	   3.8),	   which	   protruded	   into	   the	   lumen	   of	   the	   original	   large	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vacuole.	   These	   protrusions	   formed	   septae	   that	   resulted	   in	   the	   fragmentation	   of	   the	  
original	  large	  vacuole	  into	  multiple	  smaller	  ones.	  The	  intense	  fluorescence	  indicates	  that	  
these	   membranes	   are	   enriched	   with	   PI3,5P2,	   which	   suggests	   that	   vacuolar	   fission	   is	  
preceded	   by	   a	   phase	   of	   increased	   PI3,5P2	   synthesis.	   	   This	   phenomenon	   was	   not	  
observed	  in	  the	  VPA-­‐treated	  cells,	  in	  which	  fluorescent	  membranes	  were	  not	  observed	  
to	  emerge	  out	  of	  punctae.	  The	  vacuoles	  continued	  to	   increase	   in	  size	   for	  a	   few	  hours,	  
after	  which	  the	  single	  enlarged	  vacuole	  started	  to	  shrink	  in	  size,	  rather	  than	  divide	  into	  
multiple	   small	   vacuoles.	   Starvation	   for	   inositol	   in	   ino1Δ	   cells	   resulted	   is	   a	   similar	  
phenotype	  (Fig.	  3.8).	  Taken	  together,	  these	  observations	  suggest	  that	  VPA	  perturbs	  the	  
synthesis	   of	   PI3,5P2-­‐enriched	   membranes,	   possibly	   by	   decreasing	   the	   synthesis	   of	  
PI3,5P2	   during	   the	   first	   two	   hours.	   As	   a	   consequence,	   the	   vacuoles	   do	   not	   undergo	  
fission	   but	   remain	   enlarged,	   a	   phenotype	   similar	   to	   that	   of	   the	   fab1Δ	  mutant,	  which	  
cannot	  synthesize	  PI3,5P2	  	  	  (Yamamoto	  et	  al.,	  1995).	  
Electron	   microscopic	   (EM)	   analysis	   of	   cellular	   changes	   associated	   with	   VPA	  
treatment	  showed	  that	  VPA	  enhances	  vacuole	  fusion	  within	  the	  first	  hour	  of	  exposure	  
to	   the	   drug	   (Fig.	   3.9A,B).	   In	   this	   analysis,	   80%	   of	   VPA-­‐treated	   cells	   showed	   fused	  
vacuoles	  compared	  to	  about	  20%	  in	  the	  untreated	  cells	  (Fig.	  3.9A,B).	  These	  results	  are	  
consistent	   with	   the	   finding	   shown	   in	   Fig.	   3.8,	   suggesting	   that	   VPA-­‐induced	   vacuolar	  
fusion	  may	  be	  a	  consequence	  of	  decreased	  synthesis	  of	  PI3,5P2.	  
	  
	  




FIGURE	   3.8.	   	   VPA	   alters	   the	   distribution	   of	   vacuolar	   PI3,5P2.	   Wild	   type	   cells	  
constitutively	  expressing	  a	  GFP-­‐tagged	  PI3,5P2-­‐binding	  probe	  (Atg18-­‐GFP)	  were	  grown	  in	  
SM	  at	  30°C	  to	  the	  mid-­‐log	  phase.	  VPA	  was	  added	  to	  a	  final	  concentration	  of	  2	  mM.	  	  Cells	  
were	  harvested	  at	  the	  indicated	  times	  following	  addition	  of	  the	  drug,	  and	  visualized	  by	  
fluorescence	  microscopy.	   Ino1Δ	   cells	  expressing	   the	  GFP-­‐tagged	  PI3,5P2-­‐binding	  probe	  
were	  initially	  grown	  in	  I+	  medium	  and	  then	  transferred	  to	  inositol	  deficient	  medium	  to	  
initiate	  starvation.	  Cells	  were	  harvested	  at	   the	   indicated	  times	   following	  starvation	  for	  
inositol.	  Scale	  bar,	  1	  µm.	  




FIGURE	  3.9.	  	  	  VPA	  enhances	  vacuolar	  fusion.	  A,	  Electron	  micrographs	  of	  wild-­‐type	  cells	  
grown	  in	  SM	  to	  the	  mid	  log	  phase	  and	  treated	  with	  VPA	  for	  the	  indicated	  times.	  Upper	  
panel,	  untreated	  cells	   (-­‐VPA);	  bottom	  panel,	   cells	   treated	  with	  1	  mM	  VPA	   (+VPA).	  The	  
label	   V	   indicates	   the	   vacuole.	   B,	   The	   percentage	   of	   VPA-­‐treated	   cells	   with	   single	  
enlarged	  vacuoles	  was	  compared	  to	  that	  of	  untreated	  cells.	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The	  increase	  in	  PI3,5P2	  in	  response	  to	  osmotic	  stress	  is	  limited	  in	  the	  presence	  of	  VPA:	  	  
PI3,5P2	   is	   the	   least	   abundant	   of	   the	   phosphoinositides	   in	   eukaryotic	   cells,	   comprising	  
less	   than	   0.1%	   of	   all	   phosphoinositides	   (Michell	   et	   al.,	   2006).	   The	   loss	   of	   PI3,5P2	   is	  
associated	  with	  an	  increase	  in	  vacuolar	  size	  (Yamamoto	  et	  al,	  1995),	  while	  an	  increase	  in	  
levels	   of	   PI3,5P2	   is	   associated	  with	   vacuolar	   fragmentation	   (Bonangelino	   et	   al.,	   2002).	  
Osmotic	  stress	  leads	  to	  a	  20-­‐fold	  increase	  in	  levels	  of	  PI3,5P2	  (Bonangelino	  et	  al.,	  2002)	  
and	   an	   increase	   in	   vacuolar	   fission.	   To	   determine	   if	   VPA	   interrupts	   the	   synthesis	   of	  
PI3,5P2,	   I	   exposed	  WT	   cells	   harboring	   the	  GFP-­‐tagged	  PI3,5P2	   FLARE	   to	  osmotic	   stress	  
and	   monitored	   the	   cells	   for	   accumulation	   of	   fluorescence.	   While	   the	   untreated	   cells	  
showed	   an	   increase	   in	   fluorescence	   within	   minutes	   of	   exposure	   to	   0.9	   M	   NaCl,	  
significantly	  less	  fluorescence	  was	  observed	  in	  VPA-­‐treated	  cells	  (Fig.	  3.10A).	  The	  finding	  
that	  osmotic	  stress,	  which	  normally	  causes	  an	  increase	  in	  PI3,5P2	  levels	  in	  cells,	  does	  not	  
cause	   a	   similar	   increase	   in	   VPA-­‐treated	   cells,	   suggests	   that	   VPA	   compromises	   the	  
synthesis	  of	  PI3,5P2.	  	  
Consistent	  with	  the	  association	  between	  vacuole	  size	  and	  PI3,5P2	  levels,	  osmotic	  
stress	   did	   not	   induce	   vacuolar	   fission	   in	   VPA-­‐treated	   cells	   (Fig.	   3.10B).	  WT	   cells	  were	  
exposed	  to	  0.9	  M	  NaCl	  in	  the	  presence	  or	  absence	  of	  VPA,	  and	  the	  number	  of	  vacuoles	  
per	  cell	  was	  monitored	  (Fig.	  3.10C).	  For	  this	  purpose,	  about	  100	  cells	  were	  counted	  for	  
each	   condition,	   and	   the	  percentage	  of	   cells	  with	  1,	   2-­‐3,	   4-­‐5,	   or	  more	   than	  5	   vacuoles	  
were	  calculated.	  In	  the	  absence	  of	  VPA,	  osmotic	  stress	  caused	  a	  shift	  towards	  a	  higher	  
number	  of	  vacuoles	  per	  cell	  (Fig.	  3.10C).	  In	  contrast,	  about	  85%	  of	  VPA-­‐treated	  cells	  had	  
	  




FIGURE	  3.10.	  	  Synthesis	  of	  PI3,5P2	  is	  perturbed	  in	  VPA-­‐treated	  cells.	  A,	  Levels	  of	  PI3,5P2	  
are	  higher	  in	  untreated	  cells	  (-­‐VPA)	  following	  exposure	  to	  osmotic	  shock.	  Wild	  type	  cells	  
constitutively	   expressing	   the	   GFP-­‐tagged	   PI3,5P2-­‐binding	   probe	   were	   grown	   in	   SM	   at	  
30°C	   to	   the	   mid-­‐log	   phase	   and	   treated	   with	   2	   mM	   VPA	   for	   one	   hour.	   Cells	   were	  
harvested	  and	  exposed	  to	  hyperosmotic	  stress	  for	  5	  min	  in	  SM	  containing	  0.9	  M	  NaCl.	  B,	  
Vacuolar	  fragmentation	  in	  response	  to	  hyperosmotic	  stress.	  C,	  Vacuolar	  morphology	  of	  
VPA-­‐treated	   and	   untreated	   cells	   was	   analyzed	   and	   quantified.	   The	   number	   of	   cells	  
containing	  1,	   2-­‐3,	   4-­‐5,	   or	   >5	   vacuoles	  was	  determined.	   For	   each	   condition,	   about	  100	  
cells	  were	  analyzed.	  The	  results	  are	  the	  mean	  of	  three	  independent	  experiments	  ±	  S.E.	  
(error	  bars).	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single	   vacuoles	   (Fig.	   3.10C).	   This	   suggested	   that	   the	   inhibition	   of	   PI3,5P2	   synthesis	  
persists	   even	   under	   osmotic	   stress.	   Interestingly,	   when	   VPA-­‐treated	   cells	   were	   kept	  
under	  osmotic	  stress	  for	  about	  2	  hours,	  total	   lysis	  of	  cells	  was	  observed.	  This	  suggests	  
that	   VPA	  may	   cause	   cell	   wall	   defects	   or	   perturbation	   of	   the	   cell	   wall	   integrity	   (CWI)	  
pathway,	   rendering	   cells	   sensitive	   to	   the	   increased	   turgor	   pressure	   caused	   by	   the	  
osmotic	   stress	   response.	   Alternatively,	   VPA	   may	   inhibit	   the	   osmotic	   stress	   response	  
pathway.	  Taken	  together,	  these	  findings	  suggest	  that	  VPA	  causes	  a	  constitutive	  decrease	  
in	  PI3,5P2	  ,which	  cannot	  be	  rescued	  by	  increased	  osmotic	  stress.	  	  
To	  determine	  if	  decreased	  PI3,5P2	  could	  be	  explained	  by	  decreased	  levels	  of	  PI3P	  
(the	   precursor	   of	   PI3,5P2),	   I	   visualized	   the	   changes	   in	   PI3P	   levels	   using	   fab1Δ	   cells	  
transformed	  with	   a	   PI3P-­‐specific	   GFP-­‐tagged	   FLARE	   (Burd	   and	   Emr,	   1998).	   The	   fab1Δ	  
mutant	   was	   used	   because	   PI3P	   localizes	   to	   the	   vacuole	   in	   the	   absence	   of	   FAB1,	   and	  
changes	   in	   levels	   of	   PI3P	   are	   thus	   easier	   to	   detect.	   VPA	   treatment	   did	   not	   cause	   a	  
decrease	  in	  PI3P	  levels	  (Fig.	  3.11).	  This	  observation	  suggests	  that	  the	  decrease	  in	  PI3,5P2	  
levels	  may	  be	  due	  to	  altered	  regulation	  of	  Fab1p	  or	  its	  regulators	  Vac7p	  and	  Vac14p.	  
	  
	  





FIGURE	   3.11.	   	   Levels	   of	   PI3P	   are	   not	   altered	   by	   VPA.	   Wild	   type	   cells	   constitutively	  
expressing	  a	  GFP-­‐tagged	  PI3P-­‐binding	  probe	   (FYVE-­‐GFP)	  were	  grown	   in	  SM	  at	  30°C	   to	  
the	   mid-­‐log	   phase.	   VPA	   was	   added	   to	   a	   final	   concentration	   of	   2	   mM.	   	   Cells	   were	  
harvested	   at	   the	   indicated	   times	   following	   addition	   of	   the	   drug,	   and	   visualized	   by	  














The	   current	   study	   shows	   for	   the	   first	   time	   that	   inositol	   depletion	  mediated	  by	  
VPA	  causes	  perturbation	  of	  the	  V-­‐ATPase	  and	  that	  VPA	  compromises	  PI3,5P2	  synthesis.	  I	  
report	  the	  following	  novel	  findings:	  (1)	  Inositol	  depletion	  by	  VPA	  or	  starvation	  of	  ino1Δ	  
cells	   leads	   to	   perturbation	   of	   vacuolar	   structure.	   (2)	   Inositol	   is	   required	   for	   V-­‐ATPase	  
function	   and	   coupling.	   (3)	   VPA	   causes	   partial	   uncoupling	   of	   the	   V-­‐ATPase.	   Inositol	  
depletion	  mediated	   by	  VPA	   causes	   a	   decrease	   in	   V-­‐ATPase	   activity	   and	   pumping.	   The	  
pumping	   defect,	   but	   not	   activity,	   is	   rescued	   by	   inositol.	   (4)	   VPA	   perturbs	   PI3,5P2	  
synthesis,	   inhibits	   vacuole	   fission	   and	   leads	   to	   vacuolar	   enlargement.	   These	  
perturbations	  are	  not	  rescued	  by	  osmotic	  stress	  which	  upregulates	  PI3,5P2	  when	  inositol	  
is	  present.	  These	  findings	  identify	  novel	  consequences	  of	  inositol	  depletion	  and	  provide	  
evidence	  for	  a	  previously	  unidentified	  link	  between	  inositol	  levels	  and	  the	  V-­‐ATPase.	  	  
The	   findings	   that	   inositol	   starvation	   perturbs	   the	   vacuole	   (Fig.	   3.2),	   and	   that	  
inositol	   supplementation	   rescues	   the	   decreased	   V-­‐ATPase	   activity	   and	   the	   decreased	  
coupling	  observed	  in	  inositol-­‐starved	  cells,	  indicate	  that	  inositol	  is	  required	  for	  V-­‐ATPase	  
function	   and	   coupling.	   V-­‐ATPase	   responds	   to	   environmental	   cues.	   The	   V0/V1	   complex	  
disassembles	   in	  response	  to	  glucose	  deprivation	  (Kane,	  1995).	  V-­‐ATPase	  activity	   is	  also	  
modulated	   by	   ATP	   (Arai	   et	   al.,	   1989).	   This	   work	   is	   the	   first	   to	   show	   that	   inositol	   is	  
capable	  of	  modulating	  V-­‐ATPase	  activity.	  One	  mechanism	  to	  explain	  this	  is	  based	  on	  the	  
availability	  of	  glucose-­‐6-­‐phosphate	  (G-­‐6-­‐P),	  a	  substrate	  that	  can	  drive	  either	  the	  inositol	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biosynthesis	  pathway	  or	  the	  glycolytic	  pathway.	  In	  the	  absence	  of	  exogenous	  inositol,	  de	  
novo	   biosynthesis	   of	   inositol	   is	   activated,	   using	   G-­‐6-­‐P	   as	   the	   key	   substrate	   for	  myo-­‐
inositol	   3-­‐phosphate	   synthase	   to	   generate	   inositol	   3-­‐P,	   which	   is	   subsequently	  
dephosphorylated	   to	   produce	   inositol.	   However,	   when	   inositol	   is	   supplied	   in	   the	  
medium,	  de	  novo	  biosynthesis	  of	   inositol	   is	  repressed,	  thus	  more	  G-­‐6-­‐P	  is	  available	  for	  
the	  glycolytic	  pathway.	  ATP	  has	  been	  shown	  to	  modulate	  the	  tightness	  of	  coupling	  of	  V-­‐
ATPase	   activity	   and	   proton	   pumping	   (Arai	   et	   al.,	   1989).	   Furthermore,	   glucose	  
deprivation	   results	   in	   the	   rapid	   disassembly	   of	   the	   V-­‐ATPase	   complex	   (Kane,	   1995).	  
Therefore,	   it	   is	   possible	   that	   the	   availability	   of	   inositol	   ultimately	   increases	   V-­‐ATPase	  
coupling	   as	   more	   G-­‐6-­‐P	   is	   available	   for	   glycolysis	   and,	   consequently,	   more	   ATP	   is	  
generated.	  	  This	  may	  account	  for	  the	  increased	  coupling	  in	  the	  presence	  of	  inositol.	  The	  
finding	  that	  VPA	  uncouples	  V-­‐ATPase,	  and	  that	  inositol	  rescues	  coupling	  but	  not	  activity	  
(ATP	  hydrolysis)	  suggests	  that	  the	  effect	  of	  VPA	  as	  a	  consequence	  of	  inositol	  depletion	  is	  
more	   pertinent	   to	   proton	   pumping.	   	   The	   observation	   that	   activity	   is	   not	   rescued	   by	  
inositol	   suggests	   that	   VPA	   may	   perturb	   activity	   of	   V-­‐ATPase	   by	   a	   mechanism	   that	   is	  
independent	  of	  inositol,	  which	  is	  beyond	  the	  scope	  of	  this	  work.	  	  
Loss	  of	  function	  of	  V-­‐ATPase	  results	  in	  a	  vma-­‐	  phenotype	  partially	  characterized	  
by	  enlarged,	  poorly	  acidified	  vacuoles,	  and	   inability	  of	   cells	   to	  grow	  at	  high	  pH	  and	   in	  
high	  calcium	  (Kane,	  2006).	  Cells	  grown	  in	  the	  presence	  of	  VPA	  show	  enlarged	  vacuoles	  
but	  are	  able	  to	  grow	  at	  pH	  7.5	  and	  100	  mM	  calcium,	  suggesting	  that	  VPA	  compromises	  
the	   activity	  of	   the	  V-­‐ATPase,	   but	  not	   to	   the	   level	   of	   complete	   loss	  of	   function.	   This	   is	  
consistent	  with	  the	  findings	  of	  Oluwatosin	  and	  Kane	  (1998)	  that	  yeast	  cells	  must	  lose	  70-­‐
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75%	  of	  V-­‐ATPase	  function	  to	  develop	  a	  vma-­‐	  growth	  phenotype	  (Oluwatosin	  and	  Kane,	  
1998).	  
It	  was	  previously	  suggested	  that	  V-­‐ATPase	  activity	  may	  be	  modulated	  by	  PI3,5P2	  
(Weisman,	   2003;	   Baars	   et	   al.,	   2007),	   but	   no	  mechanism	  was	   proposed	   to	   explain	   this	  
possibility.	  Recently,	  Li	  et	  al.	  (2014)	  reported	  that	  V-­‐ATPase	  is	  stabilized	  and	  activated	  by	  
PI3,5P2	   (Li	   et	   al.,	   2014).	   	   In	   support	   of	   the	   role	   of	   PI3,5P2	   ,	   the	   fab1Δ	  mutant,	  which	  
cannot	  synthesize	  PI3,5P2,	  has	  decreased	  V-­‐ATPase	  activity	  (Li	  et	  al.,	  2014)	  and	  enlarged	  
vacuoles	   (Yamamoto	   et	   al.,	   1995),	   	   phenotypes	   similar	   to	   those	   caused	   by	   VPA.	   This	  
suggested	  that	  the	  inositol-­‐containing	  phosphoinosides	  in	  the	  vacuolar	  membrane	  may	  
be	  altered	   in	  response	  to	  VPA.	   I	   therefore	  hypothesized	  that	   inositol	  depletion	  caused	  
by	  VPA	  alters	  the	  levels	  of	  PI3,5P2.	  One	  possible	  consequence	  of	  this	  is	  perturbation	  of	  
the	   binding	   between	   PI3,5P2	   and	   	   V0	   subunits,	   possibly	   triggering	   a	   conformational	  
change	   that	   decreases	   the	   efficiency	   of	   pumping	   protons	   across	   the	   vacuolar	  
membrane.	  Consistent	  with	  this	  possibility,	  H+-­‐pumping	  (carried	  out	  by	  the	  membrane	  
embedded	   V0	   sector)	   was	   highly	   dependent	   on	   inositol	   supplementation	   (Figs.	   3.3B	  
and3.4B).	  	  
At	  least	  three	  possibilities	  may	  account	  for	  this	  finding.	  PI3,5P2	  may	  stabilize	  the	  
structural	   conformation	   of	   V-­‐ATPase	   by	   tethering	   the	   V0/V1	   V-­‐ATPase	   complexes	  
together.	   Chan	   et	   al.	   (2012)	   have	   shown	   that	   tethering	   of	   the	   V0/V1	   complexes	   is	  
essential	  for	  V-­‐ATPase	  coupling	  (Chan	  et	  al.,	  2012).	  Therefore,	  it	  is	  possible	  that	  altered	  
levels	  of	  PI3,5P2	  may	  partially	  disturb	  this	  tethering	  and	  thus	  cause	  a	  slight	  uncoupling	  of	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the	  V-­‐ATPase,	  but	  not	  the	  complete	  dissociation	  of	  the	  V0/V1	  complex	  seen	  in	  fab1Δ	  and	  
vac14Δ	  cells	  (Li	  et	  al.,	  2014).	  Alternatively,	  PI3,5P2	  may	  bind	  or	  recruit	  factors	  required	  
for	  activation	  of	  the	  V-­‐ATPase.	  A	  third	  possibility	  is	  that	  PI3,5P2	  may	  provide	  a	  source	  of	  
phosphate	   required	   for	   phosphorylation	   and	   activation	   of	   subunits	   A	   and	   B	   of	   the	   V-­‐
ATPase	  (Makrantoni	  et	  al.,	  2007).	  
The	   finding	   that	   vmaΔ	   mutants	   were	   sensitive	   to	   VPA	   (Fig.	   3.6)	   raised	   the	  
possibility	  that	  VPA	  may	  increase	  the	  cytosolic	  pH	  or	  cytosolic	  calcium,	  conditions	  that	  
are	  lethal	  to	  the	  vma-­‐	  	  mutants.	  	  However,	  the	  pHluorin	  assay	  shows	  that	  cytosolic	  pH	  is	  
not	  altered	  by	  VPA,	  even	  when	  V-­‐ATPase	  activity	  is	  compromised	  (Fig.	  3.7).	  Additionally,	  
WT	  cells	  were	  able	  to	  grow	  at	  high	  pH	  in	  the	  presence	  of	  VPA	  (Fig.	  3.5).	  An	  increase	  in	  
cytosolic	  calcium	  cannot	  be	  ruled	  out,	  especially	  as	  VPA	  induces	  vacuolar	  fusion	  within	  
an	  hour	  of	  exposure	  to	  the	  drug	  (Figs.	  3.9A,B),	  a	  phenomenon	  that	  has	  been	  	  associated	  
with	  increased	  release	  of	  calcium	  from	  intracellular	  stores,	  including	  from	  the	  vacuole.	  A	  
recent	  report	  by	  Zhang	  et	  al.	  (2013)	  showed	  that	  VPA	  induced	  an	  increase	  in	  cytoplasmic	  
calcium	   caused	   by	   influx	   from	   extracellular	   medium	   via	   the	   Cch1-­‐Yam8	   channel	  
complex.	   However	   this	   argues	   against	   the	   increase	   due	   to	   release	   from	   endogenous	  
sources.	  
Increased	   vacuolar	   fusion	   resulting	   in	   enlarged	   vacuoles	   is	   a	   phenotype	   that	   is	  
associated	   with	   decreased	   levels	   of	   PI3,5P2	   (Yamamoto	   et	   al.,	   1995).	   As	   mentioned	  
previously,	  PI3,5P2	  comprises	  less	  than	  0.1%	  of	  all	  phosphoinositides	  in	  the	  cell	  (Michell	  
et	  al.,	  2006).	  The	  use	  of	  the	  GFP-­‐tagged	  FLARES	  enabled	  me	  to	  monitor	  changes	  in	  the	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localization	  and	  levels	  of	  PI3,5P2	  	  over	  time	  and	  under	  different	  conditions.	  	  The	  changes	  
in	   membrane	   dynamics	   that	   preceded	   vacuolar	   fission	   were	   intriguing	   (Fig.	   3.8).	   The	  
emergence	  of	  PI3,5P2-­‐enriched	  membranes	  from	  the	  localized	  dense	  formations	  on	  the	  
vacuolar	  membrane	  suggests	   that	  an	   increase	   in	  PI3,5P2	  synthesis	   is	  a	  prerequisite	   for	  
vacuolar	   fission,	   as	   several	   small	   vacuoles	   could	   be	   seen	   following	   protrusion	   of	   the	  
PI3,5P2	  –packed	  membranes	  into	  the	  vacuolar	  space	  (Fig.	  3.8).	  	  Zieger	  and	  Mayer	  (2012)	  
reported	  similar	  structures,	  which	  they	  referred	  to	  as	  “membranous	  structures	  devoid	  
of	  protein.”	  	  The	  findings	  that	  protrusions	  did	  not	  form	  in	  the	  VPA-­‐treated	  cells	  (+VPA)	  
(Fig.	  3.8),	  and	  that	  the	  vacuoles	  did	  not	  divide,	  but	  instead,	  fused	  together	  and	  enlarged	  
(Figs.	  3.8	  and	  3.9A,B)	   are	   consistent	  with	  perturbation	  of	  PI3,5P2	  by	  VPA,	  and	   suggest	  
that	  VPA	  	  perturbs	  vacuolar	  fission.	   It	   is	  tempting	  to	  speculate	  that	  this	  observation	  of	  
the	   changes	   in	   PI3,5P2	   dynamics	   could	   identify	   a	   novel	   role	   for	   PI3,5P2	   whereby	   a	  
transient	   increase	   in	   this	   phosphoinositide	   initiates	   vacuole	   fission,	   which	   otherwise	  
does	  not	  occur	  in	  mutants	  that	  lack	  PI3,5P2.	  
The	   osmotic	   shock	   experiments	   further	   support	   perturbation	   of	   PI3,5P2	  
metabolism	  by	  VPA.	   It	   is	  well	   documented	   that	  hyperosmotic	   shock	   triggers	   a	  20-­‐fold	  
increase	  in	  levels	  of	  PI3,5P2	  along	  with	  an	  increase	  in	  vacuole	  number	  (Dove	  et	  al.,	  2002;	  
Bonangelino	   et	   al.,	   2002).	   However,	   the	   mechanism	   underlying	   this	   response	   is	   not	  
determined	   (Michell,	   2013).	   Osmotically	   shocked	   VPA-­‐treated	   cells	   did	   not	   show	   the	  
same	  level	  of	  increase	  in	  PI3,5P2	  as	  the	  untreated	  cells	  (Fig.	  3.10A).	  Consistent	  with	  this,	  
osmotic	   shock	  did	  not	  cause	  an	   increase	   in	   the	  number	  of	  multivacuoled	  cells	   treated	  
with	  VPA,	  in	  contrast	  to	  untreated	  cells	  (Fig.	  3.10B,C).	  The	  vacuoles	  remained	  enlarged	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and	   did	   not	   divide	   into	   multiple	   smaller	   ones	   (Fig.	   3.10B,C).	   	   Taken	   together,	   these	  
findings	  suggest	  that	  VPA	  impairs	  PI3,5P2	  production	  and	  that	  this	   impairment	  persists	  
even	  under	  osmotic	  stress.	  
The	  mechanism	  whereby	  VPA	   causes	   perturbation	  of	   PI3,5P2	   synthesis	   is	  most	  
likely	  due	  to	  inositol	  depletion.	  This	  is	  based	  on	  the	  observation	  that	  ino1Δ	  cells	  starved	  
for	   inositol	   show	   the	   same	   phenotype	   as	   the	   VPA-­‐treated	   cells	   (Fig.	   3.8),	   and	   that	  
inositol	  rescues	  the	  perturbed	  V-­‐ATPase	  pumping.	  Using	  the	  GFP-­‐tagged	  FLARE	  for	  PI3P,	  
I	  did	  not	  observe	  changes	  in	  PI3P	  levels	  in	  VPA	  treated	  cells	  (Fig.	  3.11).	  Fab1p,	  the	  kinase	  
that	  generates	  PI3,5P2,	  	  is	  activated	  by	  Vac7p	  and	  Vac14,	  and	  inhibited	  by	  Atg18p	  (Dove	  
et	  al.,	  2002;	  Gary	  et	  al.,	  2002;	  Bonangelino	  et	  al.,	  2002).	  It	  is	  possible	  that	  perturbation	  
of	  PI3,5P2	  synthesis	  by	  VPA	  is	  mediated	  through	  upstream	  regulators	  of	  Fab1p.	  	  
	  
Potential	  implications	  for	  the	  therapeutic	  effect	  of	  VPA	  
The	   V-­‐ATPase	   plays	   an	   essential	   role	   in	   the	   acidification	   and	   proper	   functioning	   of	  
intracellular	   compartments,	   including	   lysosomes,	   secretory	   vesicles	   and	   synaptic	  
vesicles.	   The	   proton	   gradient	   generated	   by	   the	   V-­‐ATPase	   helps	   in	   the	   uploading	   and	  
storage	   of	   neurotransmitters	   (Schuldiner	   et	   al.,	   1995).	   Specific	   inhibition	   of	   V-­‐ATPase	  
activity	  has	  been	  shown	  to	  block	  uptake	  of	  L-­‐glutamate	  and	  γ-­‐amino	  butyric	  acid	  (GABA)	  
into	  vesicles	  (Moriyama	  et	  al.,	  1990;	  Hell	  et	  al.,	  1988).	  Several	  neurotransmitter	  receptor	  
blockers	   have	   been	   shown	   to	   dissipate	   the	   pH	   gradient	   established	   by	   the	   V-­‐ATPase,	  
thereby	  altering	  the	  uptake	  of	  dopamine,	  GABA	  and	  glutamate.	  The	  V0	  complex	  of	  the	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V-­‐ATPase	  has	  also	  been	  shown	  to	  be	  involved	  in	  docking	  and	  exocytosis	  (Poea-­‐Guyon	  et	  
al.,	  2013).	  A	  number	  of	  studies	  indicate	  that	  neurotransmission	  is	  altered	  in	  response	  to	  
VPA	  (Cunningham	  et	  al.,	  2003;	  Martin	  and	  Pozo,	  2004;	  Martin	  and	  Pozo,	  2004;	  Yoshida	  
et	   al.,	   2010).	   Functional	   conservation	   is	   demonstrated	  between	  molecules	   involved	   in	  
vesicular	  trafficking	  in	  yeast	  and	  synaptic	  vesicle	  trafficking	  in	  mammalian	  neurons.	  This	  
suggests	   that	   the	   mechanistic	   link	   between	   inositol	   depletion	   caused	   by	   VPA	   and	  
perturbation	   of	   the	   V-­‐ATPase	   observed	   in	   yeast	   may	   be	   pertinent	   to	   altered	  
neurotransmission	  as	  depicted	  in	  our	  model	  (Fig.	  3.12).	  	  
	  
In	   conclusion,	   this	   study	   shows	   that	   VPA-­‐mediated	   inositol	   depletion	   leads	   to	  
impairment	  of	  V-­‐ATPase	   function	  and	  decreased	   levels	  of	  vacuolar	  PI3,5P2.	   I	   speculate	  
that	  altered	  levels	  of	  PI3,5P2	  in	  the	  vacuolar	  membrane	  may	  disrupt	  the	  conformational	  
structure	  of	  the	  V0	  sector	  of	  the	  V-­‐ATPase,	   impairing	  the	  efficiency	  V-­‐ATPase	  function.	  
This	  is	  the	  first	  demonstration	  of	  a	  link	  between	  inositol	  depletion	  and	  the	  V-­‐ATPase.	  
	  





FIGURE	  3.12.	  	  Model:	  Inositol	  depletion	  perturbs	  the	  vacuolar	  V-­‐ATPase.	  	  VPA	  inhibits	  
biosynthesis	   of	   inositol,	   the	   precursor	   of	   PI	   needed	   for	   the	   synthesis	   of	  
phosphoinositides,	   including	  PI3,5P2	  which	  is	  required	  for	  stabilization	  of	  the	  V-­‐ATPase	  
(Li	   et	   al.,	   2014).	   The	   compromised	   synthesis	   of	   PI3,5P2	   in	   response	   to	   VPA	   leads	   to	  
decreased	   activity	   and	   coupling	   of	   the	   V-­‐ATPase.	   In	   neurons,	   the	   V-­‐ATPase	   plays	   an	  
essential	   role	   in	   the	   uploading	   and	   packaging	   of	   neurotransmitters,	   and	   in	   vesicle	  
docking.	  This	  suggests	  that	  VPA	  could	  modulate	  neurotransmission	  as	  a	  consequence	  of	  
inhibiting	  the	  V-­‐ATPase,	  suggesting	  a	  novel	  therapeutic	  mechanism	  of	  VPA.	  
	  





VPA	  DECREASES	  ENDOCYTOSIS	  IN	  YEAST	  AND	  MAMMALIAN	  CELLS	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Bipolar	   disorder	   (BD)	   was	   first	   categorized	   as	   an	   illness	   in	   1854	   (Angst	   and	  
Sellarno,	  2000).	  	  It	  is	  a	  major	  psychiatric	  disease	  that	  is	  manifested	  as	  recurrent	  episodes	  
of	  mania	  and	  depression,	  and	  was	  previously	  referred	  to	  as	  “folie	  circulaire”	  or	  circular	  
madness.	  According	   to	  a	   recent	   international	   study,	  BD	  affects	   approximately	  2.4%	  of	  
the	   worldwide	   population	   (Merikangas	   et	   al.,	   2011),	   and	   was	   ranked	   by	   the	   World	  
Health	  Organization	  as	  the	  sixth	  leading	  cause	  of	  disability	  worldwide.	  The	  cause	  of	  BD	  is	  
not	  known,	  but	  a	  genetic	  predisposition	  has	  been	  reported	  (Badner	  and	  Gershon,	  2002;	  
Merikangas	   et	   al.,	   2002;	   Glahn	   et	   al.,	   2004).	   Mitochondrial	   dysfunction	   has	   been	  
suggested	   by	   Kato	   and	   Kato	   (2000)	   as	   the	   molecular	   basis	   of	   BD	   based	   on	   impaired	  
energy	   metabolism	   in	   the	   brain,	   increased	   mitochondrial	   gene	   deletions,	   and	   global	  
reduction	   of	  mitochondria-­‐related	   gene	   expression.	   Deficiency	   of	   omega-­‐3-­‐fatty	   acids	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from	  the	  diet	  has	  also	  been	  suggested	  as	  a	  contributing	  factor	  towards	  the	  development	  
of	   BD	   (Balanza-­‐Martinez	   et	   al.,	   2011).	   Neuroimaging	   studies	   of	   BD	   patients	   showed	  
structural	   and	   functional	   alterations	   in	   specific	   regions	   in	   the	   brain,	   including	   the	  
prefrontal	   and	   temporal	   cortices,	   cerebellum,	  basal	   ganglia	   and	   limbic	   system	   (Soares	  
and	  Mann,	  1997).	  A	  significant	  decrease	  in	  glial	  cells,	  neuronal	  density,	  and	  plasticity	  in	  
the	  prefrontal	  cortex	  has	  also	  been	  observed	  (Rajkowska,	  2002).	  Perturbation	  of	  density	  
and	  post-­‐translational	  modification	  of	  ion	  channels	  including	  Na+,	  K+	  and	  Ca+2	  channels,	  
were	   reported	   (Jan	   et	   al.,	   2014;	   Hori	   et	   al.,	   2014;	   Imbrici	   et	   al.,	   2013).	   Alterations	   in	  
neurotransmission	   regulation	   involving	   serotonin,	   dopamine,	   γ-­‐aminobutyric	   acid	  
(GABA),	  and	  glutamate	  have	  also	  been	  implicated	  in	  the	  pathogenesis	  of	  BD	  (Ackenheil,	  
2001;	  Shiah	  and	  Yatham,	  2000;	  Dager	  et	  al.,	  2004).	  	  While	  many	  mechanisms	  have	  been	  
proposed,	   the	  mechanism(s)	   that	   contribute	   to	   the	   pathophysiology	   of	   BD	   is/are	   not	  
known.	  
Treatment	   of	   BD	   patients	   often	   involves	   combinations	   of	   mood	   stabilizers,	  
antipsychotics,	  and	  antidepressants	  to	  counteract	  both	  mania	  and	  depression	  (Bowden,	  
2003).	  Valproate	  (VPA)	  has	  been	  successfully	  used	  as	  a	  monotherapeutic	  agent	  for	  the	  
treatment	  of	  patients	  with	  mania	  and	  depressive	  symptoms	  (Bowden,	  1995;	  Swann	  et	  
al.,	  1997).	   	  However,	   less	  than	  50%	  of	  patients	  respond	  effectively	  to	  this	  drug	  (Lewis,	  
2000).	   Several	   side	   effects	   are	   associated	   with	   VPA,	   including	   hepatotoxcicity,	  
teratogenicity,	   and	   weight	   gain.	   	   Furthermore,	   drug	   dosage	   must	   be	   continuously	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monitored	  and	  adjusted,	  and	  for	  treatment	  to	  be	  effective,	  intake	  of	  the	  drug	  cannot	  be	  
interrupted.	  Thus,	  there	  is	  a	  clear	  need	  for	  better	  treatment	  for	  BD.	  	  
The	   development	   of	   improved	   drugs	   is	   hindered	   by	   the	   fact	   that	   neither	   the	  
pathophysiology	  of	  BD,	  nor	  the	  therapeutic	  mechanism	  of	  drugs	  used	  for	  its	  treatment	  is	  
understood.	   	   Although	   several	   targets	   of	   VPA	   have	   been	   identified,	   including	   myo-­‐
inositol	   3-­‐phosphate	   synthase	   (MIPS)	   (Shaltiel	   et	   al.,	   2004;	   Ju	   et	   al.,	   2204),	   histone-­‐
deacetylase	  (HDAC)	   (Phiel	  et	  al.,	  2001),	  protein	  kinase	  C	   (PKC)	   (Chen	  et	  al.,	  1994),	  and	  
glycogen	  synthase	  kinase	  (GSK3-­‐β)	  (Chen	  et	  al.,	  1999),	  the	  contributions	  of	  these	  targets	  
to	  the	  therapeutic	  effect	  of	  VPA	  have	  not	  been	  elucidated.	  In	  the	  studies	  summarized	  in	  
Chapter	  3,	   I	   identified	   two	  new	   targets	  of	  VPA	  action,	   the	   vacuolar	  V-­‐ATPase	  and	   the	  
phosphoinositide	  PI3,5P2.	   	  Because	  PI3,5P2	  is	  required	  for	  stabilization	  of	  the	  V-­‐ATPase	  
complex,	  this	  suggested	  that	  VPA	  may	  perturb	  a	  cellular	  process	  that	  involves	  these	  two	  
components.	  One	  likely	  possibility	  is	  that	  the	  drug	  affects	  membrane	  trafficking.	  The	  V-­‐
ATPase	   is	   required	   for	   endocytosis	   at	   the	   early	   endosome	   level	   (Recchi	   et	   al.,	   2006),	  
while	   PI3,5P2	   is	   required	   for	   regulating	   flux	   through	   the	   endocytic	   pathway	   and	   for	  
sorting	  endocytosed	  cargo	  at	  the	  multivesicular	  body	  (Shaw	  et	  al.,	  2003).	  Perturbations	  
in	   the	  synthesis	  of	  either	  V-­‐ATPase	  or	  PI3,5P2	   lead	  to	  trafficking	  defects	   (Perzov	  et	  al.,	  
2002;	  Phelan	  et	  al.,	  2006).	  	  
Because	  of	  the	  intermittent	  cycling	  between	  mania	  and	  depression,	  BD	  has	  often	  
been	  associated	  with	  altered	  neurotransmission	  (Higgs	  et	  al.,	  2006;	  Knable	  et	  al.,	  2004;	  
Sanacora	   and	   Saricicek,	   2007).	   Consistent	   with	   this	   possibility,	   a	   number	   of	   studies	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indicate	  that	  neurotransmission	  is	  altered	  in	  response	  to	  VPA	  (Cunningham	  et	  al.,	  2003	  ;	  
Martin	  and	  Pozo,	  2004;	  Martin	  and	  Pozo	  2004;	  Yoshida	  et	  al.,	  2010).	  Synaptic	  inhibition	  
in	  the	  mammalian	  brain	  is	  mainly	  elicited	  by	  GABA,	  the	  chief	  inhibitory	  neurotransmitter	  
in	  the	  mammalian	  central	  nervous	  system.	  By	  binding	  to	  its	  receptors,	  GABA	  induces	  the	  
uptake	  of	  chloride	  ions,	  resulting	  in	  the	  inhibitory	  hyperpolarization	  of	  the	  postsynaptic	  
membrane.	  The	  anticonvulsant	  effect	  of	  VPA	  has	  been	  largely	  attributed	  to	  potentiation	  
of	  the	  inhibitory	  GABAergic	  response	  (Loscher,	  2002).	  However,	  whether	  this	   is	  due	  to	  
altered	   levels	  of	  GABA	  or	  modulation	  of	   the	   response	   to	  GABA	   remains	   controversial.	  
Regulation	  of	  cell	  surface	  stability	  of	  GABAA	  receptors	  is	  essential	  for	  synaptic	  inhibition.	  
The	   receptors	   undergo	   extensive	   clathrin-­‐dependent	   endocytosis	   as	   a	  mechanism	   for	  
internalization	  and	  recycling	  (Jacob	  et	  al.,	  2008).	  Altered	  trafficking	  of	  GABAA	  receptors	  
is	   associated	   with	   epilepsy	   and	   anxiety	   disorders	   (Rudolph	   and	   Mohler,	   2004).	  
Therefore,	   these	   receptors	   are	   clinically	   relevant	   as	   targets	   for	   anticonvulsant	   and	  
sedative	  drugs	   (Jacob	  et	  al.,	  2008).	  For	  example,	  benzodiazepines	  were	  found	  to	  exert	  
their	   anticonvulsant	   effect	   by	   binding	   to	   these	   receptors	   (Jacob	   et	   al.,	   2008).	  
Surprisingly,	  there	  are	  no	  published	  studies	  addressing	  the	  effect	  of	  VPA	  on	  trafficking	  of	  
GABAA	  receptors.	  	  
Another	  indicator	  that	  membrane	  trafficking	  may	  be	  relevant	  to	  the	  therapeutic	  
effect	   of	   VPA	   is	   the	   finding	   that	   VPA	   increases	   size	   of	   sensory	   neuron	   growth	   cones	  
(Williams	   et	   al.,	   2002)	   and	   promotes	   neurogenesis	   and	   neuroprotection	   (Yuan	   et	   a.,	  
2001;	   Hao	   et	   al.,	   2004).	   These	   findings	   suggest	   that	   VPA	   may	   induce	   processes	   that	  
promote	  an	  increase	  in	  cell	  surface	  area,	  such	  as	  an	  increase	  in	  synthesis	  of	  membrane	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phospholipids,	  or	  an	   imbalance	  between	  endocytic	  and	  exocytic	  processes.	  A	  study	  by	  
Xu	   et	   al.	   (2007)	   suggested	   that	   VPA	   reduces	   endocytic	   trafficking	   in	   Dictyostelium	  
through	   the	   attenuation	   of	   phospholipid	   signaling	   caused	   by	   a	   decrease	   in	   PI3,4,5P3.	  	  
Miyatake	   et	   al.	   (2007)	   showed	   that,	   in	   the	   fission	   yeast	   Schizosaccharomyces	   pombe,	  
VPA	   inhibits	   the	  glycosylation	  and	   secretion	  of	   acid	  phosphatase,	   suggesting	   that	  VPA	  
affects	  membrane	  trafficking.	  
The	  screen	  described	  in	  this	  chapter	  was	  originally	  done	  to	  identify	  regulators	  of	  
the	   enzyme	   MIPS	   that,	   when	   overexpressed,	   inhibit	   the	   enzyme,	   thereby	   causing	  
increased	  sensitivity	  to	  the	  drug	  as	  a	  consequence	  of	  decreased	  inositol	  levels.	  No	  such	  
regulators	  were	  identified.	  However,	  the	  finding	  that	  overexpression	  of	  trafficking	  genes	  
increased	  sensitivity	  to	  VPA	  (this	  chapter),	  and	  the	  earlier	  finding	  that	  VPA	  decreased	  V-­‐
ATPase	  and	  PI3,5P2	  (Chapter	  3),	  both	  of	  which	  play	  a	  role	  in	  endocytosis,	  suggested	  that	  
endocytosis	   may	   be	   perturbed	   by	   VPA.	   The	   studies	   described	   here	   show	   that	   VPA	  
decreases	  endocytosis	  in	  yeast	  and	  human	  cells,	  and	  suggest	  that	  this	  decrease	  is	  due	  to	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MATERIALS	  AND	  METHODS	  
	  
Strains,	  media	  and	  growth	  conditions	  -­‐	  The	  Saccharomyces	  cerevisiae	  BY4741	  wild	  type	  
strain	  MATa	  his3Δ1,	  leu2Δ0,	  met15Δ0,	  ura3Δ0	  was	  obtained	  from	  invitrogen.	  The	  GSK3	  
quadruple	  mutant,	  a	  null	  mutant	  for	  the	  four	  GSK3	  homologs	  in	  yeast,	  herein	  referred	  to	  
as	  Δgsk-­‐3,	   was	   a	   generous	   gift	   from	   Dr.	   Akira	   Kikuchi-­‐Hiroshima	   University	   School	   of	  
Medicine	  (Andoh	  et	  al.,	  2000).	  Cells	  were	  maintained	  on	  YPD	  medium	  (1%	  yeast	  extract,	  
2%	  bactopeptone,	  and	  2%	  glucose).	   Synthetic	  minimal	  medium	   (SM)	  contained	  all	   the	  
essential	  components	  of	  Difco®	  yeast	  nitrogen	  base	   (minus	   inositol),	  2%	  glucose,	  0.2%	  
ammonium	  sulfate,	  vitamins,	  and	  the	  four	  amino	  acids	  histidine	  (20	  mg/L),	   leucine	  (60	  
mg/L),	  methionine	  (20	  mg/L),	  and	  lysine	  (20	  mg/L),	  and	  the	  nucleobase	  uracil	  (40	  mg/L).	  
Adenine	   (20	  mg/L),	  was	  added	   to	  media	  used	   for	   growth	  of	  Δgsk-­‐3.	  Where	   indicated,	  
inositol	   was	   supplemented	   at	   a	   concentration	   of	   75	   µM.	   For	   induction	   of	   protein	  
expression,	  2%	  galactose	  and	  2%	  raffinose	  were	  substituted	  for	  2%	  glucose.	  Appropriate	  
amino	  acids	  were	  omitted	   for	   selection	  of	  cells	  carrying	  plasmids.	  For	  solid	  media,	  2%	  
agar	   was	   added.	   Growth	   in	   liquid	   cultures	   was	   monitored	   spectrophotometrically	   by	  
measuring	  absorbance	  at	  550	  nm.	  All	  incubations	  were	  at	  30°C	  unless	  otherwise	  stated.	  
	  
Screening	   the	   cDNA	   library	   –	   A	   GAL1-­‐regulated	   yeast	   cDNA	   expression	   library	   (a	  
generous	   gift	   from	   Dr.	   Anthony	   Bretscher)	   was	   used	   to	   screen	   for	   genes	   whose	  
overexpression	  increases	  sensitivity	  to	  VPA.	  For	  this	  purpose,	  BY4741	  cells	  were	  grown	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to	  the	  mid-­‐log	  phase	  in	  YPD.	  Competent	  cells	  were	  prepared	  and	  transformed	  with	  the	  
cDNA	   library	   using	   the	   lithium	   acetate	   one-­‐step	   transformation	   method	   (Ito	   et	   al.,	  
1983).	  Conditions	  were	  optimized	  to	  get	  about	  300	  colonies	  per	  plate.	  Cells	  transformed	  
with	  the	  empty	  vector	  pRS316	  were	  used	  as	  a	  negative	  control,	  and	  the	  Δgsk-­‐3,	  which	  is	  
sensitive	   to	   VPA,	   was	   used	   as	   a	   positive	   control.	   Cells	   were	   plated	   onto	   ura-­‐	   plates	  
containing	  2%	  galactose	  and	  2%	  raffinose	  and	  incubated	  at	  30°C	  for	  3-­‐4	  days.	  Colonies	  
were	   counted	   and	   then	   replica	   plated	   onto	   3	   different	   plates:	   	   I+,	   I-­‐,	   and	   I-­‐	   medium	  
containing	  VPA	  (I-­‐	  /VPA).	  Colonies	  that	  did	  not	  grow,	  or	  grew	  poorly	  in	  the	  presence	  of	  
VPA,	  were	  picked	  from	  the	  I+	  plate	  for	  further	  confirmation.	  All	  the	  colonies	  that	  were	  
picked	  were	  purified	  by	   streaking	   to	  obtain	   single	   colonies,	   from	  which	   freezer	   stocks	  
were	  prepared.	  All	  freezer	  stocks	  were	  reconfirmed	  for	  sensitivity	  to	  VPA	  by	  testing	  for	  
single	  colony	   formation:	   cells	  were	   revived	  on	  ura-­‐	  plates	   supplemented	  with	   inositol,	  
grown	   to	   the	   mid-­‐log	   phase,	   and	   then	   plated	   on	   selective	   media	   in	   the	   presence	   or	  
absence	  of	  inositol	  and	  VPA.	  	  
	  
Recovery	   of	   cDNA	   from	   yeast	   for	   gene	   identification	   -­‐	   The	   cDNA	   plasmids	   were	  
extracted	  from	  clones	  that	  were	  confirmed	  for	  increased	  sensitivity	  to	  VPA.	  	  E.	  coli	  was	  
used	  to	  amplify	  the	  plasmids,	  which	  were	  then	  purified	  and	  digested	  to	  determine	  the	  
length	  of	  the	  cDNA	  insert.	  Uniquely	  sized	  cDNAs	  were	  sequenced	  using	  the	  GAL1-­‐cDNA	  
flanking	  primer	  5’-­‐	  TGCATAACCACTTTAACT-­‐3’.	  All	  sequencing	  was	  carried	  out	  by	  ACGT,	  
Inc.	   The	   sequences	   obtained	   were	   blasted	   against	   the	   S.	   cerevisiae	   genome	   and	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identified	   using	   the	   Saccharomyces	  Genome	  Database	   (SGD).	   	   Genes	  were	   assembled	  
into	  groups	  based	  on	  functional	  relevance	  (Table	  4.2).	  
	  
Fluorescence	  microscopy	  analysis	  -­‐	  To	  visualize	  vacuolar	  membranes	  in	  vivo,	  yeast	  cells	  
were	   stained	  with	   the	   lipophilic	   dye	   FM4-­‐64	   as	   described	   (Vida	   and	   Emr,	   1995)	   with	  
slight	  modifications.	   Cells	   were	   grown	   overnight	   at	   30°C	  with	   constant	   shaking.	   Cells	  
collected	  from	  1	  ml	  cultures	  were	  resuspended	  in	  fresh	  medium	  containing	  10	  µM	  FM4-­‐
64.	  Samples	  were	  removed	  at	  5,	  30,	  60,	  120,	  and	  240	  min,	  washed,	  and	  resuspended	  in	  
a	   small	   volume	   of	   fresh	  medium	  with	   50	  mM	   PIPES.	   To	   immobilize	   cells,	   slides	  were	  
coated	  with	   a	   thin	   layer	   of	   1%	   agarose	   dissolved	   in	   SM.	   Cells	  were	   examined	   using	   a	  
fluorescence	   microscope.	   The	   plasmids	   pRS416-­‐GFP-­‐2XPHOsh2	   and	   pRS426-­‐GFP-­‐
2XPHPLCδ1	   used	   to	   localize	   PI4P	   and	   PI4,5P2,	   respectively,	   were	   a	   kind	   gift	   from	   Dr.	  
Stephen	  Jesch	  (Cornell	  University).	  
To	   visualize	   mammalian	   cells,	   U251	   glioblastoma	   cells	   and	   HEK293	   human	  
embryonic	   kidney	   cells	   (a	   generous	   gift	   from	   Dr.	   Mustafa	   Kandouz)	   were	   grown	   on	  
coverslips	  in	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  supplemented	  with	  10%	  FBS.	  
Cells	  were	  treated	  with	  1	  mM	  VPA	  for	  30	  min.	  FM4-­‐64	  was	  then	  added	  and	  cells	  were	  
incubated	  on	   ice	   for	  30	  min	  to	  allow	  for	   incorporation	  of	   the	  dye	   into	  the	  membrane.	  
Following	  incubation	  at	  37°C,	  samples	  were	  removed	  at	  5,	  15,	  30,	  60,	  and	  120	  min.	  	  At	  
each	  time	  point,	  cells	  were	  placed	  on	   ice,	  washed	  with	  phosphate	  buffered	  saline	  (1x)	  
pH	   7.4,	   acid-­‐stripped,	   washed,	   and	   immediately	   fixed	   with	   4%	   paraformaldehyde.	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Following	  DAPI-­‐staining,	   cells	  were	  washed,	  mounted	  onto	   slides,	  and	  visualized	  using	  
the	   fluorescence	   microscope.	   For	   transferrin	   uptake	   experiments,	   U251	   and	   HEK293	  
cells	   were	   serum-­‐starved	   for	   2	   h	   prior	   to	   treatment	   with	   1	   mM	   VPA	   for	   30	   min.	  
Transferrin-­‐AlexaFluor	  (20	  µg/ml)	  was	  added,	  and	  cells	  were	  incubated	  at	  37°C.	  Samples	  
(on	  coverslips)	  were	  removed	  at	  5,	  15,	  30,	  60,	  and	  120	  min,	  and	  immediately	  placed	  on	  
ice	  to	  arrest	  endocytosis.	  Cells	  were	  acid-­‐stripped,	  washed,	  fixed,	  stained	  with	  DAPI,	  and	  
visualized	  using	  the	  fluorescence	  microscope.	  	  
	  
Lucifer	  yellow	  uptake	  –	  Yeast	  cells	  were	  grown	  to	  the	  mid-­‐log	  phase,	  harvested,	  washed	  
with	   dH2O,	   and	   resuspended	   in	   medium	   to	   which	   4	   mg/ml	   of	   lucifer	   yellow	  
carbohydrazide	   (LY-­‐CH)	  were	  added.	  Cells	  were	   incubated	   for	  2	  h	  with	  gentle	  shaking,	  
harvested,	  washed	  3x	  in	  1x	  PBS	  (phosphate	  buffered	  saline),	  and	  resuspended	  in	  50	  µl	  
of	  the	  same	  buffer.	  	  
	  
Sensitivity	  to	  cell	  wall	  perturbing	  agent	  -­‐	  Wild	  type	  yeast	  cells	  were	  precultured	  in	  SM	  
to	   the	   mid-­‐log	   phase,	   washed,	   and	   spotted	   in	   a	   10-­‐fold	   serial	   dilution	   onto	   plates	  
supplemented	   with	   the	   cell	   wall	   perturbing	   agent	   Calcufluor	   white	   (CFW)	   at	   a	  
concentration	  of	  50	  mM.	  Plates	  were	  incubated	  at	  30°C	  for	  3-­‐4	  days.	  
	  
Immunoblot	   analysis	   of	   the	   cell	   wall	   integrity	   pathway	   -­‐	  Wild	   type	   yeast	   cells	  were	  
grown	  in	  SM	  at	  30°C	  with	  or	  without	  inositol	  to	  the	  mid-­‐log	  phase,	  treated	  with	  2	  mM	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VPA,	   and	   then	   shifted	   to	   39°C	   for	   1	   h.	   Cells	   were	   harvested	   on	   ice	   and	   immediately	  
stored	  at	   -­‐80°C.	   	   For	  protein	  extraction,	   cells	  were	   resuspended	   in	   lysis	  buffer	   (0.25M	  
NaOH	  and	  1%	  BME).	   Protein	  was	  precipitated	  using	  20%	  TCA,	  washed	   twice	  with	   ice-­‐
cold	   acetone,	   and	   then	   resuspended	   in	   3M	   urea,	   10%	  DTT,	   and	   1%	   SDS.	   Protein	  was	  
quantified	  using	  the	  Lowry	  method	  (Lowry	  et	  al.,	  1951).	  A	  total	  of	  350	  µg	  protein	  were	  
loaded	   into	   each	   well	   of	   a	   10%	   polyacrylamide	   gel,	   subjected	   to	   electrophoresis	   and	  
then	  transferred	  onto	  0.2	  µm	  PVDF	  membranes.	  Detection	  of	  Phospho-­‐Slt2/Mpk1p	  was	  
carried	   out	   using	   Rabbit	   Phospho-­‐p44/42	   MAPK	   (Cell	   signaling;	   1:2000	   dilution),	   and	  
goat	  anti-­‐rabbit	  IgG-­‐horseradish	  peroxidase	  conjugate	  (Cell	  signaling;	  1:10000	  dilution).	  	  
Detection	   was	   carried	   out	   using	   ECL™	   Prime	   Western	   Blotting	   Detection	   Reagent	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Identification	  of	  genes	  that	  confer	  sensitivity	  to	  VPA	  when	  overexpressed:	  
Wild-­‐type	  yeast	  cells	  were	  transformed	  with	  a	  GAL1-­‐driven	  yeast	  cDNA	  library.	  	  A	  total	  
of	   about	   21,000	   transformed	   yeast	   colonies	  were	   screened	   for	   sensitivity	   to	  VPA.	   For	  
this	   purpose,	   growth	   of	   colonies	   on	   selective	   medium	   containing	   1	   mM	   VPA	   was	  
compared	  to	  that	  of	  cells	  transformed	  with	  an	  empty	  vector	  (as	  a	  negative	  control),	  and	  
to	  Δgsk-­‐3	  cells	  that	  are	  highly	  sensitive	  to	  VPA	  (Azab	  et	  al.,	  2007)	  (as	  a	  positive	  control).	  
In	  the	  initial	  screen,	  127	  clones	  showed	  sensitivity	  to	  the	  drug.	  All	  clones	  were	  spotted	  
on	   a	   master	   plate	   for	   a	   second	   round	   of	   screening.	   Clones	   that	   showed	   weaker	  
sensitivity	  were	  eliminated,	  reducing	  the	  number	  to	  84	  clones	  that	  were	  highly	  sensitive	  
to	   VPA.	   All	   clones	   were	   streaked	   to	   obtain	   single	   colonies,	   which	   were	   used	   for	  
subsequent	   experiments.	   To	  make	   sure	   that	   each	   clone	   had	   only	   one	   type	   of	   cDNA	   ,	  
plasmids	  were	  extracted	   from	  each	  yeast	   clone	  and	  amplified	   in	  E.	   coli.	   The	  amplified	  
plasmids	  were	  purified	  and	  digested	  with	   two	   restriction	  enzymes	   that	   cut	  at	   flanking	  
regions	  of	  the	  cDNA	  insert.	  	  The	  cDNAs	  were	  sequenced,	  identified,	  and	  assembled	  into	  
groups	  based	  on	  functional	  similarities	  (Table	  4.2).	  Three	  major	  groups	  were	  identified:	  
vesicular	   trafficking	  proteins,	  glycolytic	  enzymes,	  and	   ribosomal	  proteins.	  Nine	  smaller	  
groups	  were	   also	   identified,	  with	   genes	   involved	   in	  DNA	   replication,	   protein	   and	   lipid	  
synthesis,	   and	   cell	   wall	   proteins.	   In	   the	   current	   study,	   I	   focused	   on	   one	   group,	   the	  
vesicular	  trafficking	  genes.	  The	  two	  other	  major	  groups	  will	  be	  discussed	  in	  Chapter	  5.	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RPS0B,	  RPS4A,	  RPS5,	  RPS6A,	  RPS7A,	  RPS17B,	  
RPS19B,	  RPS21A,	  RPS23B,	  RPS25A,	  RPP0,	  RPP2B,	  	  
RPL2A	  ,	  RPL2B,	  RPL3,	  RPL38,	  RPL43B,	  RDN37-­‐2,	  	  






PGK1,	  TDH1,	  TDH2,	  TDH3,	  ADH1,	  PDC1,	  ENO2,	  





VPS21,	  YAP1801,	  SEC15,	  YSC84,	  VAM3,	  EGD2,	  
AKL1,	  SHR3,	  PIL1	  
	  
10	  
V-­‐ATPase,	  ATPase	  related	  
	  
VMA2,	  OLA1,	  SKP1,	  PET9,	  ATP5,	  SSB2	   7	  
Transcription	  and	  elongation	  
factors	  
	  
TAF10,	  NPL3,	  EFT1,	  TEF2,	  EFB1	  
	  
7	  
Lipid	  biosynthesis	  	  
	  
NCP1,	  URA7,	  PHM8,	  ADK1	   5	  
DNA	  replication,	  histones	  
	  




RNR4,	  CHA1,	  APT1	   3	  
Cell	  wall	  protein	  
	  
CCW12	   2	  
G-­‐protein	  regulators	  
	  
PLP1,	  YRB1	   2	  
Mitochondrial	  morphology	  
	  
PCP1	   1	  
Heat	  shock	  proteins	  
	  
HSP104	   1	  
	   	   	  
Underlined	  genes:	  identified	  twice.	  Underlined	  and	  bold:	  identified	  tree	  times.	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VPA	  decreases	  endocytosis	  in	  yeast	  cells:	  
Membrane	  trafficking	  is	  a	  conserved	  process	  that	  is	  highly	  regulated.	  Overexpression	  of	  
proteins	   that	   negatively	   regulate	   trafficking	   is	   expected	   to	   increase	   the	   sensitivity	   of	  
cells,	  particularly	  if	  this	  process	  is	  already	  compromised	  by	  VPA.	  	  Nine	  genes	  that	  encode	  
vesicular	   trafficking	   proteins	   were	   identified	   in	   the	   cDNA	   screen	   (Table	   4.2).	  
Interestingly,	   seven	   of	   these	   genes	   are	   associated	   with	   endocytosis,	   including	  VPS21,	  
AKL1,	  SHR3,	  YSC84,	  VAM3,	  PIL1,	  and	  YAP180-­‐1.	  	  
One	  of	   these	  genes,	  AKL1,	   codes	   for	   a	   Ser-­‐Thr	   kinase	   that	  negatively	   regulates	  
endocytosis	  by	  phosphorylating	  Pan1,	  a	  protein	  that	  forms	  part	  of	  an	  endocytic	  complex	  
that	   regulates	   the	   internalization	   step	   of	   endocytosis	   (Takahashi	   et	   al.,	   2006).	  
Overexpression	  of	  AKL1	   is	  expected	  to	  perturb	  endocytosis.	   I	  monitored	  the	  uptake	  of	  
lucifer	  yellow,	  a	  fluid	  phase	  endocytic	  marker,	  in	  wild-­‐type	  yeast	  cells	  carrying	  either	  the	  
empty	  vector,	  or	  the	  vector	  with	  the	  AKL1	  gene	  (Fig.	  4.1).	  	  Although	  the	  dye	  was	  initially	  
internalized	  in	  cells	  overexpressing	  AKL1,	  it	  accumulated	  in	  prevacuolar	  compartments,	  
unlike	  in	  cells	  carrying	  the	  empty	  vector.	   Interestingly,	  the	  same	  pattern	  was	  observed	  
in	   VPA-­‐treated	   cells	   (Fig.	   4.1)	   suggesting	   that	   VPA	   perturbs	   trafficking	   in	   a	   manner	  
similar	  to	  that	  caused	  by	  overexpression	  of	  AKL1.	  
Another	   approach	   to	   determine	   if	   VPA	   affects	   endocytosis	   is	   to	   monitor	   the	  
uptake	  of	  the	  lipophilic	  fluorescent	  dye	  FM4-­‐64,	  which	  is	  routinely	  used	  as	  a	  marker	  for	  
endocytic	  trafficking	  (Vida	  and	  Emr,	  1995;	  Perzov	  et	  al.,	  2002).	  Yeast	  cells	  were	  treated	  
with	  VPA	  for	  1	  h	  before	  the	  addition	  of	  FM4-­‐64.	  Uptake	  of	  the	  dye	  was	  observed	  over	  a	  
period	  of	  4	  hours.	  In	  untreated	  cells,	  the	  dye	  reached	  the	  vacuoles	  in	  the	  first	  hour	  (Fig.	  	  






FIGURE	  4.1.	  	  VPA	  treatment	  phenocopies	  overexpression	  of	  AKL1.	  Wild-­‐type	  yeast	  cells	  
containing	  an	  empty	  vector	  pRS316	  (EV)	  or	  the	  vector	  expressing	  AKL1	  were	  grown	  to	  
the	   mid-­‐log	   phase	   in	   SM,	   treated	   with	   2	   mM	   VPA,	   and	   stained	   with	   the	   endocytic	  
marker	  lucifer	  yellow,	  as	  described	  in	  Materials	  and	  Methods.	  All	  images	  were	  taken	  at	  
















FIGURE	  4.2.	  	  Endocytosis	   is	  decreased	   in	  VPA-­‐treated	  cells.	  Wild-­‐type	  yeast	  cells	  were	  
grown	  to	  the	  mid-­‐log	  phase	  in	  SM,	  treated	  with	  2	  mM	  VPA,	  and	  stained	  with	  FM4-­‐64,	  as	  
described	  in	  Materials	  and	  Methods.	  To	  monitor	  internalization	  and	  uptake	  of	  the	  dye,	  
samples	  were	  removed	  at	  the	  indicated	  times	  following	  addition	  of	  the	  dye.	  All	  images	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4.2).	   However,	   in	   VPA-­‐treated	   cells,	   the	   FM4-­‐64	   dye	   was	   not	   apparent	   in	   vacuolar	  
membranes	   until	   the	   4th	   hour,	   suggesting	   that	   VPA	   treatment	   markedly	   slows	   the	  
endocytic	  process	  in	  yeast	  cells.	  	  
	  
VPA	  compromises	  PI4,5P2	  levels:	  
VPA	  causes	  a	  decrease	  in	  intracellular	  inositol	  (Vaden	  et	  al.,	  2001),	  which	  is	  required	  for	  
the	  synthesis	  of	  phosphoinositides.	  The	  phosphoinositide	  PI4,5P2,	  which	   is	  abundant	   in	  
the	   plasma	   membrane	   (Thorner	   and	   Strahl,	   2007),	   binds	   and	   controls	   more	   than	   30	  
membrane	   proteins	   that	   regulate	   endocytosis,	   either	   by	   binding	   to	   the	   actin	  
cytoskeleton,	  or	  by	  regulating	  other	  proteins	  of	  the	  endocytosis	  machinery	  	  (Smythe	  and	  
Ayscough,	  2006;	  deHart	  et	  al.,	  2003).	  Thus	  perturbation	  of	  PI4,5P2	  levels	  may	  destabilize	  
these	   proteins.	   This	   led	   me	   to	   hypothesize	   that	   VPA	   causes	   a	   decrease	   in	   PI4,5P2	  
synthesis	   thereby	   causing	   a	   decrease	   in	   endocytosis.	  The	   presence	   of	   a	   large	   pool	   of	  
PI4,5P2	   in	   the	   plasma	   membrane	   makes	   it	   difficult	   to	   detect	   changes	   in	   newly	  
synthesized	   PI4,5P2	   (King	   et	   al.,	   2009).	   Therefore,	   I	   used	   the	   indirect	   approach	   of	  
monitoring	   levels	   of	   PI4P,	   the	   sole	   precursor	   of	   PI4,5P2	   in	   yeast	   (Thorner	   and	   Strahl,	  
2007),	  as	  a	  marker	  for	  changes	  in	  PI4,5P2	  synthesis	  in	  response	  to	  VPA.	  	  PI4P	  is	  delivered	  
by	  Golgi	   vesicles	   to	   the	  plasma	  membrane,	  where	   it	   is	   phosphorylated	  by	   the	  PI4P	  5-­‐
kinase	  Mss4	  to	  generate	  PI4,5P2	  (Homma	  et	  al.,	  1998).	  As	  Fig.	  4.3	  shows,	  the	  fluorescent	  
punctae	  representing	  the	  GFP-­‐tagged	  PI4P-­‐specific	  FLAREs	  carried	  by	  Golgi	  vesicles	  are	  
absent	  from	  VPA	  treated-­‐cells	  grown	  in	  the	  absence	  of	  inositol,	  suggesting	  that	  in	  the	  	  
	  







FIGURE	  4.3.	  	  VPA	  alters	  the	  trafficking	  of	  PI4P.	  Wild	  type	  cells	  constitutively	  expressing	  
a	  GFP-­‐tagged	  PI4P-­‐binding	  probe	  were	  grown	  in	  SM	  at	  30°C	  to	  the	  mid-­‐log	  phase.	  VPA	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absence	  of	  sufficient	  precursor,	  levels	  of	  PI4,5P2	  are	  compromised	  and	  may,	  thus,	  cause	  
destabilization	  of	  membrane	  proteins	  that	  regulate	  endocytosis.	  
	  
VPA	  inhibits	  processes	  regulated	  by	  Rho1,	  a	  protein	  that	  is	  dependent	  on	  PI4,5P2:	  
One	  of	  the	  proteins	  that	  are	  activated	  and	  stabilized	  by	  PI4,5P2	  in	  the	  plasma	  membrane	  
is	  the	  small	  G	  protein,	  Rho1	  (Levin,	  2011).	   	  Rho1	  activates	  a	  wide	  array	  of	  targets	  that	  
regulate	   several	   processes,	   including	   organization	   of	   the	   actin	   cytoskeleton,	   β-­‐glucan	  
synthesis,	  gene	  expression,	  exocytosis,	  and	  PKC-­‐cell	  wall	  integrity	  (CWI)	  signaling	  (Levin	  
2011).	   The	   actin	   cytoskeleton	   is	   a	   major	   regulator	   of	   endocytosis	   and	   membrane	  
trafficking	   in	   yeast	   (Smythe	   and	   Ayscough,	   2006).	   Thus,	   decreased	   PI4,5P2	   levels	   are	  
expected	  to	  destabilize	  Rho1	  and	  thereby	  disturb	  the	  organization	  of	   the	  cytoskeleton	  
required	   for	   the	   endocytic	   process.	   In	   the	   same	   manner,	   other	   processes	   that	   are	  
regulated	  by	  Rho1	  are	  expected	  to	  be	  perturbed.	  	  
β-­‐1,3-­‐glucan,	  the	  main	  structural	  component	  of	  the	  yeast	  cell	  wall,	  is	  synthesized	  
by	  a	  glucan	  synthase	  complex,	  the	  regulatory	  subunit	  of	  which	  is	  Rho1	  (Drgonova	  et	  al.,	  
1996;	  Qadota	  et	  al.,	  1996;	  Mazur	  and	  Baginsky,	  1996).	  Cells	  grown	   in	   the	  presence	  of	  
the	   cell	   wall	   perturbing	   agent	   CFW	   exhibited	   marked	   sensitivity	   to	   VPA	   (Fig.	   4.4A),	  
suggesting	   that	   VPA	   causes	   defects	   in	   cell	   wall	   biosynthesis.	   This	   is	   consistent	   with	  
perturbation	   of	  β-­‐1,3-­‐glucan	   synthesis,	   which	   is	   regulated	   by	   Rho1.	   	   The	   observation	  
that	   inositol	   rescues	   this	   defect	   supports	   the	   hypothesis	   that	   decreased	   PI4,5P2	   may	  
destabilize	  Rho1.	  
	  






FIGURE	  4.4.	   	   	  VPA	  causes	  cell	  wall	  defects	  and	   increases	  thermosensitivity.	  Wild	  type	  
yeast	  cells	  were	  grown	  to	  the	  mid-­‐log	  phase	  and	  spotted	  in	  ten-­‐fold	  serial	  dilutions	  on	  A,	  
plates	   supplemented	   with	   50	   mM	   Calcufluor	   white	   and	   incubated	   at	   30°C,	   or	   B,	   SM	  
plates	  incubated	  at	  the	  indicated	  temperatures	  for	  3-­‐4	  days.	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The	   PKC-­‐CWI	   pathway	   is	   also	   regulated	   by	   the	   PI4,5P2-­‐dependent	   Rho1	   (Fig.	  
4.5A).	   It	   is	   employed	   by	   yeast	   cells	   to	   protect	   cells	   in	   response	   to	   environmental	  
stresses,	   including	   heat	   stress	   (Levin,	   2011),	   hypo-­‐osmotic	   stress	   (Davenport	   et	   al.,	  
1995)	   and	   cell	   wall	   biogenesis	   mutations	   (De	   Noble	   et	   al.,	   2000).	   VPA-­‐treated	   cells	  
showed	   thermosensitivity	   at	   37°C,	   and	   growth	   was	   completely	   abolished	   at	   39°C	  
(Fig.4.4B),	   suggesting	   that	   in	   the	  presence	  of	   the	  drug,	   cells	   are	  unable	   to	   respond	   to	  
heat	  stress.	  	  
To	   investigate	   if	   temperature	   sensitivity	   is	   due	   to	   perturbation	   of	   the	   CWI	  
pathway,	  cells	  were	  grown	  at	  30°C,	  treated	  with	  VPA,	  and	  then	  transferred	  to	  39°C	  for	  1	  
h,	   a	   condition	   that	   induces	   CWI	   signaling.	   Activation	   of	   the	   CWI	   pathway	   is	   typically	  
monitored	  by	  phosphorylation	  of	  the	  Slt2/Mpk1	  MAP	  kinase	  (de	  Noble	  et	  al.,	  2000).	  As	  
shown	   in	   Fig.	   4.5B,	   at	   39°C,	   in	   the	   absence	  of	   inositol,	   untreated	   cells	   showed	  a	  high	  
level	   of	   phosphorylation	   of	   Slt2	   indicating	   activation	   of	   the	   CWI	   pathway.	   However,	  
phosphorylated	   Slt2	   was	   not	   observed	   in	   VPA-­‐treated	   cells.	   Supplementation	   with	  
inositol	   moderately	   rescued	   this	   effect	   (Fig.	   4.5B).	   These	   results	   indicate	   that	   VPA	  
inhibits	   activation	  of	   the	  CWI	  pathway	  at	   elevated	   temperatures	   as	   a	   consequence	  of	  
inositol	   depletion.	   Taken	   together,	   these	   data	   demonstrate	   that	   three	   processes	  
regulated	  by	  the	  PI4,5P2-­‐dependent	  Rho1,	  are	  disrupted	  by	  VPA,	  including	  endocytosis,	  
cell	   wall	   biosynthesis,	   and	   CWI	   signaling.	   	   This	   suggests	   that	   by	   decreasing	   	   PI4,5P2	  
levels,	   VPA	   may	   destabilize	   membrane	   proteins,	   including	   Rho1.	   In	   addition	   to	   the	  
observed	  decrease	  in	  PI4P	  (Fig.	  4.3),	  this	  provides	  further	  supportive	  evidence	  that	  	  






FIGURE	  4.5	   	   	  VPA	  perturbs	  the	  cell	  wall	   integrity	  pathway.	  A,	  Signaling	  cascade	  of	  the	  
CWI	  pathway.	  B,	  Wild	  type	  yeast	  cells	  were	  precultured	  in	  SM	  at	  30°C	  in	  the	  presence	  or	  
absence	  of	  inositol	  and	  treated	  with	  VPA	  for	  1	  h.	  Cells	  were	  then	  transferred	  to	  39°C	  	  for	  
1	   h.	   Total	   protein	   extracts	   were	   fractionated	   by	   SDS-­‐PAGE	   and	   transferred	   to	   PVDF	  
membranes.	  Phosphorylated	  Slt2	  was	  detected	  using	  rabbit	  Phospho-­‐p44/42	  MAPK,	  and	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decreased	   endocytosis	   in	   VPA-­‐treated	   cells	   may	   be	   due	   to	   decreased	   PI4,5P2	   in	   the	  
plasma	  membrane.	  	  
	  
VPA	  decreases	  constitutive	  endocytosis	  in	  mammalian	  cells:	  	  
To	  determine	   if	   perturbation	   of	   endocytosis	   by	  VPA	   is	   conserved	   in	  mammalian	   cells,	  
incorporation	   of	   FM4-­‐64	   was	   observed	   in	   glioblastoma	   cells	   treated	   with	   VPA.	   In	  
mammalian	   cells,	   this	   dye	   is	   taken	   up	   by	   endocytic	   vesicles	   and	   accumulates	   in	  
endosomes	   (Henkel	   et	   al.,	   1996).	  As	   shown	   in	   Fig.	   4.6,	   the	  untreated	   cells	   show	  clear	  
punctae	   indicative	   of	   accumulation	   of	   the	   dye	   in	   vesicles.	   However,	   the	   rate	   of	  
incorporation	   was	   significantly	   less	   in	   VPA-­‐treated	   cells,	   as	   labeling	   was	   diffuse	   even	  
after	  120	  min.	  	  
	  
Internalization	  of	  transferrin	  is	  decreased	  in	  VPA-­‐treated	  cells:	  
Clathrin-­‐mediated	  endocytosis	  (CME)	  is	  the	  mechanism	  responsible	  for	  internalization	  of	  
many	  cell	  surface	  receptors,	   including	  the	  GABAA	  receptors	  (Kittler	  et	  al.,	  2000).	  These	  
receptors	  have	  been	  implicated	  in	  the	  therapeutic	  mechanism	  of	  anticonvulsants	  (Jacob	  
et	   al.,	   2008).	   	   To	   explore	   if	   VPA	   perturbs	   CME,	   I	   examined	   the	   effect	   of	   VPA	   on	  
internalization	  of	  Alexa-­‐fluor-­‐conjugated	  transferrin,	  a	  marker	  that	  is	  routinely	  used	  for	  
detection	  of	  CME	  (Le	  Roy	  and	  Wrana,	  2005).	  As	  shown	  in	  Fig.	  4.7,	  at	  15	  min,	  decreased	  
accumulation	  of	   endocytic	   vesicles	  was	  observed	   in	  VPA-­‐treated	   cells,	   suggesting	   that	  
VPA	   may	   decrease	   the	   internalization	   of	   the	   transferrin	   receptors.	   Following	  
internalization,	   transferrin	   remains	  bound	   to	   its	   receptor	  and	   is	   then	   recycled	  back	   to	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the	  surface,	  where	   it	   is	   released	   into	  the	  medium.	  The	  disappearance	  of	   the	  dye	  from	  
the	  perinuclear	  region	  in	  untreated	  cells	  (after	  90	  min)	  was	  not	  detected	  in	  VPA-­‐treated	  























FIGURE	  4.6.	  	  Endocytosis	  is	  decreased	  in	  VPA-­‐treated	  glioblastoma	  cells.	  Glioblastoma	  
U251	  cells	  were	  grown	  in	  DMEM	  with	  10%	  FBS.	  Serum-­‐starved	  cells	  were	  treated	  with	  1	  
mM	  VPA	  and	  the	  endocytic	  marker	  FM4-­‐64	  was	  added,	  as	  described	  in	  Materials	  and	  
Methods.	  To	  monitor	  internalization	  and	  uptake	  of	  the	  dye,	  samples	  were	  removed	  at	  











FIGURE	  4.7.	  	  Internalization	  of	  transferrin	  is	  decreased	  in	  VPA-­‐treated	  glioblastoma	  
cells.	  	  Glioblastoma	  U251	  cells	  were	  grown	  in	  DMEM	  with	  10%	  FBS.	  	  Serum-­‐starved	  cells	  
were	  treated	  with	  1	  mM	  VPA.	  Uptake	  of	  transferrin	  was	  monitored	  at	  the	  indicated	  












This	   study	  was	  carried	  out	   to	   identify	  novel	  pathways	  or	  processes	   that	  are	  altered	   in	  
response	  to	  VPA-­‐treatment	  and	  may,	  thus,	  underlie	  the	  therapeutic	  effect	  of	  the	  drug.	  
The	  majority	  of	  the	  genes	  identified	  in	  the	  cDNA	  screen	  fell	  into	  three	  major	  categories:	  
ribosomal	   proteins,	   glycolytic	   enzymes,	   and	   proteins	   involved	   in	   vesicular	   trafficking	  
(Table	  4.2).	   I	   focused	  on	   trafficking	  as	  my	  previous	   studies	   showed	   that	  VPA	  perturbs	  
the	  vacuole	  by	  decreasing	  V-­‐ATPase	  activity	  and	  perturbing	  PI3,5P2	  	  levels,	  both	  of	  which	  
are	   involved	   in	   endocytic	   trafficking.	   This	   led	   me	   to	   hypothesize	   that	   VPA	   perturbs	  
endocytosis.	   The	   following	   are	   my	   findings:	   1)	   VPA	   decreases	   endocytosis	   in	   yeast;	  
evidence	  suggests	  that	  decreased	  endocytosis	   is	  due	  to	  perturbed	  PI4,5P2	   levels	   in	  the	  
plasma	  membrane.	   	  2)	  Perturbation	  of	  endocytosis	  by	  VPA	  is	  conserved	  in	  mammalian	  
cells.	  	  	  
	  	   The	   observations	   that	   VPA	   causes	   a	   phenotype	   similar	   to	   that	   resulting	   from	  
overexpression	  of	  AKL1,	  which	  perturbs	  endocytic	  trafficking	  (Fig.	  4.1),	  and	  that	  FM4-­‐64	  
trafficking	  to	  the	  vacuolar	  membrane	   is	  delayed	   in	  VPA-­‐treated	  cells	   (Fig.	  4.2),	  suggest	  
that	   VPA	   delays	   but	   does	   not	   completely	   inhibit	   endocytosis.	   A	   possible	   mechanism	  
whereby	   VPA	   affects	   endocytic	   trafficking	   is	   by	   decreasing	   levels	   of	   PI4,5P2,	   which	  
activates	   and	   stabilizes	   membrane	   proteins	   that	   regulate	   endocytosis	   (DeHart	   et	   al.,	  
2007).	  PI4,5P2-­‐dependent	  membrane	  proteins	  anchor	  the	  actin	  cytoskeleton,	  which	  is	  a	  
major	   regulator	   of	   membrane	   trafficking	   in	   yeast,	   and	   also,	   recruit	   other	   proteins	  
required	   for	   the	  endocytic	  process	   (Smythe	  and	  Ayscough,	  2006;	  DeHart	  et	  al.,	  2007).	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Temperature-­‐sensitive	   mss4	   mutants	   were	   shown	   to	   be	   defective	   in	   receptor	  
internalization	  (Derevieres	  et	  al.,	  2002),	  indicating	  that	  PI4,5P2	  is	  required	  for	  endocytic	  
trafficking.	  	  	  	  
King	   et	   al.	   (2009)	   have	   shown	   that	   the	  presence	  of	   a	   large	  PI4,5P2	   pool	   in	   the	  
plasma	  membranes,	  and	  the	  dynamic	  changes	  associated	  with	  its	  role	  as	  a	  precursor	  for	  
the	   signaling	   molecules	   IP3	   and	   DAG,	   obscure	   detection	   of	   changes	   in	   levels	   of	   this	  
phosphoinositide.	   This	   is	   in	   agreement	   with	   a	   study	   I	   have	   done	   using	   a	   GFP-­‐tagged	  
FLARE	  that	  specifically	  binds	  PI4,5P2,	  	  where	  the	  high	  intensity	  of	  fluorescence	  observed	  
did	   not	   reveal	   differences	   in	   PI4,5P2	   levels	   in	   plasma	  membranes	   of	   VPA-­‐treated	   and	  
untreated	   cells	   (data	   not	   shown).	   Therefore,	   I	   used	   two	   indirect	   approaches	   to	  
determine	  if	  VPA	  alters	  PI4,5P2	  levels;	  (i)	  visualization	  of	  PI4P,	  the	  precursor	  of	  PI4,5P2,	  
and	  (ii)	  assays	  of	  PI4,5P2-­‐dependent	  functions.	  	  
Studies	  by	  Pawolleck	  and	  Williams	  (2009)	  and	  Xu	  et	  al.	   (2007)	  have	  shown	  that	  
VPA	   causes	   a	   decrease	   in	   PI4P	   and	   PI4,5P2,	   an	   effect	   that	   was	   phenocopied	   by	  
attenuation	   of	   phosphoinositide	   signaling	   in	   Dictyostelium.	   Furthermore,	   VPA	   was	  
shown	   to	   decrease	   PI4P	   and	   PI4,5P2	   levels	   	   in	   a	   dose-­‐	   and	   time-­‐dependent	   manner	  
(Chang	   et	   al.,	   2011).	   These	   reports	   are	   consistent	  with	  my	   finding	   that	   VPA	   causes	   a	  
decrease	   in	   PI4P	   (Fig.	   4.3)	   and	   support	   my	   conclusion	   that	   PI4,5P2	   is	   decreased	   in	  
response	  to	  VPA	  treatment	  of	  yeast	  cells.	  	  
The	   rationale	   for	   the	   second	   approach,	   assay	   of	   PI4,5P2	  -­‐dependent	   functions,	  
was	  that	  if	  decreased	  endocytosis	  caused	  by	  VPA	  is	  due	  to	  decreased	  PI4,5P2,	  then	  other	  
processes	  that	  are	  dependent	  on	  PI4,5P2,	   	  would	  be	  disrupted	  in	  the	  presence	  of	  VPA.	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Rho1,	  the	  functional	  ortholog	  of	  the	  mammalian	  RhoA	  (Qadota	  et	  al.,	  1994),	   is	  a	  small	  
GTPase	  that	  regulates	  several	  processes,	  including	  actin	  organization,	  CWI,	  and	  β-­‐glucan	  
synthesis	  through	  independent	  effectors.	  It	  resides	  in	  the	  plasma	  membrane	  where	  it	  is	  
activated	   and	   stabilized	   by	   binding	   to	   PI4,5P2	   via	   a	   polybasic	   domain	   (Yoshida	   et	   al.,	  
2009).	  mss4	  mutants,	  which	   are	   defective	   in	   PI4,5P2	   production,	   have	  been	   shown	   to	  
display	  defects	  in	  actin	  organization	  and	  CWI	  at	  elevated	  temperatures	  (Desrevieres	  et	  
al.,	  1998),	  thus,	  confirming	  the	  importance	  of	  PI4,5P2	  for	  Rho1	  activity.	  
Three	   processes	   regulated	   by	   Rho1	   were	   perturbed	   in	   response	   to	   VPA.	   This	  
suggests	   that	   VPA	   perturbs	   Rho1	   activity,	   either	   by	   inhibiting	   Rho1	   directly,	   or	   by	  
perturbing	   PI4,5P2	   which	   is	   required	   for	   activation	   and	   stabilization	   of	   Rho1.	   The	  
observation	   that	   inositol	   supplementation	   rescued	   the	   cell	  wall	   defect	   (Fig,	   4.4A)	   and	  
the	   temperature	   sensitivity	   of	   VPA-­‐treated	   cells	   (Fig.	   4.4B)	   suggests	   that	   observed	  
perturbations	   caused	   by	   VPA	   are	   inositol	   dependent,	   and	   likely	   due	   to	   a	   decrease	   in	  
PI4,5P2.	  
The	   PKC-­‐CWI	   pathway	   protects	   the	   cell	   from	   environmental	   stress	   that	   could	  
damage	   the	   protective	   cell	  wall,	   such	   as	   heat	   stress	   (Kamada	   et	   al.,	   2005)	   and	   hypo-­‐
osmotic	   shock	   (Davenport	   et	   al.,	   1995).	   Yeast	   cells	   grown	   in	   I-­‐	   medium	   at	   30°C	   and	  
shifted	   to	   39°C	   showed	   increased	   levels	   of	   phosphorylated	   Slt2	   (Fig.	   4.5B),	   which	  
indicates	  activation	  of	  CWI.	  However,	  under	  the	  same	  conditions,	  VPA-­‐treated	  cells	  did	  
not	  show	  an	  equivalent	  increase	  in	  P-­‐Slt2,	  suggesting	  that	  VPA	  inhibits	  activation	  of	  the	  
CWI	   pathway.	   	   Interestingly,	   heat	   shock	   activates	   the	   PI4P	   5-­‐kinase	  Mss4,	   causing	   an	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increase	   in	   PI4,5P2	   (Desrivieres	   et	   al.,	   1998;	   Aduhya	   and	   Emr,	   2002).	   It	   has	   been	  
suggested	   that	   this	   increase	   is	   required	   for	   activation	   of	   the	   CWI	   pathway	   at	   high	  
temperatures	  (Levin,	  2011).	  The	  finding	  that	  VPA	  inhibits	  activation	  of	  CWI	  at	  39°C,	  and	  
that	  inositol	  supplementation	  rescues	  this	  effect	  (Fig.	  4.5),	  suggests	  that	  attenuation	  of	  
CWI	  by	  VPA	  is	  due	  to	  perturbed	  synthesis	  of	  PI4,5P2.	  Another	  significance	  of	  this	  result	  is	  
that	  attenuation	  of	  CWI	  signaling	  by	  VPA	  signifies	  that	  VPA	  inhibits	  PKC.	  	  Although	  VPA	  
has	  been	  shown	  to	  inhibit	  mammalian	  PKC	  in	  cell	  extracts	  (Chen	  et	  al.,	  2004),	  the	  effect	  
of	   VPA	   on	   PKC	   in	   yeast	   has	   not	   been	   reported	   before,	   and	  may	   be	   of	   importance	   to	  
regulation	  of	  inositol	  biosynthesis,	  as	  discussed	  in	  Chapter	  3.	  	  
Taken	   together,	   the	   results	   presented	   here	   suggest	   that	   VPA-­‐mediated	  
perturbation	   of	   cell	   wall	   biosynthesis,	   the	   CWI	   pathway,	   and	   endocytosis	   are	   due	   to	  
decreased	   PI4,5P2	   synthesis.	   Although	   these	   findings	   are	   indirect,	   two	   different	  
approaches	   support	   the	   conclusion	   that	   the	   decrease	   in	   PI4,5P2	   may	   underlie	   the	  
mechanism	   whereby	   VPA	   causes	   decreased	   endocytosis.	   Nevertheless,	   the	   possibility	  
remains	  that	  other	  mechanisms	  may	  be	  involved	  as	  well	  (Fig.	  4.8).	  
Perturbation	   of	   V-­‐ATPase	   and	   PI3,5P2	   by	   VPA	   (Chapter	   3)	   is	   consistent	   with	  
decreased	  endocytosis	  shown	  here.	  V-­‐ATPase	  null	  mutants	  have	  a	  markedly	  decreased	  
rate	  of	  endocytosis	  (Perzov	  et	  al.,	  2002).	  It	  is	  possible	  that	  reduced	  V-­‐ATPase	  activity	  in	  
response	   to	  VPA	  results	   in	  decreased	   lumenal	  acidification	  of	  vesicles.	  This	  may	  affect	  
membrane	   recruitment	   of	   components	   required	   for	   the	   endocytic	   machinery.	  
Furthermore,	  PI3,5P2	  is	  required	  for	  regulating	  flux	  through	  the	  endocytic	  pathway	  and	  
	  	  	  	  
	  
122	  
for	   sorting	   endocytosed	   cargo	   at	   the	   multivesicular	   body	   (Shaw	   et	   al.,	   2003).	   It	   is	  
possible	   that	   more	   than	   one	   mechanism	   may	   underlie	   perturbation	   of	   endocytosis	  
caused	  by	  VPA.	  
How	  might	  decreased	  endocytosis	   relate	   to	   the	  therapeutic	  effect	  of	  VPA?	  The	  
mechanism	   that	   underlies	   the	   GABAergic	   effect	   caused	   by	   VPA	   is	   a	   subject	   of	  
controversy.	  	  An	  increase	  in	  GABA	  levels	  following	  VPA	  treatment	  has	  been	  observed	  in	  
cultured	   mammalian	   cells,	   human	   plasma,	   and	   rat	   brains	   (MacDonald	   et	   al.,	   1979;	  
Loscher	   and	   Schmidt,	   1980;	   Patsalos	   et	   al.,	   1981).	   The	  mechanism	   that	   underlies	   the	  
increase	  in	  GABA	  levels	  in	  response	  to	  VPA	  is	  not	  known.	  Several	  mechanisms	  have	  been	  
proposed.	   For	   example,	   VPA	   was	   shown	   to	   elevate	   GABA	   levels	   by	   increasing	   the	  
availability	   of	   the	   GABA	   precursor,	   α-­‐ketoglutarate,	   through	   the	   inactivation	   of	   α-­‐
ketoglutarate	  dehydrogenase	  (Luder	  et	  al,	  1990).	  Decreased	  breakdown	  of	  GABA	  by	  the	  
two	  catabolic	  enzymes,	  GABA	  transaminase	  and	  succinate	  semialdehyde	  dehydrogenase	  
(SSD),	  was	  also	  reported	  (Loscher,	  1993;	  Whittle	  and	  Turner,	  1978).	  Modulation	  of	  the	  
post-­‐synaptic	  response	  has	  also	  been	  suggested	  as	  a	  possible	  mechanism	  for	  the	  VPA-­‐
induced	  GABAergic	  effect.	  Cunningham	  et	  al.	  (2003)	  showed	  that	  VPA	  prolongs	  the	  post-­‐
synaptic	  inhibitory	  response	  by	  binding	  to	  the	  regulatory	  site	  of	  the	  GABA	  receptors	  on	  
the	   postsynaptic	   membrane.	   Thus,	   there	   is	   no	   consensus	   as	   to	   how	   VPA	   elicits	   its	  
GABAergic	  inhibitory	  effect.	  	  
In	   glioblastoma	   cells,	   VPA	  decreased	   the	   incorporation	  of	   FM4-­‐64	   into	   vesicles	  	  
(Fig.	  4.	  6).	   	   It	  also	  decreased	   the	   internalization	  and	  recycling	  of	   transferrin	   (Fig.	  4.	  7).	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This	  suggests	  that	  VPA	  decreases	  clathrin-­‐dependent	  endocytosis,	  the	  same	  mechanism	  
responsible	  for	  internalization	  of	  GABAA	  receptors.	  Therefore,	  it	  is	  tempting	  to	  speculate	  
that	  VPA	  may	  decrease	  internalization	  of	  GABAA	  receptors,	  prolonging	  their	  exposure	  to	  
the	   inhibitory	   effect	   of	   GABA	   present	   in	   the	   synapse.	   	   In	   support	   of	   this	   speculation,	  
phosphorylation	  of	  the	  GABAA	  receptors	  by	  PKC	  and	  GSK-­‐β	  is	  required	  for	  internalization	  
and	  trafficking	  of	  these	  receptors	  (Tyagarajan	  et	  al.,	  2011;	  Brandon	  et	  al.,	  2000;	  Clayton	  
et	  al.,	  2010).	  Interestingly,	  both	  kinases	  are	  inhibited	  by	  VPA	  (Chen	  et	  al.,	  1994;	  Chen	  et	  
al.,	  1999;	  Kim	  et	  al.,	  2005),	  suggesting	  that	  inhibition	  of	  PKC	  and	  GSK-­‐β	  by	  VPA	  may	  be	  
another	  mechanism	  whereby	  VPA	  inhibits	  endocytosis.	  
In	   conclusion,	   the	   aim	   of	   this	   study	  was	   to	   identify	   cellular	   functions	   that	   are	  
affected	  by	  VPA.	  Here	  I	  show	  that	  VPA	  perturbs	  endocytosis,	  and	  that	  this	  perturbation	  
is	  conserved	  in	  yeast	  and	  human	  cells.	  Decreased	  endocytosis	  by	  VPA	  may	  be	  due	  to:	  1)	  
decreased	   V-­‐ATPase	   activity	   and	   PI3,5P2	   levels,	   2)	   decreased	   PI4,5P2	   levels,	   or	   3)	  	  	  
inhibition	  of	  PKC	  and	  GSK-­‐β.	  While	  several	  mechanisms	  have	  been	  suggested	  to	  explain	  
the	   GABAergic	   effect	   caused	   by	   VPA,	   none	   have	   addressed	   the	   trafficking	   of	   GABAA	  
receptors.	   I	  propose	  decreased	  endocytosis	  as	  a	  novel	  effect	  of	  VPA	  that	  may	  underlie	  











FIGURE	  4.8.	  	  Model:	  VPA	  causes	  a	  decrease	  in	  endocytosis.	  VPA	  inhibits	  biosynthesis	  of	  
inositol,	  the	  precursor	  of	  phosphatidylinositol	  (PI)	  required	  for	  the	  synthesis	  of	  the	  two	  
phosphoinositides	  PI3,5P2	  and	  PI4,5P2.	  Two	  mechanisms	  that	  may	  underlie	  the	  decrease	  
in	   endocytosis	   observed	   in	   VPA-­‐treated	   yeast	   cells	   are	   perturbation	   of	   PI3,5P2	   which	  
decreases	  V-­‐ATPase	   coupling,	   and	  perturbation	  of	   PI4,5P2	   required	   for	   stabilization	  of	  













The	   studies	   described	   in	   this	   dissertation	   show	   novel	   findings	   pertaining	   to	  
regulation	  of	  inositol	  biosynthesis	  and	  cellular	  consequences	  of	  inositol	  depletion.	  These	  
findings	   will,	   hopefully,	   contribute	   to	   a	   better	   understanding	   of	   the	   therapeutic	  
mechanism	   of	   action	   of	   the	   inositol-­‐depleting	   drug,	   VPA.	   Although	   my	   studies	   have	  
answered	  some	  questions	   raised	  by	   those	  who	  embarked	  on	   this	  project	  before	  me,	   I	  
now	  raise	  new	  questions	  based	  on	  the	  work	   I	  have	  done,	  and	  hope	  that	  they	  enthuse	  
future	   students	   to	   continue	  with	   this	   exciting	   project.	   Highlighted	   in	   this	   chapter	   are	  
some	  unanswered	  questions	  that	  require	  continued	  investigation.	  
	  
Kinases	  that	  regulate	  myo	  inositol	  3-­‐phosphate	  synthase	  (MIPS):	  	  
The	   inositol	   biosynthesis	  pathway	   is	  highly	   conserved,	   and	   is	   regulated	  at	   the	   level	  of	  
the	   first	   and	   rate-­‐limiting	   enzyme,	   MIPS.	   In	   Chapter	   2,	   I	   showed	   that	   MIPS	   is	  
postranslationally	  regulated,	  and	  that	  at	  least	  three	  phosphosites	  that	  are	  conserved	  in	  
yeast	   and	   human	   MIPS	   play	   a	   role	   in	   its	   regulation.	   Phosphosite	   prediction	   analysis	  
showed	   that	   the	   two	   inhibitory	   phosphosites,	   S184	   and	   S374,	   lie	   within	   recognition	  
sequences	  for	  PKA	  and	  PKC,	  respectively,	  while	  S296,	   is	  within	  a	  recognition	  sequence	  
for	   GSK3.	   Preliminary	   experiments	   showed	   that	   both	   PKC	   and	   PKA	   decreased	   MIPS	  
activity	   in	   vitro,	   while	   GSK3	   increased	   activity	   (data	   not	   shown).	   While	   these	   results	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seem	  to	  correlate	  with	  the	  predictions,	  further	  experiments	  are	  necessary	  to	  elucidate	  
the	   role	   of	   these	   kinases	   in	   regulating	  MIPS.	   In	   vitro	   experiments	   using	   purified	   and	  
dephosphorylated	   MIPS	   should	   clearly	   show	   the	   effect	   of	   each	   kinase	   on	  
phosphorylation	   and	   activity	   of	  MIPS.	   The	   use	   of	   the	   site	  mutants	   as	   controls	   would	  
greatly	  facilitate	  these	  studies.	  	  
Another	  question	  of	  fundamental	  importance	  to	  the	  mechanism	  of	  VPA	  is,	  which	  
of	  the	  identified	  residues	  (if	  any)	  are	  phosphorylated	  in	  response	  to	  VPA?	  	  MIPS	  purified	  
from	   VPA-­‐treated	   cells	   shows	   a	   higher	   level	   of	   phosphorylation	   than	   enzyme	   from	  
untreated	   cells.	   Answering	   this	   question,	   would	   be	   crucial	   to	   demonstrate	   the	  
mechanism	  by	  which	  VPA	  inhibits	  MIPS	  and	  which	  is	  targeted	  by	  VPA.	  Identification	  of	  
the	  kinase	  may	  help	  identify	  upstream	  regulators	  of	  MIPS	  that	  may	  be	  directly	  affected	  
by	  VPA.	  
In	   a	   previous	   study,	   Ju	   and	   Greenberg	   (2003)	   showed	   that	   VPA	   causes	   an	  
increase	  in	  the	  transcriptional	  level	  of	  INO1,	  the	  gene	  coding	  for	  MIPS,	  concomitant	  with	  
a	  decrease	  in	  inositol	  biosynthesis.	  This	  indicates	  that	  inositol	  depletion	  does	  not	  result	  
from	  perturbation	   of	   INO1	   transcription.	   The	   current	   study	   shows	   that	   VPA	   increases	  
MIPS	   phosphorylation.	   It	   would	   be	   interesting	   to	   determine	   if	   there	   is	   a	   direct	  
correlation	   between	   increased	   phosphorylation	   and	   decreased	   inositol	   levels	   in	  
response	   to	   VPA.	   What	   is	   the	   time	   frame	   during	   which	   the	   protein	   is	   modified	   by	  
phosphorylation?	   	   These	   studies	   were	   previously	   hindered	   by	   the	   lack	   of	   available	  
antibodies	   that	   detect	   MIPS.	   Now	   that	   the	   phosphosites	   have	   been	   identified,	  
antibodies	  could	  be	  designed	  that	  specifically	  recognize	  phosphorylated	  MIPS.	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Regulation	   of	   human	   MIPS	   –	   Surprisingly,	   not	   much	   is	   known	   about	   regulation	   of	  
human	  MIPS.	   In	   Chapter	   2,	   I	   showed	   that	   the	   three	   regulatory	   phosphosites	   initially	  
identified	  in	  yeast	  MIPS,	  are	  conserved	  in	  the	  human	  homolog.	  	  Shaltiel	  et	  al.	  (2004	  and	  
2007)	   showed	   that	  VPA	  decreased	   inositol	  biosynthesis	   in	  human	  prefrontal	   cortex	  by	  
inhibiting	  MIPS.	   Thus,	   it	   is	   likely	   that,	   similar	   to	  what	  we	  observed	   in	   yeast,	   VPA	  may	  
decrease	   human	   MIPS	   activity	   by	   increasing	   its	   phosphorylation.	   Although	   we	   have	  
shown	  that	  VPA	  increases	  the	  phosphorylation	  of	  yeast	  MIPS,	  similar	  experiments	  were	  
not	   done	   with	   the	   human	   enzyme.	   	   It	   is	   particularly	   important	   to	   determine	   if	   the	  
kinases	   PKC	   and	   GSK3	   regulate	   human	   MIPS,	   because	   although	   earlier	   studies	   have	  
shown	  that	  VPA	  inhibits	  mammalian	  PKC	  and	  GSK3	  (Chen	  at	  al.	  1994;	  Chen	  et	  al.,	  1999),	  
no	   connection	   has	   been	  made	   between	   inositol	   depletion	   and	   the	   inhibition	   of	   these	  
two	  enzymes.	  Elucidating	  the	  effect	  of	  PKC	  and	  GSK3	  on	  human	  MIPS	  would	  be	  of	  direct	  
relevance	  to	  the	  mechanism	  by	  which	  VPA	  causes	  inositol	  depletion	  in	  human.	  	  	  	  	  
	  	  
VPA	  as	  a	  tool	  to	  uncover	  regulation	  of	  Fab1:	  	  
In	  Chapter	  3,	  I	  showed	  that	  VPA	  inhibits	  the	  PI3,5P2-­‐dependent	  osmotic	  stress	  response.	  
Cells	  respond	  to	  hyperosmotic	  stress	  by	  activating	  two	  pathways	  -­‐	   the	  high	  osmolarity	  
glycerol	   (Hog1)	   pathway,	   which	   initiates	   a	   long	   term	   response,	   and	   the	   PI3,5P2-­‐
dependent	  immediate,	  short	  term	  response	  (Bonangelino	  et	  al.,	  2002).	  The	  latter	  leads	  
to	   a	   20-­‐fold	   increase	   in	   PI3,5P2,	   which	   triggers	   an	   increase	   in	   the	   number	   of	   small	  
vacuoles,	   thereby	   increasing	   total	   vacuole	  membrane	   surface	   area.	   	   	   The	   finding	   that	  
VPA	   blocks	   the	   rapid	   increase	   in	   PI3,5P2	   suggests	   that	   VPA	  may	   perturb	   activation	   of	  
	  	  	  	  
	  
128	  
Fab1,	  the	  kinase	  that	  generates	  PI3,5P2	  from	  PI3P.	  Fab1	  is	  regulated	  by	  two	  activators,	  
Vac7	  and	  Vac14,	  which	  form	  part	  of	  a	  multimeric	  complex	  on	  the	  vacuolar	  membrane.	  
There	  are	  no	  published	  studies	  describing	  how	  these	  two	  activators	  respond	  to	  stress.	  
Are	   they	   activated	   by	   phosphorylation,	   for	   example	   by	   the	   Hog1	   kinase?	   Is	   it	   a	  
coincidence	  that	  both	  pathways	  are	  activated	  at	  the	  same	  time	  in	  response	  to	  osmotic	  
stress?	  Does	  VPA	  perturb	  activation	  of	  Vac7	  and	  Vac14,	  thus	  negatively	  affecting	  Fab1	  
and,	  hence,	  preventing	  an	  increase	  in	  PI3,5P2?	  One	  approach	  to	  address	  these	  questions	  
is	  to	  determine	  if	  the	  Fab1	  pathway	  is	  regulated	  by	  the	  Hog1	  kinase,	  in	  which	  case	  the	  
pathway	   would	   be	   altered	   by	   deleting	   or	   overexpressing	   HOG1.	   	   	   A	   complementary	  
approach	   would	   be	   to	   ascertain	   if	   Vac7	   and	   Vac14	   are	   phosphoproteins,	   and	   if	   VPA	  
affects	  their	  activity	  by	  altering	  phosphorylation	  of	  these	  proteins.	  
While	   the	   HOG1	   stress	   response	   pathway	   has	   been	   extensively	   studied,	   not	  
much	  is	  known	  about	  the	  osmotic	  stress	  response	  that	  depends	  on	  PI3,5P2.	  This	  is	  a	  very	  
promising	  area	  because	  it	  is	  becoming	  increasingly	  evident	  that	  PI3,5P2	  has	  many	  more	  
functions	  than	  previously	  thought	  (Ho,	  2012).	  Answering	  the	  questions	  addressed	  here	  
would	   not	   only	   identify	   the	  mechanism	   by	  which	   VPA	   inhibits	   the	   PI3,5P2-­‐dependent	  
response	   to	   osmotic	   stress,	   but	   may	   also	   uncover	   a	   novel	   regulatory	   mechanism	   of	  
PI3,5P2	  synthesis.	  
	  
Does	   VPA	   cause	   temperature	   sensitivity	   as	   a	   consequence	   of	   altered	   plasma	  
membrane	  lipid	  composition?	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In	  Chapter	  4,	  I	  showed	  that	  VPA	  inhibits	  growth	  of	  cells	  at	  elevated	  temperatures.	  The	  
response	   of	   Scaccharomyces	   cerevisiae	   to	   heat	   stress	   involves	   two	   phases.	   Initially,	  
growth	   is	   arrested	   for	   about	   an	   hour	   (Shin	   et	   al.,	   1987),	   during	   which	   cells	   gain	  
thermotolerance.	  	  This	  involves	  an	  increase	  in	  trehalose	  accumulation	  and	  activation	  of	  
heat	  shock	  proteins	   (Weimken,	  1990;	  Lindquist	  and	  Craig,	  1988).	   In	   the	  second	  phase,	  
degradation	  of	   trehalose	   takes	   place,	   and	   cells	   resume	  growth	   (Hottiger	   et	   al.,	   1992).	  
The	   heat	   stress	   response	   is	   also	   characterized	   by	   a	   dramatic,	   transient	   increase	   in	  
sphingolipids	  and	  ceramides	  within	  the	  first	  15	  min	  and	  1	  hr,	  respectively	  (Jenkins	  et	  al.,	  
1997;	  Chen	  et	  al.,	  2013).	  In	  two	  separate	  studies,	  Desrevieres	  et	  al.	  (1998)	  and	  Audhya	  
and	   Emr	   (2002)	   showed	   that	   heat	   shock	   causes	   an	   increase	   in	   PI4,5P2,	   which	   is	  
predominantly	  found	  in	  the	  plasma	  membrane.	  Interestingly,	  the	  synthesis	  of	  the	  three	  
lipids,	   sphingolipids,	   ceramides,	   and	  PI4,5P2,	  is	  perturbed	   in	   inositol	   limiting-­‐conditions	  
(Henry	  et	  al.,	  2014).	  Thus,	  it	  is	  likely	  that	  thermosensitivity	  caused	  by	  VPA	  may	  be	  due	  to	  
the	  inositol-­‐depleting	  effect	  of	  the	  drug.	  	  It	  would	  be	  interesting	  to	  find	  out	  if	  VPA	  alters	  
the	  phospholipid	  content	  of	  cells	  grown	  at	  elevated	  temperature.	   	  For	   this	  purpose,	   it	  
would	  be	  essential	  to	  measure	  the	  lipids	  at	  different	  times	  following	  the	  transfer	  of	  cells	  
to	  a	  high	  growth	  temperature.	  	  
Another	  interesting	  finding	  in	  Chapter	  4	  was	  that	  VPA	  perturbs	  activation	  of	  the	  
CWI	  pathway	  when	  cells	  are	  shifted	  from	  30°C	  to	  39°C	  for	  1	  h.	  	  This	  signaling	  pathway	  is	  
activated	  in	  response	  to	  growth	  at	  elevated	  temperatures	  (Kamada	  et	  al.,	  1995;	  Zarzov	  
et	   al.,	   1996).	  However,	   its	   activation	   is	   detectable	   after	   about	   20	  min	   (Kamada	  et	   al.,	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1995),	  suggesting	  that	  CWI	  signaling	  is	  detecting	  a	  secondary	  effect	  of	  exposure	  to	  high	  
temperature	   (Levin,	   2011).	   It	   is	   tempting	   to	   speculate	   that	   one	   or	   more	   of	   the	  
phospholipids	  PI4,5P2,	  sphingolipids,	  or	  ceramides	  may	  constitute	  the	  secondary	  	  effect	  
in	  question,	   and	   that	  perturbation	  of	   these	   lipids	  as	  a	   result	  of	  VPA-­‐mediated	   inositol	  
depletion	  leads	  to	  decreased	  activation	  of	  CWI	  signaling.	  Deletion	  mutants	  for	  synthesis	  
of	   each	   of	   the	   phospholipids,	   or	   commercially	   available	   inhibitors	   (Jesch	   et	   al.,	   2010)	  
could	   be	   used	   to	   determine	   if	   any	   of	   these	   phospholipids	   are	   required	   for	   CWI	  
activation.	  
In	   the	   same	   context,	   I	   would	   like	   to	   draw	   attention	   to	   glycosylphosphatidyl	  
inositol	  (GPI)	   lipids,	  which	  are	  synthesized	  from	  PI	  and	  used	  to	  anchor	  several	  cell	  wall	  
proteins	  (Pittet	  and	  Conzelmann,	  2007).	  Surprisingly,	  the	  effect	  of	  VPA	  on	  this	  group	  of	  
inositol-­‐lipids	  has	  never	  been	  addressed	  in	  our	  lab.	  It	  would	  be	  interesting	  to	  find	  out	  if	  
levels	  of	  GPI	  are	  altered	  in	  response	  to	  VPA,	  as	  this	  may	  uncover	  new	  cellular	  processes	  
affected	  by	  the	  drug.	  	  
	  
What	  is	  the	  mechanism	  underlying	  decreased	  endocytosis	  in	  response	  to	  VPA?	  
One	  of	  the	  main	  aims	  of	  this	  study	  was	  to	  elucidate	  the	  mechanism	  of	  action	  of	  VPA	  by	  
identifying	   cellular	   processes	   that	   are	   affected	   by	   this	   drug.	   The	   studies	   in	   Chapter	   4	  
show	  that	  VPA	  perturbs	  endocytosis	   in	  both	  yeast	  and	  mammalian	  cells.	  This	   is	  by	  no	  
means	   the	   end	   of	   the	   story.	   I	   hypothesize	   that	   VPA	   potentiates	   the	   inhibitory	   GABA-­‐
mediated	  effect	  (Johannessen,	  2000;	  Loscher,	  2002)	  by	  decreasing	  the	  internalization	  of	  
the	   GABAA	   receptors,	   thus	   prolonging	   exposure	   of	   the	   receptors	   to	   GABA.	   The	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hypothesis	   is	   supported	   by	   the	   finding	   that	   VPA	   perturbs	   clathrin-­‐mediated	  
internalization	  depicted	  by	  Fig.	  4.7	  shown	  in	  Chapter	  4.	  A	  further	  test	  of	  the	  hypothesis	  
would	   be	   to	   determine	   if	   VPA	   perturbs	   the	   internalization	   of	   GABAA	   receptors	   in	  
mammalian	   cells.	   This	   experiment	   is	   challenging	   but	   doable.	   A	   decrease	   in	  
internalization	  of	  the	  receptors	  would	  suggest	  a	  new	  mechanism	  that	  may	  explain	  how	  
VPA	  may	  potentiate	  the	  inhibitory	  effect.	  	  
	  What	   is	   the	   mechanism	   responsible	   for	   the	   VPA-­‐mediated	   decrease	   in	  
endocytosis?	   Several	   studies	   have	   shown	   that	   phosphoinositides,	   ceramides,	   and	  
sphingolipids	   play	   a	   role	   in	   regulating	   endocytosis	   by	   recruiting	   proteins,	   acting	   as	  
signaling	  molecules,	  or	  by	  playing	  a	  structural	  role	  (Munn	  et	  al.,	  1999;	  Chen	  et	  al.,	  1995;	  
Zanolari	  et	  al.,	  2000).	  While	  it	   is	  possible	  that	  the	  VPA-­‐mediated	  defect	  may	  be	  due	  to	  
altered	  phospholipid	  composition	  of	   the	  plasma	  membrane,	  an	   intriguing	  possibility	   is	  
that	  the	  defect	  may	  be	  due	  to	   inhibition	  of	  the	  kinases	  PKC	  and	  GSK3ß,	  both	  of	  which	  
are	  required	  for	  phosphorylation	  of	  proteins	  essential	  for	  the	  internalization	  step	  of	  the	  
GABA	   receptors	   (Brandon	   et	   al.,	   2000;	   Tyagarajan	   et	   al.,	   2011).	   Interestingly,	   both	  
kinases	  are	  inhibited	  by	  VPA	  (Chen	  et	  al.,	  1994;	  Chen	  et	  al.,	  1999).	  If	  inhibition	  of	  these	  
two	   enzymes	   is	   responsible	   for	   the	   observed	   VPA-­‐mediated	   decrease	   in	   endocytosis,	  
this	  would	  uncover	  a	  novel	  effect	  of	  VPA	  that	  has	  not	  been	  identified	  before.	  	  
	  
Is	  there	  cross	  talk	  between	  the	  glycolytic	  and	  inositol	  biosynthetic	  pathways?	  
The	   cDNA	   screen	   discussed	   in	   Chapter	   4	   showed	   that	   overexpression	   of	   any	   of	   ten	  
different	  glycolytic	  enzymes	  caused	  increased	  sensitivity	  to	  VPA	  (Table	  4.2	  and	  Fig.	  5.1).	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This	   finding	   raises	   the	   possibility	   that	   accumulation	   of	   glycolytic	   enzymes	   or	   products	  
causes	   sensitivity	   to	   the	   drug.	   Overexpression	   was	   not	   deleterious	   to	   cells	   in	   the	  
absence	  of	  VPA.	  At	  least	  three	  possibilities	  may	  explain	  these	  findings:	  	  
1)	  	  Glycolytic	  intermediates	  negatively	  affect	  a	  process	  already	  compromised	  by	  
VPA.	  For	  example,	  some	  intermediates	  may	  inhibit	  enzymes	  of	  the	  inositol	  biosynthetic	  
pathway,	  causing	  a	  further	  decrease	   in	   inositol	   levels.	   	   In	  support	  of	  this,	   the	  study	  by	  
Shi	  et	  al.	   (2005)	  showed	  that	  dihydroxyacetone	  phosphate	   (DHAP)	  and	  glyceraldehyde	  
3-­‐phosphate	  (G-­‐3-­‐P),	  two	  glycolytic	  intermediates,	  inhibit	  the	  activity	  of	  MIPS.	  Thus,	  it	  is	  
possible	  that	  accumulation	  of	  other	  intermediates	  may	  inhibit	  MIPS	  and	  cause	  a	  further	  
decrease	  in	  inositol	  biosynthesis.	  Inositol	  levels	  could	  be	  quantified	  in	  each	  of	  the	  clones	  
expressing	   the	   glycolytic	   genes	   and	   compared	   to	   levels	   in	  wild-­‐type	   cells.	   Clones	   that	  
show	  decreased	  inositol	  levels	  may	  identify	  new	  MIPS	  inhibitors.	  	  
2)	   Glycolysis	   and	   the	   inositol	   biosynthetic	   pathway	   depend	   on	   glucose-­‐6-­‐
phosphate	   (G-­‐6-­‐P)	   as	   the	  primary	  precursor.	   Two	  enzymes,	  MIPS	  and	  phosphoglucose	  
isomerase	  (PGI),	  use	  G-­‐6-­‐P	  as	  a	  substrate.	  MIPS	  converts	  G-­‐6-­‐P	  to	  inositol	  3-­‐P,	  while	  PGI	  
converts	   G-­‐6-­‐P	   to	   fructose-­‐6-­‐P	   (Fig.	   5.	   1).	   It	   is	   possible	   that	   overexpressing	   glycolytic	  
enzymes	  shifts	   the	  reaction	   in	   favor	  of	  glycolysis,	  and	  away	  from	   inositol	  biosynthesis,	  
leading	  to	  increased	  sensitivity	  to	  VPA.	  What	  determines	  the	  direction	  of	  the	  reaction?	  	  
It	  is	  tempting	  to	  speculate	  that	  the	  flux	  of	  the	  reaction	  may	  be	  regulated	  by	  a	  metabolic	  
signal,	   for	   example,	   an	   allosteric	   regulator	   that	   responds	   to	   altered	  ATP	   levels.	   In	   the	  
event	  of	  ATP	  shortage,	  the	  regulator	  may	  direct	  the	  flux	  towards	  glycolysis.	  	  
	  






FIGURE	  5.1	  	  Overexpression	  of	  glycolytic	  enzymes	  increases	  sensitivity	  to	  VPA.	  Shown	  
in	  blue	  are	  the	  genes	  encoding	  the	  glycolytic	  enzymes	  that	  were	  identified	  in	  the	  cDNA	  
screen	  described	  in	  Chapter	  4.	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3)	   Some	  glycolytic	  enzymes	  have	  additional	   roles.	   For	  example,	   glyceraldehyde	  
phosphate	   dehydrogenase	   (GAPDH),	   which	   converts	   glyceraldeyde-­‐3-­‐phosphate	   to	  
glycerate	   1,3-­‐bisphosphate	   is	   involved	   in	   several	   non-­‐glycolytic	   processes,	   including	  
apoptosis	   (Tarze	  et	  al.,	  2007),	   transcription	  activation,	  ER	  to	  Golgi	   shuttling	   (Tisdale	  et	  
al.,	   2004),	   and	   fast	   axoplasmic	   transport	   (FAT)	   (Zala	   et	   al.,	   2013).	   GAPDH	   provides	  
glycolytic	  energy	  for	  FAT,	  which	  is	  responsible	  for	  vesicular	  transport	  and	  movement	  of	  
organelles,	   including	   synaptic	   vesicles,	   to	   and	   from	   the	   neuron	   cell	   body	   along	   the	  
axoplasm.	   Interruption	   of	   this	   process	   is	   associated	   with	   neurodegenerative	   diseases	  
(Chevalier-­‐Larsen	   and	   Holzbaur,	   2006).	   The	   cDNA	   screen	   (Chapter	   4)	   showed	   that	  
overexpression	  of	  triose	  phosphate	  dehydrogenase	  (TDH),	  the	  yeast	  homolog	  of	  GAPDH,	  
confers	   sensitivity	   to	   VPA.	   This	   raises	   the	   possibility	   that	   by	   increasing	   glycolytic	   flux	  
(and	  decreasing	   inositol	   biosynthesis),	  VPA	  may	   increase	  activation	  of	  GAPDH/TDH.	   In	  
neurons,	  this	  would	  increase	  the	  efficiency	  of	  FAT,	  which	  would	  be	  of	  great	  significance	  
if	   FAT	   is	   defective	   in	   neurons	   of	   BD	   patients.	   In	   yeast,	   however,	   the	   only	   two	   known	  
functions	  of	  TDH	  are	  in	  gluconeogenesis	  and	  glycolysis	  (Boucherie	  et	  al.,	  1995).	  Thus,	  a	  
study	   to	   determine	   if	   TDH	  plays	   a	   role	   in	   vesicular	   trafficking	   in	   yeast	  may	   uncover	   a	  
novel	  mechanism	  that	  has	  not	  been	  reported	  previously	  for	  this	  enzyme!	  
	  
Does	  VPA	  perturb	  the	  unfolded	  protein	  response	  (UPR)	  pathway?	  
The	  UPR	  pathway	  is	  generally	  activated	  in	  response	  to	  ER	  stress	  caused	  by	  accumulation	  
of	  misfolded	  protein	   in	   the	  ER	   lumen.	   	  Three	  mechanisms	  help	  alleviate	   the	  ER	  stress,	  
including	   attenuation	   of	   protein	   synthesis,	   targeting	   the	   misfolded	   proteins	   for	  
	  	  	  	  
	  
135	  
degradation,	  and	  properly	  folding	  existing	  proteins	  (Kim	  et	  al.,	  2005).	  Results	  of	  several	  
screens	  for	  VPA	  sensitivity	  indicate	  that	  VPA	  may	  perturb	  the	  UPR	  pathway.	  A	  study	  by	  
Shulin	  Ju	  (2005	  PhD	  dissertation)	  showed	  that	  cells	  exhibit	  increased	  resistance	  to	  VPA	  
in	  response	  to	  overexpression	  of	  Ubi4,	  a	  ubiquitin	  that	  marks	  proteins	  and	  targets	  them	  
for	   selective	   degradation.	   Thus,	   VPA	   may	   perturb	   selective	   degradation	   of	   misfolded	  
proteins.	   In	   Chapter	   4,	   I	   showed	   that	   overexpression	   of	   ribosomal	   proteins	   increases	  
sensitivity	  to	  VPA.	  It	  is	  possible	  that	  an	  increase	  in	  ribosome	  biogenesis	  ensues,	  leading	  
to	  increased	  protein	  synthesis	  and	  accumulation	  of	  misfolded	  proteins.	  It	  is	  also	  possible	  
that	   overexpression	   of	   proteins	   stresses	   cells	   and	   causes	   accumulation	   of	   misfolded	  
proteins.	  Thus,	  perturbation	  of	  the	  UPR	  by	  VPA	  may	  explain	  the	  increased	  sensitivity	  of	  
cells	  when	  proteins	  are	  overexpressed.	  	  
Furthermore,	   ribosomal	   proteins	   have	   extra-­‐ribosomal	   functions,	   including	  
regulation	   of	   gene	   expression,	   DNA	   repair,	   DNA	   replication,	   and	   repression	   of	  
translation	  (Warner	  and	  Mclntosh,	  2009;	  Weisberg,	  2008).	  The	  INO1	  gene	  is	  particularly	  
sensitive	  to	  defects	  in	  general	  transcription	  factors	  (Henry	  et	  al.,	  2014).	  It	  is	  possible	  that	  
some	  of	  the	  ribosomal	  proteins	  identified	  in	  the	  screen	  may	  perturb	  the	  transcription	  of	  
INO1	  and,	  thus,	  account	  for	  the	  increased	  sensitivity	  to	  VPA.	  	  
In	   conclusion,	  VPA	   is	   a	  drug	   that,	   for	   years,	  has	  been	   successfully	  used	   for	   the	  
treatment	  of	  two	  devastating	  illnesses,	  BD	  and	  epilepsy,	  without	  knowing	  how	  it	  elicits	  
its	  therapeutic	  effect.	  It	  is	  very	  likely	  that	  the	  effect	  involves	  more	  than	  one	  mechanism	  
and	   numerous	   targets.	   The	   identification	   of	   novel	   targets	   and	   cell	   processes	   that	   are	  
perturbed	  by	  VPA,	  undoubtedly	  uncovers	  new	   leads	   towards	  potential	  mechanisms	  of	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action	  of	   this	   drug.	   These	  mechanisms	  may	  be	   responsible	   for	   the	   therapeutic	   effect,	  
side	  effects,	  or	  may	  even	  shed	  light	  on	  the	  pathophysiology	  of	  a	  disorder	  that	  remains	  

























And	  a	  final	  thought...	  
	  
During	   my	   work	   on	   this	   project,	   I	   had	   the	   chance	   to	   train	   a	   student	   who	   is	  
afflicted	   with	   bipolar	   disorder.	   	   Needless	   to	   say,	   she	   is	   one	   of	   the	   smartest,	   most	  
thoughtful,	  creative,	  and	  cheerful	  persons	   I	  have	  ever	  met.	   I	  have	  often	  thought	  of	  her	  
during	  my	  work.	  
It	  is	  heart-­‐wrenching	  to	  see	  the	  increase	  in	  number	  of	  people	  affected	  by	  mental	  
disorders	  and	  the	  devastating	  consequences	  that	  ensue.	  In	  spite	  of	  all	  the	  advancements	  
that	  are	  generated	  by	  science,	  there	  is	  no	  proper	  cure	  for	  these	  disorders.	  
	  
I	  hope	  that	  my	  work	  contributes	  to	  the	  advancement	  of	  research	  in	  this	  area.	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Inositol	   is	  a	  six-­‐carbon	  cyclitol	   that	   is	  ubiquitous	   in	  biological	   systems.	   It	   is	  a	  
precursor	  for	  the	  synthesis	  of	  numerous	  biologically	  important	  compounds,	  including	  
inositol	   phosphates	   and	   phosphoinositides	   that	   are	   essential	   for	   cell	   function	   and	  
viability.	   Inositol	   compounds	   play	   a	   role	   in	   membrane	   formation,	   gene	   regulation,	  
signaling,	   regulation	   of	   ion	   channels,	   and	   membrane	   trafficking.	   	   Furthermore,	  
inositol	  regulates	  hundreds	  of	  genes,	   including	  those	  involved	  in	  the	  biosynthesis	  of	  
inositol	   and	   phospholipids.	  While	   transcriptional	   regulation	   of	   inositol	   biosynthesis	  
has	   been	   extensively	   studied	   and	   well	   characterized,	   regulation	   of	   inositol	  
biosynthesis	  at	  the	  enzymatic	  level	  has	  not	  been	  addressed.	  The	  current	  study	  shows	  
that	  myo-­‐inositol	  3-­‐phosphate	  synthase	   (MIPS),	   the	  enzyme	  that	  catalyzes	   the	  rate-­‐
limiting	  step	  in	  inositol	  biosynthesis,	  is	  a	  phosphoprotein.	  Mass	  spectrometry	  analysis	  
identified	  five	  phosphosites,	  three	  of	  which	  are	  conserved	  in	  yeast	  and	  human	  MIPS.	  
Analysis	   of	   phosphorylation-­‐deficient	   and	   phosphomimetic	   site-­‐mutants	   of	   both	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yeast	  and	  human	  MIPS	  indicated	  that	  the	  three	  conserved	  sites	  affect	  MIPS	  activity.	  
Two	  of	  the	  phosphosites	  are	  inhibitory,	  and	  one	  is	  critical	  for	  activity.	  	  
Previous	  studies	  have	  shown	  that	  valproate	  (VPA),	  a	  branched	  chain	  fatty	  acid	  
that	  has	  been	  successfully	  used	  for	   the	  treatment	  of	  bipolar	  disorder,	  epilepsy,	  and	  
migraine,	  causes	   inositol	  depletion	  by	   inhibiting	  MIPS	   in	  vivo	  but	  not	   in	  vitro,	  which	  
suggests	   that	   inhibition	   is	   indirect.	   	   Elimination	   of	   the	   two	   inhibitory	   phosphosites	  
caused	   an	   increase	   in	   MIPS	   activity,	   conferred	   a	   growth	   advantage,	   and	   partially	  
rescued	   sensitivity	   to	   VPA,	   suggesting	   that	   VPA-­‐mediated	   inositol	   depletion	   may	  
result	  from	  phosphorylation	  of	  MIPS.	  	  
Decreased	   IP3	  signaling	  caused	  by	   Inositol	  depletion	  has	  been	  proposed	  as	  a	  
mechanism	   that	   underlies	   the	   therapeutic	   effect	   of	   VPA.	   However,	   no	   direct	  
correlation	   between	   altered	   IP3	   signaling	   and	   the	   therapeutic	   effect	   has	   been	  
established.	  Because	  of	  the	  versatility	  of	  inositol	  compounds,	  inositol	  depletion	  may	  
have	  more	   far-­‐reaching	   consequences	   that	  may	  account	   for	   the	  effect	  of	  VPA.	  This	  
study	  showed	  that	   inositol	  depletion	  caused	  by	  VPA	  or	  by	  starvation	  of	   ino1Δ	   cells,	  
which	   cannot	   synthesize	   inositol,	   perturbs	   vacuolar	   structure,	   decreases	   vacuolar	  
ATPase	  (V-­‐ATPase)	  proton	  pumping,	  and	  causes	  partial	  un-­‐coupling	  of	  the	  V-­‐ATPase.	  
These	   perturbations	   were	   rescued	   by	   inositol	   supplementation.	   Furthermore,	   VPA	  
compromised	  the	  synthesis	  of	  PI3,5P2,	  which	  	   is	  necessary	  for	  stabilization	  of	  the	  V-­‐
ATPase	  complex.	  Osmotic	  stress,	  known	  to	  increase	  PI3,5P2	  levels,	  did	  not	  rescue	  the	  
compromised	  PI3,5P2	  levels,	  nor	  did	  it	  induce	  vacuolar	  fragmentation	  in	  VPA-­‐treated	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cells,	   suggesting	   that	   perturbation	   of	   the	   V-­‐ATPase	   is	   a	   consequence	   of	   altered	  
PI3,5P2	  homeostasis	  under	   inositol-­‐limiting	  conditions.	  These	   findings	   identify	  novel	  
consequences	  of	  inositol	  depletion	  and	  provide	  evidence	  for	  a	  previously	  unidentified	  
link	  between	  inositol	  levels	  and	  the	  V-­‐ATPase.	  
To	  identify	  novel	  pathways	  and	  processes	  that	  are	  altered	  in	  response	  to	  VPA,	  
a	   yeast	   cDNA	   library	  was	   screened	   for	   genes	   that	   increase	   sensitivity	   to	  VPA	  when	  
overexpressed.	   	   One	   of	   the	   major	   categories	   identified	   was	   endocytic	   trafficking	  
genes,	  which	  led	  to	  the	  hypothesis	  that	  VPA	  perturbs	  endocytosis.	  The	  study	  showed	  
that	  VPA	  perturbs	  endocytosis	   in	  yeast	  and	  human	  cells.	  Evidence	  showed	   that	   the	  
likely	   mechanism	   underlying	   decreased	   endocytosis	   by	   VPA	   is	   decreased	   PI4,5P2	  
levels.	  	  
Taken	  together,	  my	  studies	  led	  to	  three	  major	  novel	  findings.	  First,	  I	  identified	  
a	  regulatory	  mechanism	  of	  inositol	  biosynthesis	  characterized	  by	  phosphorylation	  of	  
the	   rate-­‐limiting	   enzyme	   myo-­‐inositol	   3-­‐phosphate	   synthase	   (MIPS).	   Second,	   I	  
demonstrated	   that	   the	   highly	   conserved	   vacuolar	   ATPase	   (V-­‐ATPase)	   is	   a	   target	   of	  
VPA.	   Third,	   my	   studies	   indicated	   that	   VPA-­‐mediated	   inositol	   depletion	   perturbs	  
endocytosis	   in	   both	   yeast	   and	   mammalian	   cells.	   These	   findings	   suggest	   new	  
mechanisms	  that	  may	  underlie	  the	  therapeutic	  action	  of	  VPA,	  and	  identify	  potential	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